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ABSTRACT 
 
 
Periodontitis is a leading chronic oral inflammatory disease and primary cause of 
permanent tooth loss estimated to affect 47.2% of adults in the United States. Damage to the tooth-
supporting apparatus, which includes periodontal ligament (PDL) fibers that anchor the tooth root 
to alveolar bone, subsequently initiates osseous tissue resorption. Multi-tissue morbidity is a 
significant challenge given lack of predictability in reconstructing tissues with physiologic 
functionality native to healthy periodontium. Tissue engineering strategies have potential to 
address existing deficiencies in clinically-induced regeneration through combinational approaches 
using biomaterials, growth factors, and cell-based therapy. The purpose of this work was to 
develop scaffolds incorporating micropatterned topography for guidance of cell growth and 
periodontal tissue formation, in conjunction with localized, spatiotemporally-controlled growth 
factor delivery via gene therapy vectors.  
 Micropatterned polycaprolactone (PCL) films were designed to assess PDL cell orientation 
in vitro, with incorporation of the patterned film into a 3D-printed PCL scaffold for evaluation of 
varying topography on oriented tissue formation in an ectopic murine model. Specifically, pillars 
with varying groove depths (30um, 10um) and groove widths (15um, 60um) were used for the 
scaffold “PDL” region in combination with human PDL (hPDL) cell seeding, while the 3D-printed 
base served as a region for osseous tissue formation via delivery of human gingival fibroblasts 
(hGFs) transduced with adenoviral bone morphogenetic protein (Ad-BMP7). Micropatterned films 
with pillars containing deeper grooves (30um) provided greater control over hPDL cell orientation 
and subsequent alignment of soft collagenous tissue compared to non-grooved pillars or an 
amorphous PCL film, with significant (p<0.05) differences in percentage of aligned cells in vivo 
observed at 6 weeks post-implantation.  
 In order to improve spatially-controlled delivery of BMP7 and platelet-derived growth 
factor (PDGF-BB) using developed 3D-printed, micropatterned scaffolds, each region of the 
scaffold was separately immobilized with AdBMP7 and AdPDGF-BB, respectively, using 
xiv 
 
 
chemical vapor deposition (CVD)-based surface modification prior to cell seeding. A separate 
scaffold was developed for a rat fenestration defect, with the 3D-printed scaffold region replaced 
by an amorphous PCL film to accommodate the 0.5mm defect thickness. Evaluation of these cell-
seeded scaffolds showed significant (p<0.05) bone formation in regions with immobilized 
AdBMP7 compared to regions immobilized with empty vectors (Ad-empty) and non-cell seeded 
regions immobilized with AdBMP7.  A more detailed assessment of single (BMP7) and dual 
(BMP7 and PDGF-BB) growth factor delivery effects in combination with varying scaffold 
topography (i.e., patterned film versus amorphous film in the “PDL” region) was performed using 
the fenestration defect model. Micro-CT data showed significantly higher (p<0.05) bone formation 
in groups with AdBMP7 immobilization and gingival fibroblast cell seeding compared to groups 
with Ad-empty. Collagen III and periostin expression was higher in groups with dual growth factor 
delivery, with significantly (p<0.05) higher periostin expression in groups combining patterned 
film with single or dual growth factors at week 6. Nanoindentation assessment showed higher 
elastic moduli for regenerated bone and PDL-like tissue regions at bone-PDL interface in patterned 
film groups with dual growth factors (positive control) compared to amorphous films with Ad-
empty at week 9 (p<0.05 and p<0.01, respectively). Positive control group also showed no 
significant differences in bone, PDL-like tissue stiffness at 3 and 9 weeks when compared to native 
tissues. These data indicate improvement in periodontal regeneration when combining scaffold 
micro-topography cues with localized growth factor expression, thereby contributing to 
development of next-generation scaffolds specific to periodontal regenerative medicine. 
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CHAPTER 1 
INTRODUCTION 
The “Scaffold Design and Development” section of this dissertation chapter includes excerpts 
from sections written as a contribution to the following book chapter:  
 
Decker AM, Pilipchuk SP, Araujo-Pires AC, Giannobile WV. Bioengineering of the periodontal 
ligament. In: Kapila SD, Goonewardene M, eds. Interdisciplinary Therapy: Using Contemporary 
Approaches for Complex Cases. Monograph 52, Craniofacial Growth Series, Center for Human 
Growth and Development, The University of Michigan, Ann Arbor, 2016:195-242. 
 
1.1 Problem Statement  
Periodontitis is a leading chronic oral inflammatory disease and primary cause of 
permanent tooth loss estimated to affect 47.2% of adults in the United States, with a prevalence of 
70% for adults aged 65 years and older [1]. Damage to the tooth-supporting apparatus, which 
includes periodontal ligament (PDL) fibers that anchor the tooth root to the alveolar bone, 
subsequently initiates osseous tissue resorption. Multi-tissue morbidity is a significant challenge 
for current clinical periodontal regenerative therapies, which lack predictability in reconstructing 
three dimensionally accurate tissues with physiologic functionality native to the healthy 
periodontium [2, 3]. Tissue engineering strategies have shown the potential to address existing 
deficiencies in clinically-induced periodontal regeneration through combinational approaches 
using biomaterials, growth factors, and cell-based therapy [4, 5]. Recent studies indicate that 
alveolar bone-PDL interface tissue regeneration can be guided using bi- and multi-phasic material 
scaffolds with and without bioactive factors that are developmentally-linked to periodontal tissue 
formation [6–10]. However, few studies have focused on whether precise topographical features 
can influence the physiological and functional properties of regenerated periodontal tissues 
through contact guidance [11, 12], and none have examined this potential affect using a 3-D 
hierarchical multiscale scaffold design. This research is necessary to optimize scaffold constructs 
to serve as guiding platforms for anatomically-native tissue formation that is required to re-
2 
 
 
establish tissue functionality in vivo--thereby justifying further exploration in pre-clinical models 
for translational periodontal regenerative medicine.   
 
1.2 Existing Limitations of Current Clinical Periodontal Regenerative Therapies 
Damage to periodontal tissues resulting from trauma, chronic infection, congenital defects, 
or surgical resection requires clinical intervention. In the oral cavity, the alveolar processes of the 
mandible and maxilla line the tooth sockets and provide structural support and maintenance for 
teeth as part of the periodontium, which also consists of the periodontal ligament (PDL), 
cementum, and gingiva. Advanced periodontal disease alters alveolar bone morphology and 
destroys surrounding tooth-supporting tissues, thereby necessitating tooth extraction. Current 
clinical treatment for periodontal defects consist of re-establishing oral hygiene to stem 
progressive soft tissue and bone loss by controlling inflammation through removal of plaque and 
calculus. Restoration of some periodontal tissues can be achieved through tissue repair, although 
not necessarily regeneration, using surgical procedures, occlusive barrier membranes, and 
osteoconductive biomaterials in combination with recombinant growth factor proteins [13]. An 
autologous graft for alveolar bone restoration is considered the gold standard due to low risk of 
immunogenicity or disease transmission that could be associated with an allograft or xenograft. 
However, critical limitations of this approach include donor site morbidity and inadequate supply 
of graft tissue. An armamentarium of resorbable and non-resorbable commercially-available 
osteoconductive ceramic (i.e., calcium phosphates, bioactive glass) or polymeric (i.e., 
methylmethacrylate, poly-α-hydroxy acids) alloplasts and their composites are used clinically for 
intraoral bone maintenance and augmentation [14, 15], and in conjunction with growth factor 
delivery [4, 16], for dental implant stabilization in tooth extraction sockets. The capacity of bone 
grafts to regenerate intraoral osseous tissues predictably, however, is compromised by factors such 
as variability in defect type and size, growth factor instability, patient health status, and surgical 
technique.  
Even more so than intraoral bone regeneration, the formation of physiologically functional 
PDL which anchors the cementum-coated tooth root to the alveolar bone remains an elusive 
achievement and a major clinical challenge. The PDL consists of vascularized, innervated 
connective tissue with highly organized fibers composed primarily of collagen type I and III. PDL 
fibers are perpendicularly oriented between the cementum and alveolar bone, where their ends 
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(Sharpey's fibers) insert into these mineralized tissues to stabilize the tooth root, transmit occlusal 
forces, and provide sensory function. Presence of bone and cementum is crucial for the formation 
of functional PDL, and regeneration of the full bone-PDL-cementum complex would negate the 
need to extract otherwise healthy teeth with compromised periodontal apparatus. Guided tissue 
regeneration (GTR) is a surgically-based technique using cell-impermeable barrier membranes to 
control the formation of pocket or long junctional epithelium tissue formation in place of PDL 
along the tooth root due to epithelial down-growths that fill periodontal defects. While regenerative 
periodontal surgery with GTR shows considerable reduction in probing pocket depth, radiographic 
evidence of increased bone fill, and clinical attachment gains that are indicative of increased 
collagen fiber attachment to the cemental surface, the overall quality and degree of periodontal 
healing varies widely [2, 17]. For example, GTR may provide space maintenance for tissue repair 
by endogenous progenitor cells, but PDL connective tissue repair may be disorderly or result in 
bone-like tissue in place of periodontal regeneration.  
Periodontal wound healing can also be enhanced through the use of recombinant growth 
factors (GFs) and platelet rich plasma (PRP) which contains concentrated suspensions of 
autologous platelets that secrete bioactive GFs at the wound site. Some commonly-used bioactive 
agents in the clinic are derived from the following GF families: platelet derived growth factors 
(PDGFs), bone morphogenetic proteins (BMPs) within the β-transforming growth factor (β-TGF) 
superfamily, fibroblast growth factors (FGFs), among others. These are necessary biologics which 
regulate periodontal and mesenchymal stem cell migration, differentiation, proliferation, 
chemotaxis, and cell-specific extracellular matrix (ECM) production. Pre-clinical and clinical 
studies have shown time- and dose-dependent GF-induced regeneration of alveolar bone with 
BMP-2, BMP-7, PDGF-BB, and FGF-2 [18–21]; periodontal ligament with PDGF-BB [22]; and 
cementum with BMP-7 [23, 24] . The efficacy of these agents varies depending on delivery system, 
dosages, and release kinetics. Food and Drug Administration (FDA)-approved biologics used for 
periodontal regenerative therapies include rhPDGF-BB in the osteoconductive delivery vehicle β-
tricalcium phosphate (β-TCP) (GEM-21S®) and rhBMP-2 in a collagen sponge (Infuse®). 
However, pharmacologic dosing is often required to mitigate the transient biological activity of 
GFs at local delivery sites due to short half-lives  and proteolytic degradation, although use of 
supra-physiological doses can evoke local and systemic toxicity [25]. Localized GF delivery is 
therefore necessary to decrease total dosage needed without compromising function. Pre-clinical 
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studies using gene therapy indicate that this limitation may be addressed through the transduction 
(using viral elements) or transfection (using non-viral elements) of a target cell population to 
express GF-encoding genes over a period of time necessary to achieve desired therapeutic effects. 
This is supported by multiple studies using gene therapy for periodontal tissue regeneration: 
Sustained and localized PDGF-B gene expression using direct delivery in periodontal lesions was 
observed for up to 21-35 days after cell transduction [26], and has been shown to stimulate alveolar 
bone and cementum regeneration [27, 28], whereas ex vivo BMP-7 gene transfer using dermal 
fibroblast transduction resulted in predictable bridging of periodontal bone defects [29]. Safety 
concerns regarding risk of virus dispersion and lack of spatio-temporal control of gene expression 
limit the predictability of this approach and its translation into clinically-viable solutions, thereby 
requiring the investigation of novel methods of gene delivery. Overall, tissue engineering 
approaches using scaffolds alone or in combination with growth factor, cell and/or gene delivery 
have the potential to address existing challenges in managing periodontal tissue loss and increase 
clinical options for their controllable regeneration. Given the limitations of current periodontal 
regenerative therapies, the main goal of this research work is to design a scaffold-based delivery 
vehicle that can be used for the regeneration of the alveolar bone-PDL-cementum complex in 
conjunction with localized, controlled PDGF-BB and BMP-7 delivery using gene therapy (Figure 
1.1).   
 
 
Figure 1.1 Scaffold Fabrication Techniques Combined with Gene Therapy 
Areas of improvement addressed for current periodontal tissue engineering strategies: increased 
topographical precision of scaffold fabrication (Aim I) combined with spatiotemporally controlled 
gene therapy (Aim II) using the scaffold as a gene delivery vehicle to regenerate periodontal tissues 
in a loaded periosseous defect model (Aim III). Figure modified from [5].  
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1.2 Scaffold Design and Development for Periodontal Regeneration 
A biomaterial scaffold is ideally intended to provide a cell-adhesive, three-dimensional 
microstructural framework for the guidance and support of physiologically functional tissue 
formation—reminiscent of the extracellular matrix (ECM) that provides native “scaffolding” in 
healthy tissue. Several important scaffold development criteria include: (1) biological 
functionality capable of supporting cell infiltration, proliferation, and differentiation, (2) ECM-
mimicking permeable microstructure with porosity to facilitate nutrient and oxygen delivery and 
exchange, (3) rate of degradation consistent with rate of tissue regeneration and remodeling, (4) 
mechanical properties to maintain tissue defect architecture and support applied loads such as 
mastication-induced compressive forces on the periodontal ligament, (5) neovascularization for 
tissue homeostasis and reperfusion, and (6) targeted cell, growth factor, and/or gene delivery for 
enhanced regenerative capacity.  
 
1.2.1 Biological, synthetic materials as scaffolds 
While scaffolds formed from naturally-derived materials including proteins (i.e., collagen, 
fibrin, gelatin, hyaluronic acid) and polysaccharides (i.e., chitosan, alginate) have innate biological 
functionality, their mechanical properties and rates of degradation cannot be as precisely tailored 
as is possible with synthetically-derived materials. Synthetic polymers are used widely in the 
clinic, with members of the polyester family most prevalent due to their proven safety profile, 
biodegradable properties, and biocompatibility. Among these, poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), their co-polymer poly(lactic-co-glycolic acid) (PLGA), and 
polycaprolactone (PCL) have been extensively investigated in pre-clinical studies for PDL 
regeneration.  Additionally, ceramic-based material--most commonly used as bone grafts in 
periodontal regeneration studies--include calcium phosphate (CaP)-derived matrices (i.e., 
tricalcium phosphate (TCP) and hydroxyapatite (HA)) and bioactive glass. Instead of serving as 
scaffolds for directed growth of periodontal ligament, these are mostly employed as barrier 
membranes for guided bone regeneration, and can assist in maintaining the space needed for 
connective tissue growth that may have PDL-like formation [30].  The method of delivering a 
scaffold to the site of defect varies depending on material properties, with naturally-based protein 
scaffolds frequently seen in the form of highly hydrated gels or particulates, whereas synthetic 
materials are more likely to be delivered in solid form [31-33].  
6 
 
 
Among the various candidate scaffolds for periodontal ligament regeneration, biological 
polymers are advantageous given their low cytotoxicity and immunogenicity, including their 
resemblance to an endogenous ECM. Most commonly formed as hydrogels or sponges, these 
polymers and polysaccharides can be used to fill irregular defects and provide a delivery vehicle 
with high cell-seeding efficiency. Hydrogels are typically prepared by chemically or physically 
crosslinking the polymer chains, using chemical crosslinkers or pH-based reactions, respectively 
[34]. Cell-encapsulation within hydrogels prior to transplantation can be used for cell and gene 
delivery into periodontal defects. Collagen scaffolds alone can still facilitate improved periodontal 
tissue formation as compared to a lack of treatment [35], but not to the same extent as with cell-
based and growth factor-based delivery. Jin et al used a collagen matrix to deliver adenoviral 
PDGF-B to the periodontium, stimulating PDL formation and cementogenesis with fiber insertion, 
including vascularization and newly-formed periodontium not observed with collagen matrix 
alone.  Interestingly, the majority of the collagen matrix delivered in combination with PDGF-B 
was resorbed by 2 weeks, with more scaffold remnants present at lesions sites with collagen matrix 
alone [36]. It is likely that the addition of growth factors increases the rate of tissue regrowth and 
invasion into the scaffold, thereby increasing its rate of degradation.  
 
1.2.2 Cell sheet technology as an alternative to biodegradable scaffolds 
Given the importance of biological factor delivery and retention of a viable cell population 
at the site of the defect, cell sheet engineering has emerged as a novel approach for targeted cell 
delivery without the use of biodegradable scaffolds.  Cell sheet monolayers with intact cell-cell 
contacts and ECM can be harvested non-enzymatically using thermo-responsive polymeric surface 
cell culture plates that enable controlled cell adhesion [37]. In vitro cultures of human-derived 
hPDL cell sheets show periostin expression and high alkaline phosphatase activity [38], and 
several studies confirm their potential for PDL regeneration using small and large animal models 
[39]. Despite this scaffold-free approach, the incorporation of supporting synthetic [40] or natural 
membranes [41] can be useful for increased cell sheet stability and ease of transplantation. 
Therefore, the most promising approaches for the regeneration of PDL lie in the design and 
fabrication of scaffolds that can be appropriately suited to the delivery of cells and growth factors 
that will stimulate the regenerative process and allow for the remodeling and growth of tissue that 
is structurally and functionally-similar to native ligament.  
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1.2.3 Micropatterning and Multiphasic Scaffold Design 
The complex hierarchical organization of periodontal tissues has brought into focus the 
need for multi-phasic biomaterial constructs that can recapitulate the structural integrity of the 
bone-ligament interface. Microscale technologies have been indicated for use in fabricating 
scaffolds that facilitate control of multiple tissue organization and positioning, as required for the 
regeneration of an bone-ligament interface [42, 43]. Surface topography on the micro- and nano-
scale (10-100,000 nm) profoundly affects cell behavior, including adhesion, migration, alignment, 
intracellular signaling pathways, and ultimately tissue formation in combination with biochemical 
cues. This phenomenon has been explored using a variety of cell types on a diverse range of 
biomaterial surfaces [44-49]. Although few in number, existing studies that have investigated the 
effect of micropatterned surfaces on PDL cells showed high elongation and alignment relative to 
formed grooves and ridges on polystyrene, silicone rubber, and glass slide surfaces [50]. Among 
microscale technologies, soft lithography is specifically used for micro- and nano-patterning of 
material surfaces and has been widely applied for the study of cell behavior on topographic 
substrates since its transition from microelectronics industry to biologically-based research. It 
provides a methodology for creating 2-D and 3-D curved and ordered structures (> 500 nm) 
including grooves, pillars, wells, and pits, in a variety of materials--an undertaking that is not yet 
possible using current 3-D printing technology that is low-resolution in comparison. The most 
widely employed soft-lithography method is replica molding, which consist of producing an 
elastomeric mold, usually made of polydimethylsiloxane (PDMS), that contains a desired micro-
structure pattern which is replicated on a polymer by filling the mold with the pre-polymer 
solution, curing it, and peeling the polymer off to obtain the patterned surface [51].  
To translate microscale technology into an implant with clinical relevance, it is necessary 
to integrate microscale features into a three-dimensional scaffold that matches a given defect with 
appropriate dimensionality and bulk properties. Such an approach has already been established in 
dentistry with the use of nanoscale surface topology on dental implants to promote 
osseointegration and cell adhesion. However, the exploration of this approach for the guidance and 
regeneration of periodontal tissues is still nascent. Recent studies have focused on the applicability 
of electrospinning and additive manufacturing technology (3-D printing) as predictably 
reproducible methods of fabricating structures with cell-guiding features or controllable internal 
architectures, respectively. While electrospinning can produce linear polymer fibers on the order 
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of 5nm-1um that are structurally similar to ECM, these fibers have poor mechanical properties 
inconsistent with those necessary to mimic bone or ligament structure [52]. Commonly employed 
3-D printing processes for the fabrication of bone scaffolds include fused deposition modeling 
(FDM) and selective laser sintering (SLS). Whereas FDM relies on extrusion to produce simple 
patterned polymeric stacks, SLS allows the processing of powdered biocompatible polymers via a 
focused laser beam that deposits the polymer layer by layer to create a computer-aided design 
(CAD)-based replica, making it useful in combination with medical imaging technology for pre-
operative surgical planning and implant design. Polycaprolactone (PCL)--an FDA-approved, 
hydrolytically-biodegradable polyester used as a bone graft substitute--is easily manufactured into 
a variety of shapes, porosities, and with variable mechanical properties using SLS due to its low 
melting point (59-64°C) [53]. PCL, which degrades over a period of 2-4 years in vivo, has been 
the material of choice in multi-phasic scaffolds developed for the attempted regeneration of the 
periodontium: Park et al. used 3-D printed wax-based molds to cast PCL for the bone compartment 
of an image-based bi-phasic scaffold (6, 7); Costa et al. and Vaquette et al. employed FDM-
deposited PCL for the bone compartment and electrospun PCL for the PDL region (8, 9);  and Lee 
et al. used a layered 3-D printed scaffold with three PCL interphases for the cementum, PDL, and 
alveolar bone (10). Given PCL's malleability and ability to be formed into polymeric matrices of 
various physical and mechanical properties that can be designed to match tissues that are being 
targeted for regeneration, this research focuses on the use of PCL to develop the following bi-
phasic hierarchical scaffold compartments: (1) a 3-D micropatterned PCL surface via replica 
molding that mimics the native dimensions of mature periodontal ligament, (2) a 3-D printed bone 
compartment fabricated via SLS technology.  
 
1.4 Novel Gene Therapy-Based Approaches for Tissue Repair 
Gene therapy has been shown to offer the potential for highly targeted, effective methods 
of growth factor delivery with reduced dosing requirements. However, these methods frequently 
involve use of viral vectors such adenoviruses and retroviruses, causing concerns of systemic 
health effects through virus dispersion and reduced transduction efficiency, thereby limiting their 
clinical translation. Chemical vapor deposition (CVD) has emerged as a viable surface 
modification technique for the bioconjugation of biomaterial surfaces with specific functional 
groups to immobilize viral vectors--allowing localized gene delivery directly from the biomaterial 
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surface [54]. CVD can be used for 2-D and 3-D surface engineering to evenly coat structures with 
complex geometry and porosity while conforming to surface topology. The surface polymerization 
occurs via monomer sublimation, activation, and subsequent deposition, negating the need for 
catalysts, solvents, or plasticizers, which renders the polymer coating cyto-compatible. Poly(p-
xylylene) (PPX) polymers are selected for the CVD process given their biocompatibility and 
ability to accommodate various functional groups in their structure, including amines, aldehydes, 
alcohols, and anhydrates [55]. This technique has been used in conjunction with gene therapy to 
functionalize inert polymer surfaces such as that of PCL to induce spatiotemporal control of gene 
delivery via cell signaling adenoviral gradients for cell growth and transduction [56-58]. Two 
specific adenovirus binding techniques have been utilized to controllably transduce cells: Hu et al 
[56] tethered adenoviral vectors to the surface of aminated PPX-coated PCL using a sequence of 
virus-biotin-avidin-biotin-PCL to spatially control C4 fibroblast cell transduction; Zhang et al [58] 
simplified this technique by using an anti-adenovirus antibody immobilization on CVD-coated 
PCL via an amide chemical bond to transduce bone marrow stromal cells with Runx2 to drive their 
differentiation into an osteogenic lineage in vitro, resulting in 6.5-fold increases in alkaline 
phosphatase (ALP) activity and matrix mineralization. While this approach is promising, it is yet 
to be used in conjunction with growth factor gene delivery. One of the aims of this work was to 
investigate CVD reactive polymer coatings using PCL as a vehicle for the controlled transduction 
of cells with PDGF-B and BMP-7 in the PDL and bone regions, respectively, of the proposed 
biphasic microstructured scaffold. This novel approach allows for better containment of gene 
therapy vectors to the treatment site and could improve the bioavailability of these growth factors 
through increased transduction efficiency of the local cell population.  
 
1.5 Thesis Aims 
 
Current clinical periodontal regenerative therapies are limited by lack of predictable 
periodontal tissue regeneration, with the biggest challenge being lack of physiologically functional 
periodontal ligament tissue formation. Likewise, local delivery of growth factors to stimulate 
biologically-mediated regeneration is frequently compromised by short half-life, limited 
bioactivity, and proteolytic degradation. To address these limitations, this works focused on 
developing a novel PCL-based substrate that incorporates micropatterned topography for the 
guidance of cell growth and periodontal tissue formation, in conjunction with localized, 
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spatiotemporally controlled gene delivery to direct cellular growth factor expression. The potential 
of microscale technology to be used for guided 3-D periodontal tissue regeneration has not been 
examined, and cell guidance of patterned substrates has only been investigated on 2-D surfaces. 
One major challenge has been the incorporation of patterned substrates, which are often thin films 
without any bulk properties, into larger macroscale devices that can be used as implants. Here, this 
limitation is overcome by creating a bi-phasic scaffold, the foundation of which is based on a 3-D 
printed PCL scaffold that supports bone formation. This mimics the size ratio of alveolar bone to 
PDL seen in vivo, where the PDL region is a thin area of vascularized connective tissue that 
anchors the tooth root to the bone. The result of this study advances the area of scaffold fabrication 
and growth factor delivery for ligament-bone interface engineering and achieves a new generation 
of more predictable and controlled matrices for periodontal regenerative medicine.  
 
AIM 1: Design micropatterned polymer films for directed orientation of human 
periodontal ligament (hPDL) cells in a biphasic bone-ligament scaffold and evaluate effect 
of varying film topography on oriented tissue formation in an in vivo model. 
 
Hypothesis 1: Micropatterning of PCL films will provide greater control over hPDL cell 
orientation and subsequent formation of aligned periodontal ligament tissue between the 
alveolar bone-PDL and PDL-dentin interfaces.  
 
AIM 2: Investigate effect of spatially-controlled growth factor delivery on bone-PDL 
tissue complex regeneration in vivo using a biphasic scaffold with surface immobilization 
of growth factors in the PDL and bone regions of the scaffold.  
 
Hypothesis 2: Spatially-controlled delivery of BMP-7 and PDGF-B will facilitate bone and 
PDL tissue formation, respectively, in combination with the architectural and 
topographical cues for cell contact guidance established for each region of the biphasic 
micropatterned PCL scaffold.  
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AIM 3: Design micropatterned scaffolds for, and evaluate in, a mechanically-loaded in 
vivo defect model to determine tissue regeneration in combination with localized, dual 
growth factor delivery.  
 
Hypothesis 3: Biphasic micropatterned scaffolds will enable the formation of periodontal 
tissues under biomechanical loading conditions in vivo and reactive polymer coatings 
formed on regions of the scaffold via CVD will facilitate BMP-7 and PDGF-B gene 
delivery for establishment of physiologically functional periodontium.  
 
1.6 Dissertation Contents 
 
 Chapter 2 of this dissertation provides an in-depth review of currently-used scaffolds for 
bone and periodontal ligament regeneration, in addition to covering the most relevant growth 
factors, with an emphasis on various methods of growth factor delivery based on gene therapy in 
order to provide a broad understanding of the biological factors that promote soft and osseous 
tissue regeneration. Chapter 3 presents the unique design of a 3D-printed scaffold for a single-
patient case study, highlighting the potential of 3D printing as a means of creating customized 
scaffolds that mimic the necessary structural characteristics that can fit a peri-osseous defect. At 
the same time, this chapter also addresses some of the limitations of this approach that inform the 
further improvements in scaffold design and growth factor delivery that are undertaken in research 
presented in Chapters 4 and 5. Specifically, Chapter 4 describes the development of 3D printed, 
micropatterned scaffolds that are shown to promote aligned collagenous tissue formation using an 
ectopic murine model, with particular focus on the identification of scaffold topography that is 
optimal for cellular alignment that leads to tissue alignment. Chapter 5 focuses on the 
improvement of growth factor delivery using the same scaffold system and animal model through 
immobilization of adenoviral vectors that allow for localized growth factor delivery via 
transduction of the seeded cell population. This chapter further describes applying this 
methodology to study the formation of bone in a rat fenestration defect—a mechanically loaded 
site that is more representative of the conditions that are present in a true defect, except for use of 
athymic (T-cell deficient) animals to prevent a cross-species incompatibility response due to the 
presence of human-derived cells. Chapter 6 focuses on a thorough analysis of the effects of dual 
(platelet-derived growth factor (PDGF-BB) and bone morphogenetic protein (BMP7)), as well as 
12 
 
 
single (BMP7 only) growth factor delivery in the scaffold compartments developed to guide the 
regeneration of PDL and alveolar bone, specific to a rat fenestration defect. This study utilizes 
chemical vapor deposition (CVD) in order to allow for the controlled immobilization of adenovirus 
encoding a specific growth factor onto a given region of the scaffold. Chapter 7 offers concluding 
remarks that summarize the findings presented in Chapters 3-6, the novelty of the work, and 
existing limitations. Finally, a look into future applications of this work and its potential for 
promoting regeneration of the periodontium is presented.  
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CHAPTER 2 
 
CURRENT AND PROSPECTIVE CLINICAL TECHNIQUES FOR TISSUE 
ENGINEERING TO PROMOTE BONE AND PERIODONTAL REGENERATION IN 
THE ORAL CAVITY 
 
Originally published as a review article in Dental Materials. Additional description of scaffolds 
for periodontal ligament-specific regeneration are derived from sections written as a contribution 
to a book chapter entitled “Bioengineering of the Periodontal Ligament”: 
 
Pilipchuk SP, Plonka AB, Monje A, Taut AD, Lanis A, Kang B, Giannobile WV. Tissue 
engineering for bone regeneration and osseointegration in the oral cavity. Dent Mater. 
2015;31(4):317-338. 
 
Decker AM, Pilipchuk SP, Araujo-Pires AC, Giannobile WV. Bioengineering of the 
periodontal ligament. In: Kapila SD, Goonewardene M, eds. Interdisciplinary Therapy: 
Using Contemporary Approaches for Complex Cases. Monograph 52, Craniofacial Growth 
Series, Center for Human Growth and Development, The University of Michigan, Ann 
Arbor, 2016:195-242. 
 
 
 
2.1 Introduction  
The alveolar processes of the mandible and maxilla line the alveolus and provide structural 
support and maintenance for teeth as part of the periodontium, consisting of the periodontal 
ligament (PDL), cementum, connective tissue, and gingiva. Alveolar bone is especially susceptible 
to inflammation-induced bone resorption due to high rates of progressive periodontitis—a leading 
chronic oral inflammatory disease estimated to affect 47.2% of adults in the United States, with a 
prevalence of 70% for adults aged 65 years and older [1]. Advanced periodontal disease alters 
alveolar bone morphology and destroys surrounding tooth-supporting tissues, thereby 
necessitating tooth extraction. Since the existence of alveolar bone is mutually connected to the 
dentition and other periodontal tissues, the alveolar ridge continues to resorb following tooth 
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removal even if a dental implant is placed into a fresh extraction socket. Physiologically, this is 
caused by continuous bone remodeling in response to mechanical loading changes that occur with 
alterations in the applied force and strain distribution to the osseous tissue during mastication, as 
stipulated by Wolff's Law [2]. Ridge or socket preservation and augmentation using bone grafting 
materials is a clinically viable approach to maintain any remaining bone following tooth extraction 
and further condition it in preparation for dental implant placement. Sufficient bone volume, 
height, and width are necessary to ensure implant stability and osseointegration that can sustain 
optimal bone-implant contact biomechanical loading. Other dental procedures that involve 
grafting include maxillary sinus floor augmentation, which is employed for patients with bone loss 
in the posterior maxilla that houses premolar and molar teeth [3]. Bone defects in the oral cavity 
resulting from trauma, chronic infection, congenital defects, or surgical resection require clinical 
intervention, most frequently using autologous bone grafting techniques. However, critical 
limitations of this approach include donor site morbidity and inadequate supply of graft tissue. 
Tissue engineering approaches using scaffolds alone or in combination with growth factor, cell 
and/or gene delivery have the potential to address existing challenges in managing bone loss and 
increase clinical options for controllable regeneration of intraoral osseous tissues.  
 
2.2  Scaffolds 
2.2.1  Intraoral bone grafts  
An autologous bone graft is considered the gold standard due to low risk of 
immunogenicity or disease transmission that could be associated with an allograft (genetically 
different donor from the same species) or xenograft (donor from another species). Most 
importantly, bone transplanted from the patient is native to its host environment and readily 
associates with the remnant tissue, providing a pre-established population of viable cells and 
growth factors necessary for osteogenesis. Local sites such as the maxillary tuberosity or 
mandibular symphysis can be used for harvesting of small autologous grafts [4]. Nevertheless, 
there are several key reasons for a critical need of alternative grafts capable of substituting the 
autograft: limited availability of autologous tissue for larger bone defects, donor site morbidity 
and potential wound-based infections, as well as prolonged operative times [5]. Although lacking 
in osteogenicity, allografts and xenografts can be prepared to have osteoconductive and 
osteoinductive properties. Bone allografts are available as fresh/fresh-frozen, freeze-dried, or 
19 
 
 
demineralized and freeze-dried. The mechanical properties of allografts derived from a living 
donor or cadaveric tissue are changed substantially during extensive tissue processing involving 
decellularization, sterilization, and preservation for clinical use [6]. Such tissue treatment removes 
viable cells that are osteogenic and osteoinductive in nature, leaving behind a structurally 
supportive framework primarily composed of minerals and proteins—termed the extracellular 
matrix (ECM).  The allograft ECM serves as a scaffold for osteoblasts originating from the bone 
defect into which the graft is placed to facilitate new bone formation. Depending on the method of 
processing, an allograft can also be osteoinductive if it retains the biological properties necessary 
to recruit mesenchymal stem cells to the site and stimulate their differentiation into osteoprogenitor 
cells.  One example is demineralized bone matrix (DMB), which has reduced levels of calcium 
and phosphorus and is primarily type I collagen, but can be considered osteoinductive if it retains 
factors such as bone morphogenetic proteins (BMPs) and transforming growth factor-β (TGF-β) 
[7]. As expected, DMB shows an increased rate of resorption relative to a mineralized bone graft 
during tissue remodeling in vivo. In addition, derivation of DBM involves grinding of bone to 
obtain particulates as opposed to processing the allograft in its native structural form, making it 
useful for small to moderate defects [8]. 
Xenografts offer another alternative for bone replacement in dental regeneration, with most 
products derived from coral, porcine, or bovine sources. A recent study comparing implant 
placement into sinus floors augmented with  an autologous mandibular bone graft versus a 
commercially-available bovine xenograft found equivalent implant survival rates over an 
observational period of 5 years [9]. However, implant survivability depends on many factors, 
including patient demographics and surgical technique, thereby warranting longer-term 
evaluations and more comprehensive consideration of factors that may influence the clinical 
outcome. Extensive meta-analysis of histomorphometric and bone graft healing time results for 
sinus floor augmentation described in the literature over a period of 16 years concluded that 
autologous bone grafts result in higher total bone volume levels compared to other bone grafting 
materials [10]. Another comprehensive systematic review of treatment modalities used to evaluate 
dental implant survival rates in maxillary sinus grafts employed statistically robust methodology 
to correct for study effects. It concluded that application of grafting membranes for guided bone 
regeneration supplementary to a bone graft was more important for implant survival rate over 
factors such as which bone substitute material was selected for the surgery [11]. These results 
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indicate the difficulty of identifying specific factors that influence final clinical outcomes and 
underline the fact that there is no unified consensus on whether non-patient derived grafts can 
perform at the same level as autografts for not only bone regeneration but also implant performance 
at augmented bone sites. Each case is patient-specific and requires thorough consideration of all 
contributing factors, including the health of the patient's native bone and its suitability for grafting 
procedures. 
 
2.2.2 Natural and synthetic matrices for bone regeneration  
In addition to standard grafting procedures using bone-derived materials, a number of 
natural and synthetic materials have become commercially available for use in oral surgery. 
Scaffolds that are architecturally and/or biologically compatible for bone regeneration are 
frequently based on one or more of the bone's naturally-occurring proteins or minerals, including 
organic (predominantly collagen type I) and inorganic (hydroxyapatite, a calcium phosphate 
mineral) components [12]. Calcium phosphate (CaP) materials are subdivided into ceramics and 
cements, which vary in their rate of in vivo degradation, structure, and mechanical strength. 
Common synthetic CaP bone substitutes include hydroxyapatite (HA) ceramics, β-tricalcium 
phosphate (β-TCP) cements, and biphasic calcium phosphates (BCPs) [13, 14]. Fragility and poor 
fatigue resistance of these ceramics and cements requires their use at non-load bearing bone 
replacement sites or as coatings on load-bearing metal implants for increased bone-to-implant 
contact. Coating a dental implant surface (i.e., titanium, stainless steel, or an cobalt-chrome alloy) 
with CaP-derivatives has been extensively investigated using various surface coating deposition 
techniques to improve implant stability and rate of osseointegration [15, 16]. In addition to 
containing minerals native to osseous tissue, these biomaterials retain an interconnected porous 
architecture--allowing adequate space through increased surface area for bone ingrowth via cell 
infiltration, blood vessel formation, nutrient/oxygen transport, and waste elimination. Ongoing 
studies are being performed to determine the optimum porosity for bone ingrowth and 
corresponding bone substitute resorption rate, since an ideal regenerative scenario would consist 
of a biomaterial resorption rate timed with new osseous tissue ingrowth [17]. Likewise, there are 
ongoing investigations to confirm the utility of using CaP bone substitutes for implant coating. For 
example, recent studies of hydroxyapatite coatings on titanium cups for orthopaedic-based 
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implants such as femoral stems did not show significant differences between HA-coated and non-
coated stems and may not constitute a clinical advantage [18].  
Bioactive glass (BG), a silicon oxide with substituted calcium first developed in the 1960s 
by Professor Larry Hench, is a biocompatible glass-ceramic material approved by the US Food 
and Drug Administration (FDA) for use as a synthetic intraoral bone graft (termed 45S5 
Bioglass®). Upon exposure to aqueous solutions the highly reactive surface converts to a gel layer 
that mineralizes to form a osteoconductive hydroxycarbonate apatite layer that chemically binds 
with osseous tissues [19]. Bioglass® also has a reported reduced modulus of 35 GPa that is similar 
to that of cortical bone (Elongitudinal = ~14-20 GPa) [20, 21]. Comparatively, the elastic moduli of 
HA single crystals and β-TCP are in the range of 54-79 GPa and 120-162 GPa, respectively [22, 
23]. This makes BG an attractive option for metal implant coating, reducing the potential for stress 
shielding and subsequent bone resorption which occurs with decreased bone loading [24]. To date, 
studies using dental implants coated with BGs have not conclusively shown significant increases 
in osseointegration relative to other coatings such as HA [25]. However, novel exploratory 
combinations for dental implant coatings using BG are promising: one example is the 
incorporation of BGs with HA and the polymer poly(lactide-co-glycolide) (PLGA), which 
indicates rapid bone-like apatite formation in vitro, with potential antimicrobial activity on oral 
bacteria [26]. 
Polymeric materials that have been commercialized or are currently under investigation for 
intraoral bone regeneration are either naturally- or synthetically-derived. Natural materials that 
consist of polymeric networks (i.e., collagen, alginate) have been extensively investigated as 
composite materials with other bone replacement grafts, including β-TCP and HA [27]. Major 
advantages of a tissue-sourced polymer such as collagen include its biocompatibility, 
biodegradability, and ability to readily bind growth factors critical for osteoinduction, including 
BMPs. Currently, collagen is the most commercially-available natural polymer on the market for 
use in periodontal bone regeneration as a sponge, membrane, or in particulate form combined with 
other bone grafts [28]. It is expected that future research will continue to focus on the development 
of a more diverse array of naturally-derived, fully-resorbable polymeric bone grafts combined with 
non-immunogenic materials such as alginate and chitosan that can be engineered for growth factor, 
cell, and/or gene delivery. Such delivery devices may also include synthetically-derived resorbable 
materials whose physical, mechanical, and degradation properties can be more easily controlled 
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via polymer chemical composition and molecular weight. Historically, oral surgery has utilized 
non-resorbable synthetic membranes as cell-occlusive barriers for guided bone regeneration, 
among which the most broadly used material has been expanded polytetrafluoroethylene (ePTFE) 
[29]. Unnecessary patient discomfort and added cost of a follow-up visit to remove the membrane 
has increased demand for resorbable alternatives. Examples of widely-investigated resorbable 
polymers for applications in bone regeneration include poly-α-hydroxy esters such as polyglycolic 
acid (PGA), polylactic acid (PLA), and PLGA. The ease of processing synthetic materials enables 
their fabrication into a variety of structurally-diverse forms, including thin films, meshes, fibers, 
and porous foams. An existing disadvantage of these materials is their bulk erosion in vivo due to 
hydrolysis that can induce foreign body reactions to acidic polymer degradation products, 
increasing the potential for fibrous tissue encapsulation during wound healing. Although studies 
of PLGA utility for guided bone regeneration are still limited, there is evidence that its use as a 
barrier membrane results in alveolar bone regeneration that is on par with that observed using a 
collagen-based membrane [30]. Other copolymer combinations that yield useful properties for 
osseous tissue regeneration include PLGA with poly(ethylene glycol) (PEG), a widely used 
biocompatible hydrophilic drug delivery carrier. PEG-PLGA thermo-sensitive copolymers can be 
encapsulated with osteoinductive factors and polymerized into a gel-like structure for delivery into 
an osseous defect, possibly in combination with other mechanically durable bone grafts [31]. PCL 
is another biodegradable polymer with significant research indicating its suitability for bone 
regeneration. An inert material, it shows increased osteoblast adhesion, spreading, and 
proliferation when coated with CaP or HA [32], and multiple studies have indicated PCL's 
potential to promote alveolar bone formation in periodontal defects [33, 34]. With greater emphasis 
placed on materials that can be used for exogenous factor delivery to accelerate and improve 
existing periodontal tissue defect treatments, polymers such as PCL and PEG which are already 
FDA-approved as drug delivery devices are expected to be more extensively investigated in pre-
clinical models of intraoral bone regeneration in the coming years.  
 
2.2.2 Natural and synthetic matrices for periodontal ligament regeneration  
The presence of antimicrobial properties and anti-inflammatory effects of naturally-
occurring materials such as chitosan also make them applicable matrices and periodontal ligament 
(PDL) cell-carriers for periodontal tissue regeneration [35]. Composite collage/chitosan scaffolds 
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can be formed for mechanical reinforcement, and have shown increased human PDL cell adhesion 
and growth compared to collagen or chitosan alone. Composite scaffolds increased the retention 
of water, contributing to an increase in pore size and thereby the total internal surface area available 
for PDL cell invasion [36].  To prolong the residence time of scaffolds in vivo for complete tissue 
growth and remodeling, increased stiffness and a decreased rate of degradation of natural matrices 
is preferable, and can be accomplished through their integration with synthetic polymers.   
Synthetic biodegradable polymers such as PLGA and PCL are used clinically in drug 
delivery systems, surgical sutures, and orthopedic fixation devices. These hydrolytically 
degradable materials undergo cleavage of polymer chains to oligomers and monomers, producing 
lower molecular weight molecules in the process [37]. As with naturally-derived matrices, these 
polymers are most applicable for periodontal regeneration when used in combination with cell and 
growth factor delivery [38, 39], as the material itself has little biological functionality, although it 
can be improved with the application of protein coatings. However, one of the key advantages of 
synthetic polymers includes their ability to be formed and processed in a variety of ways to yield 
highly aligned structures that can be achieved using electrospinning--a technology allows for the 
formation of long, thin fibers on the nano and micron scale. This technique offers potential for 
controlled fiber orientation that can be used to influence cell behavior through structural and 
physical cues that mimic ECM architecture, and allows control over a variety of parameters that 
determine fiber dimension, density, and porosity [40]. Chen et al used electrospun PLGA/gelatin 
sheets that were applied at tooth extraction sites in combination with dentin matrix, resulting in 
the formation of PDL-like tissues [41]. 
Typically, poly-α-hydroxy acids such as PLGA result in an inflammatory reaction 
involving multinucleated cells. Rates of degradation vary depending on the molecular weight and 
copolymer ratios of PLGA, allowing it to be more easily tailored to the expected rate of tissue re-
growth at the defect site. After treatment of critical-size supra-alveolar periodontal defects in dogs 
with rhGDF-5-coated β-TCP/PLGA scaffolds, Kwon et al observed limited residual rhGDF-5/β-
TCP/PLGA in two of five sites at 8 weeks, with higher residual amounts present in four of five 
sites with β-TCP/PLGA only [42]. Given that residual material may obstruct periodontal tissue 
regeneration, it has been noted with synthetic materials as much as with natural materials that 
incorporation of growth factors increases the rate of carrier remodeling. In fact, Koo et al also 
noted this using a ceramic-based calcium carbonate carrier with TGF-β in a critical-size, supra-
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alveolar periodontal defect: the growth factor was found to accelerate the degradation of the carrier 
relative to calcium carbonate without TGF-β [43].   
 
2.3 Engineering Scaffolds for Intraoral Bone Regeneration  
The development of scaffolds that are optimal for regeneration of osseous tissues requires 
a design strategy which adheres to established knowledge of the mechanical, chemical, structural, 
and biological properties of natural bone that make it a functional entity. Therefore, key 
considerations in such scaffold design include: (1) biocompatibility/non-toxic degradation; (2) 
bioactivity, enabling cell interaction with material surface; (3) maintenance of a 3-D shape after 
implantation; (4) adequate porosity and pore diameter/distribution/orientation; (5) mechanical 
properties similar to tissue targeted for regeneration (i.e., Young's modulus); (6) degradation 
mechanics (i.e., bulk erosion, surface erosion); (7) degradation rate, ideally matching the rate of 
tissue regeneration; and (8) osteoconductive/inductive and angiogenic factors to influence 
infiltrating cell populations and promote blood vessel invasion [44, 45].  
While a broad range of instructive carrier materials in various forms have been investigated 
for bone regeneration, the addition of cells and application of growth factor delivery strategies can 
significantly influence the regenerative outcome by engineering the environment that closely 
matches that of the target tissue in its native state (see Figure 1). Current strategies include the use 
of bone-marrow stromal cells and stem cell varieties including mesenchymal (MSCs), adipose-
derived (ADSCs) and induced pluripotent (iPSCs). Analyses of cell-specific markers and 
transcription factors such as Runx2, alkaline phosphatase (ALP), osteocalcin, osteopontin, and 
osteonectin allow for the determination of osteogenicity during stem cell differentiation into bone-
derived cells [46]. Clinically-applicable cell therapy is focused on the use of patient-derived stem 
cells that are undifferentiated, given that terminally-differentiated cells are difficult to expand ex 
vivo relative to more highly proliferative stem/progenitor cells. Likewise, the use of stem cells 
allows for a more completely physiological repair process that involves the differentiation of 
MSCs or iPSCs not only into bone-derived cells but also cell types involved in neovascularization, 
such as endothelial cells. However, despite significant progress and tremendous potential in cell 
therapy, critical challenges remain in transitioning the use of iPSCs into clinically-applicable 
approaches. Since the creation of iPSCs involves the reprogramming of somatic cells via 
transcription factors to produce cells with embryonic stem cell-like properties, there is risk of 
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epigenetic and genetic defect accumulations, immunogenic responses, or tumor formations. While 
the immunogenic response can be mediated through use of a patient’s native somatic cells, 
overexpression of transcription factors or presence of partially-reprogrammed iPSCs are known to 
cause teratoma formation, requiring significant efforts to address these safety concerns prior to the 
consideration of iPSCs for patient-based treatments [47].  
 
 
 
Figure 2.1 Scaffold Material Selection, Cell Therapy, And Growth Factor Delivery 
A combination of various approaches in scaffold material selection, cell therapy, and growth factor 
delivery is required to achieve optimal tissue regeneration that mimics the mechanical, chemical, 
structural, and biological properties of natural bone that make it a physiologically functional entity. 
Abbreviations: [Scaffolds] Polyglycolic acid (PGA), polylactic acid (PLA), poly(lactic-co-glycolic 
acid) (PLGA), poly(ethylene glycol) (PEG), hydroxyapatite (HA), β-tricalcium phosphate (β-
TCP); [Cell Therapy] Osterix (Osx), alkaline phosphatase (ALP), osteoprotegerin (OPG), bone 
sialoprotein (BSP); [Growth Factors] bone morphogenetic protein (BMP), transforming growth 
factor-beta (TGF-β), insulin-like growth factor (IGF), fibroblast growth factor (FGF), platelet-
derived growth factor (PDGF), vascular endothelial growth factor (VEGF).  
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With advancements in cell therapy, there has been a simultaneous increase in novel 
scaffold fabrication techniques that emphasize greater control over surface topography, internal 
microstructure, and pore interconnectivity. Traditionally, porous scaffolds have been widely 
explored as bone graft substitutes for cell attachment given the importance of allowing adequate 
room for tissue ingrowth and vascularization (i.e., pore size of 150-500 µm) [48]. While natural 
materials retain their bioactivity, synthetic non-immunogenic materials have several advantages 
for development of clinically-translatable scaffolds, including added flexibility in manufacturing, 
reproducibility, sterilization, and storage times. Electrospinning and solid freeform fabrication 
(SFF) are two scaffold fabrication techniques which allow increased control over scaffold 
morphology: Electrospinning is a polymer-processing technique used for creating polymer fibers  
on the nano and micron scale to influence cell behavior through structural and physical cues that 
mimic ECM architecture. In addition to allowing control over a variety of parameters that 
determine fiber dimension, density, and porosity, electrospinning can readily be used for mass 
production of fiber-based scaffolds [49]. More recently, 3-D printing technology has been adapted 
for use in bone tissue engineering via solid freeform fabrication (SFF), a rapid prototyping 
technique. This process consists of developing a computer-aided design (CAD) file that specifies 
the exact dimensional features of the desired scaffold which is then transferred to a 3-D printer 
that reproduces the file to yield a printed version of the design with structural integrity. Selective 
laser sintering (SLS) is an example of a process that creates objects layer-by-layer using polymeric, 
ceramic, or metal powders that the machine sinters. During sintering, the powder is heated below 
the melting point, causing its particle boundaries to fuse together at locations dictated by the CAD-
based file. When creating a porous material, the sizes and characteristics of the individual pores 
within the material are limited by the machine's resolution and ability to support a specific printing 
material [50]. Studies using SLS for bone regeneration have focused on PCL-based printed 
scaffolds, showing that these are mechanically-appropriate to support bone tissue formation and 
can be used as BMP-7 and BMP-2 growth factor carriers following biofunctionalization [51, 52]. 
This technology is especially applicable for clinically-based studies given that patient-specific 
anatomical bone defects can be obtained using computed tomography (CT) scans and reproduced 
to yield a scaffold with appropriate structural dimensions. A recent publication by Park et al 
proposes a potential future application of image-based PCL SFF-based scaffolds for clinical 
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periodontal regeneration (see Figure 2), indicating that further pre-clinical investigation and 
verification of these technologies will bring them closer to translation into clinical practice [53].  
 
Figure 2.2 Formation of SFF-based Scaffolds for Clinical Application 
 Solid free-form fabrication (SFF), or rapid prototyping, is emerging as a clinically-viable 
approach for tissue engineering of anatomically precise scaffolds for periodontal, including 
intraoral bone, regeneration. This method is based on obtaining a CT scan of the patient-specific 
defect, generating a CAD-based file of a scaffold with an appropriate fit to the defect, and 3-D 
printing the final version to obtain a polymer-based scaffold with structural integrity that can be 
used as a cell therapy and growth factor delivery platform to enhance the regenerative process. 
Reproduced with permission from Park CH et al [52]. 
 
While novel methods of scaffold development and cell therapy are being explored for bone 
regeneration, there is already an established array of clinically-applicable therapeutic factors and 
delivery strategies. In order to better understand existing clinical applications and the nature of 
ongoing pre-clinical studies, the remainder of this review focuses on the areas of growth factor 
delivery for oral bone regeneration and highlights some of the key studies that have moved 
previously experimental therapies into today's mainstream clinical applications in periodontal 
regeneration.  
 
2.4 Growth Factors and Protein Delivery 
 Growth factor delivery (GFD) is of critical importance in mediating the scaffold 
environment and subsequent cellular response. Growth factors are soluble polypeptides that bind 
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to cell membrane receptors and influence cellular function, and the inclusion of 
osteoinductive/conductive factors (BMP, TGF-β, IGF, FGF-2, PDGF) guides the cell 
differentiation and tissue formation process in bone regenerative therapies. Likewise, 
vascularization is vital for the sustainability of newly-formed tissue, and necessitates the inclusion 
of GFs with angiogenic properties (PDGF, VEGF, FGF-2, and TGF-β). Scaffold-based GFD as 
opposed to bolus injection of the therapeutic factors into the defect site has several advantages, 
including the potential for improved control over GF release kinetics and localization. A major 
challenge in GFD involves the need for release profiles that mimic those present during natural 
tissue repair or morphogenesis. Sequential or simultaneous spatiotemporal delivery of multiple 
GFs can be achieved using scaffolds based on the therapeutic time window during which GF 
delivery is optimal for tissue regeneration, and can involve the combination of factors involved in 
both tissue formation and angiogenesis. For example, sequential delivery of GF combinations 
consisting of BMP-2 and TGF-β or VEGF and BMP showed increased bone formation when 
compared to single GFD [54, 55]. GF rate of release is governed by how it is bound to the scaffold, 
which can involve (1) mixing the GF with scaffold particles, (2) physical encapsulation within the 
scaffold, (3) chemical immobilization, and (4) affinity-based binding. Current clinical application 
of GFs for bone regeneration typically involves the use of biomaterial carriers, yet the factor is 
usually mixed in and physically adsorbed onto the graft particles and lacks more sophisticated 
modes of delivery that would enable spatiotemporal control over release kinetics or dual GFD. 
Other modes of delivery currently investigated in pre-clinical studies are promising: Physical 
encapsulation of GFs within the scaffold, for example, can be achieved using polymeric 
microparticles (1-100µm) with varying surface areas through which the encapsulated GF diffuses 
at a rate that is dependent on carrier particle size, with a larger size leading to slower diffusion. 
GFs can also be conjugated on the scaffold surface via covalent immobilization, while heparin-
binding GFs such as BMP-2 can be presented using affinity-based binding by conjugating heparin 
to biomaterials [56, 57]. These modes of GFD have potential for future applications in clinical 
studies, allowing for a broad range of release profiles and controlled spatiotemporal presentation 
of multiple GFs using carriers that serve as temporary support structures for osseous tissue 
engineering strategies.  
Growth factors and proteins act locally on the activity of periodontal cell populations to 
modulate bone formation and enhance the regenerative response (see Table A1.1 in Appendix). A 
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diverse range of bone matrix-based proteins have been isolated and are delivered alone or in 
combination with a synthetically- or naturally-derived bone graft. An overview of some of the 
factors and proteins that are featured most prominently in oral-based surgery or currently being 
investigated in pre-clinical (see Table A1.2 in Appendix) and clinical studies (see Table A1.3 in 
Appendix) is presented. 
 
2.5  Pre-clinical Studies using Growth Factor and Protein Delivery  
2.5.1 Platelet-derived growth factor (PDGF)  
PDGF's primary role is the promotion of soft-tissue healing. It was introduced to improve 
healing of diabetic ulcers, and was later approved for periodontal regeneration [58, 59]. In vitro 
studies show that PDGF stimulates cell populations key for periodontal regeneration, increasing 
cementoblast DNA synthesis and regulating osteopontin expression [60]. PDGF stimulates PDL 
cell chemotaxis and mitosis, and has synergistic proliferative effects when combined with 
allografts [61, 62]. PDL cells may modulate bone formation by increasing osteoblast proliferation 
and blocking osteoblast differentiation and expression of the mineralized tissue markers 
osteopontin and osteonectin [63-65]. In canine and primate models, application of PDGF, often 
combined with insulin-like growth factor (IGF), to periodontal defects resulted in increased bone, 
cementum, and PDL formation [66-72]. In a canine class III furcation defect model, guided tissue 
regeneration (GTR) with PDGF-BB and ePTFE membranes stimulated PDL formation in early 
stages followed by total periodontal regeneration [73]. PDGF/IGF-1 for guided bone regeneration 
(GBR) at implants placed into extraction sockets showed increased early (3-week) histologic and 
clinical bone formation [66, 74, 75]. When combined with xenograft, PDGF at immediate implants 
in canines resulted in enhanced radiographic bone gain when used without a collagen membrane 
[76]. PDGF also enhanced lateral GBR in dogs when used with a collagen membrane and xenograft 
or alloplastic graft material. In another canine model testing for vertical ridge augmentation, PDGF 
in a xenogeneic block graft showed increased histologic bone gain when used without a collagen 
membrane [77, 78]. 
 
2.5.2  Bone morphogenetic proteins 
BMPs are members of the transforming growth factor-beta (TGF-β) superfamily and have 
strong osteoinductive properties, especially BMP-2, -4, -6, -7, and -9 [79, 80]. BMP-2 and BMP-
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7 stimulate PDL cell differentiation into osteoblasts and increase expression of mineralized tissue 
markers when combined with PDL cells or osteoblasts in vitro, although doses greater than 10 
ng/mL may be toxic to cells [81-85]. BMPs have also been shown to down-regulate proliferation 
and mineralization of cementoblasts and gingival fibroblasts. They are used primarily to enhance 
bone formation for implant site development. When applied to periodontal intrabony defects, 
BMPs showed enhanced speed and quantity of bone formation but limited cementogenesis, 
complicated by ankylosis and root resorption [86-92]. Commercially, rhBMP-2 is approved for 
extraction socket and sinus augmentation. In rat extraction sockets, BMP-2 was shown to increase 
the speed and quantity of bone formation via its osteoinductive effects [93]. In sinus augmentation 
models in various species, BMP-2 consistently improved histologic and radiographic bone gain 
[94-98] and there are indications that it may provide significant vertical and horizontal ridge 
augmentation. Delivery of BMP-2 via grafting materials may modulate its effects on bone 
formation, contour, and quality [99-103]. Possible complications of BMP-2 delivery shown in 
canine ridge augmentation models include increased incidence of seromas and wound failure 
[100]. When compared to BMP-2, BMP-4 has been shown to have comparable effects on bone 
gain and improved bone quality in a rat ridge augmentation model [99]. BMP-7, also known as 
osteogenic protein-1 (OP-1), has similar applications as BMP-2 [104-110]. BMPs may be suitable 
for periodontal regeneration as demonstrated in canine class III furcations and its modulatory 
effects on cementoblast mineralization in vitro [104, 111]. 
 
2.5.3  Fibroblast growth factor-2 
FGF-2 was initially found to stimulate proliferation of bovine fibroblasts. It has effects in 
soft tissues by inducing proliferation of gingival epithelial cells, gingival and connective tissue 
fibroblasts, and PDL cells [112-116].  Interestingly, FGF-2 inhibits mineralization and ALP 
expression by PDL cells but allows them to maintain their differentiation potential and express 
bone regulatory compound osteopontin [113, 117]. These features, coupled with its strong 
angiogenic potential, may allow FGF-2 to promote an environment favoring periodontal 
regeneration [113, 118]. FGF-2 applied topically has been studied in primate and canine class II 
furcation defect models, where it significantly increased regeneration of PDL, cementum, and bone 
without adverse effects [115, 119]. GTR with FGF-2 and a collagen membrane resulted in more 
defect fill in dog class III furcations versus control groups [120].  
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2.5.4 Growth/differentiation factor-5  
Like BMPs, GDF-5 is another member of the TFG-β superfamily and shares a similar 
structure [121]. It stimulates PDL cell proliferation, early osteoblast differentiation, and 
extracellular matrix synthesis by both cell types [122, 123]. It has been shown to significantly 
increase periodontal regeneration in canines and primates with a β-TCP carrier [124, 125]. Various 
other carriers tested in dog periodontal regeneration showed a primarily positive effect [126, 127]. 
In implants, GBR with GDF-5/β-TCP carrier showed increased peri-implant bone, while GDF-5 
coated implants had increased stability determined by pull-out test in rabbits [128]. GDF-5 has 
also been used in mini-pig sinus augmentation, where it enhanced bone formation with a β-TCP 
carrier [129, 130]. In lateral ridge augmentation with a coated Bio-Oss® block, GDF-5 resulted in 
increased mineralized tissue formation [131]. 
 
2.5.5  Teriparatide 
The osteoporosis medication teriparatide consists of parathyroid hormone’s first 34 amino 
acids. In vitro and depending on cell state, teriparatide influences PDL cell survival and causes 
osteoblast-like behavior with increased osteoprotegerin expression [132, 133]. It has been tested 
in rats with induced osteoporosis, where it caused increased bone mineralization and formation in 
extraction sockets and prevented periodontal bone loss [134, 135]. In canine GBR, teriparatide 
improved bone formation around implants [136, 137]. 
 
2.6  Clinical Applications of Growth Factor and Protein Delivery  
Periodontal regenerative therapies focus on bone regeneration to provide implant site 
development. Guided bone/tissue regeneration is the most well-documented technique for targeted 
bone regeneration and is designed to exclude undesired cells using barrier membranes [138] . 
Under certain circumstances (i.e., defect shape and size) both procedures have shown high 
predictability; nonetheless, due to the non-osteogenic characteristics of available biomaterials 
(xeno-/allo-geneic), some shortcomings have arisen for challenging situations (i.e., vertical bone 
augmentation). The application of growth factor and protein delivery might overcome these 
limitations by inducing the proliferation of MSCs to achieve bone formation [139, 140]. Indeed, 
this approach has shown very promising results from countless pre-clinical studies [141, 142] (see 
Table A1.3 in Appendix), which has aroused enthusiasm among clinicians.  
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Within osseous regeneration, PDGF-BB has been tested for infrabony defects and alveolar 
bone regeneration. Recently, a multicenter randomized double-masked clinical trial aimed to 
evaluate the long-term stability of periodontal defects in patients with localized severe 
periodontitis filled with rhPDGF-BB in a β-TCP scaffold vs. scaffold alone. Results from this 
study showed that the use of PDGF-BB (0.3 mg/mL) after a 36-month follow-up achieved 87% of 
bone gain compared to the control group (53.8%). It was also found that, albeit not reaching 
statistical difference, the steady increase of clinical attachment level and linear bone gain suggest 
the long-term stability when using this growth factor [143]. These findings were in agreement with 
results obtained by Jayakumar et al. in a shorter follow-up clinical trial [144]. These demonstrated 
that after 6 months, a significant increase in bone fill (65.6%) was achieved when using 0.3 mg/mL 
of PDGF-BB vs. β- TCP alone (47.5%) [59]. Nevins et al. also reported that the use of PDGF-BB 
in combination with demineralized freeze-dried allogeneic bone graft is capable of attaining 
complete regeneration of the attachment apparatus for infrabony and Class II furcation defects 
[145]. Therefore, PDGF-BB seems to promote periodontal regeneration in a safe and effective 
manner. However, the available data is still limited to draw clear conclusions about its potential. 
Likewise, PDGF-BB has also been recently used for increasing the predictability of alveolar bone 
regeneration. Nevins et al. evaluated the effect of PDGF-BB compared with enamel matrix 
derivative (EMD) and two other grafting materials upon newly formed bone in socket regeneration 
[146]. Due to the small sample size and weak defect standardization it was not possible to draw a 
clear line between groups; nevertheless, ridge morphology for implant placement was more 
convenient for the PDGF-BB group. More recently, the same group [147] studied in a case-series 
the effect of PDGF-BB in combination with equine/bovine grafting materials on bone regeneration 
of large extraction site defects. Histologic results revealed new bone formation in association with 
remaining graft particles and no evidence of inflammatory cell infiltration. Accordingly, 
horizontal/vertical alveolar bone augmentation might become a more predictable technique with 
the use of PDGF-BB.  
In 2007, rhBMP-2 was approved by FDA as an alternative to autologous bone grafting in 
alveolar ridge augmentation and sinus elevation procedures [148] due to its osteoinductive 
potential [149]. Results obtained for sinus augmentation indicate that when compared to 
autogenous bone, no differences can be observed by means of vertical bone gain and density [150]. 
Nonetheless, if rhBMP-2 is grafted with autologous bone it seems to increase cell activity, osteoid 
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lines and vascular supply [151,153]. Contrasting these findings, Kao et al. showed that when 
rhBMP-2 was blended with bovine-derived xenogeneic graft, less bone formation was found. 
Authors claimed that this may be due to the enhancement of osteoclast differentiation by the 
adjustment of RANKL, a protein involved in bone remodeling and regeneration [154]. 
Additionally, the safety of the growth factor was demonstrated by lack of an immune response in 
any of the studies [150-152]. Therefore, agreement was found between human clinical trials and 
preclinical studies [153]. However, more clinical studies need to be conducted focusing on the 
effect of the carrier and dose-dependent responses [154]. Other findings indicate that rhBMP-2 
preserves alveolar ridge heights while also increasing their horizontal dimensions [155-157]. 
Fiorellini et al. noted the dose-dependence of the protein, showing that a 1.5 mg/mL dose was 
more optimal than 0.75 mg/mL. Nevertheless, it is worthy to note that although overall safety of 
rhBMP-2 was demonstrated, moderate signs of local inflammation were present, which may be a 
trigger for an impaired healing process.  
BMP-7 has been predominantly studied for sinus augmentation. Using a small sample size 
case study, Corinaldesi et al. compared the use of rhBMP-7 with deproteinized bone (0.5g) vs. 
deproteinized bone alone (2g). Although there were no observed differences by means of bone 
gain, newly formed bone was statistically greater for the control group (19.9% vs. 6.6%) 4 months 
after grafting [158].  
Another recently studied growth factor is GDF-5, which has been used for periodontal 
regeneration, alveolar bone and sinus augmentation procedures. A pilot randomized clinical trial 
was conducted to study the effect of GDF-5 embedded in β-TCP for infrabony periodontal defects 
of chronic periodontitis patients. Six months after therapy the clinical attachment gain for the test 
group was almost double compared to the level gained in the control group (3.4mm vs. 1.7mm), 
although this was not statistically significant [159]. To date, only one study has appraised the use 
of rhGDF-5 for sinus augmentation: Koch et al. found that at 4 months GDF-5 behaved similarly 
to an autologous graft in terms of bone formation (28% vs. 32%) [160]. Notably, larger bone 
augmentation occurred in the composite group of GDF-5 combined with β-TCP regardless of the 
time point assessed.  
After being evaluated in pre-clinical model and showing its effectiveness in regenerating 
periodontal defects, FGF-2 has also been tested for human use due to its robust angiogenic and 
mitogeneic potential [119]. Kitamura et al. showed in a Phase 2B multicenter randomized clinical 
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trial that at 36 weeks after periodontal surgical therapy, bone fill was 35% greater when used with 
0.3% FGF-2 compared to the carrier alone [161]. An insignificant increase occurred from 36 up to 
72 weeks, which may be explained by different patterns of healing (regeneration vs. long-
junctional epithelium).  
Currently, teriparatide is being investigated for craniofacial regeneration [161]. One 
clinical trial assessing its effect on periodontal regeneration in moderate to severe chronic 
periodontitis patients showed that the adjuvant of teriparatide administration combined with 
vitamin D daily with periodontal surgery had a favorable influence on attachment levels and bone 
repair. In addition, it is worthy to mention that improvements were correlated with baseline levels 
of 1.25 dihydroxyvitamin D3 (better results with baseline levels >20ng/dL) [163]. The use of 
teriparatide might increase the reliability in cases of poor bone density. Kuchler et al. conducted a 
randomized controlled feasibility study to appraise the effect of 20 μg of teriparatide daily during 
28 days on mandibular dental implants, finding that after a healing period of 9 weeks, new bone-
volume-per-tissue-volume for the teriparatide group was 17.6% and 15.4% for the control group. 
In addition, it was shown that bone-to-implant contact was shown to be higher in the periosteal 
and medullary compartment for the test group, but not for the cortical compartment (5% vs. 4.4%, 
respectively) [164]. Based on these findings, the safety and efficacy of several growth factors have 
been documented, but more clinical trials are necessary to validate these preliminary studies.  
 
2.7 Cell and Gene Delivery  
To enhance the therapeutic potential of growth factor delivery, gene therapy has emerged 
as a method of establishing sustained growth factor expression through the transduction of cell 
populations via viral and non-viral delivery mechanisms that alter gene expression. Currently 
investigated methods of vector delivery for intraoral bone regeneration and existing pre-clinical 
studies of their success are addressed below: 
 
2.7.1  Methods of Gene Delivery 
2.7.1.1 Therapeutic viral gene delivery  
Targeted gene delivery can be achieved using viral vectors engineered to infect cells with 
genetic material that will compensate for defective gene(s) or produce a beneficial protein product, 
without causing disease.  This highly effective cellular uptake and favorable intracellular 
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trafficking abilities make recombinant viral vectors suitable for both in vivo and ex vivo 
application.  Gene expression following transfection is generally efficacious and long-lasting, 
ranging from several weeks to months depending on the vector type and target tissue [165].  
Furthermore, the genetic material can either be integrated into the host chromosome or transported 
into the nuclei of infected cells without chromosomal integration. 
Recombinant viral vectors include adenovirus, adeno-associated virus (AAV), and 
retrovirus, among others.  Adenoviruses are large, double-stranded DNA viruses that infect non-
dividing cells without integrating into the host chromosome, resulting in relatively short-term gene 
expression.  AAVs are ssDNA viruses with a similar biological profile as adenoviruses, but with 
the primary added benefit of integration competence.  Although AAVs have a broad tropism, they 
require adenovirus co-infection for replication cycle completion.  In contrast, lentiviruses – part of 
the retrovirus family – will infect both dividing and non-diving cells to provide stable gene 
expression by integrating into the host genome.   
Each of the recombinant viral vectors has its advantages and disadvantages (see Table 4).  
Risks for potential immunogenicity and insertional mutagenesis continue to raise safety concerns 
with some recombinant viral vectors, which will be circumvented through an improved 
understanding of our immune response and the viruses themselves.  
 
2.7.1.2  Therapeutic non-viral gene delivery  
Non-viral methods rely on the combination of nucleic acids with synthetic or natural 
vectors, as well as physical forces to deliver genetic information to a target cell population [166].  
In general, non-viral gene delivery can be utilized to introduce new genetic material or down-
regulate the expression of abnormal genes at the mRNA level.  Compounds such as cationic lipids 
and polymers form condensed complexes with negatively charged nucleic acids to protect and 
facilitate their cellular uptake and intracellular transport.  Additionally, physical forces,  
including but not limited to electroporation, form transient defects in the plasma and nuclear 
membranes to further facilitate the transport of genes into the nucleus.  Major advantages of non-
viral gene delivery include delivery of significantly larger fragments of genetic information and 
lack of a risk for immunogenicity and infection [167-169].  Further research is required to improve 
the variability of gene expression and specificity of the cell types being transfected using non-viral 
methods for gene delivery. 
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Table 2.1 Viral and non-viral vectors utilized in tissue engineering [168]. 
2.8  Safety and Regulatory Considerations of Cell and Gene Therapy  
The translation of cell- and gene-based therapies to the clinic is intrinsically linked with 
reducing or eliminating significant risks associated with the treatment to the patient and improving 
the clinical outcome. Regulatory policies established by the FDA stipulate that the safety and 
efficacy of a given treatment must be verified prior to its approval for clinical use. In addition to 
the safety issues associated with processing cells ex vivo, other considerations involve the selected 
cell source, handling and expansion protocols, including best practices for maintaining cells during 
transportation, scaffold seeding, and transplantation [170]. While the current safety profile of 
iPSCs still presents significant barriers to clinical translation, cell-based therapy using MSCs has 
successfully been applied for treatment of degenerative diseases and investigated as a potential 
 
Vector Type Advantages Disadvantages  Pre Clinical 
Studies 
Adenovirus viral High transduction 
rate; transfection of 
wide range of cell 
types 
High immunogenic 
potential; transient gene 
expression  
[168, 203, 204] 
Chang et al.[169];  
Jin et al. [171] 
Lentivirus viral Non-immunogenic; 
sustained gene 
expression 
Risk for insertional 
mutagenesis; transduction 
limited to dividing cells 
[168, 203, 204] 
Xiang et al. [174],  
Logan et al.[175] 
Adeno-
associated 
virus 
viral Little/no 
immunogenicity; 
transduction in both 
dividing and non-
dividing cells; 
sustained gene 
expression 
Accommodates only very 
small size transgenes; 
production of high titers is 
difficult 
 [168, 203, 204] 
 
Cirelli et al. [172];  
Warrington et al.[173] 
Plasmid non-
viral 
Non-immunogenic; 
transfection of wide 
range of cell types; 
localized gene 
expression 
Very low transfection 
efficiency; transient gene 
expression 
 [168, 204] 
Liu et al. [205]; 
Huang et al. [176] 
Nucleic 
acid/polymer 
complexes 
non-
viral 
Targeted down 
regulation of gene 
expression 
Low transfection 
efficiency; very transient 
effects on gene expression; 
potential for 
immunogenicity [166, 206] 
Iwanaga et al. [207];  
Kotopoulis et al.[208] 
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clinically-viable approach for dental-based tissue engineering strategies. For example, human 
dental pulp-derived mesenchymal stem cells (DPSC) can be processed using current good tissue 
practices (cGTP) within a 5 day period post-isolation from an extracted tooth, banked via 
cryopreservation, and recovered prior to treatment [171]. In the presence of a scaffold that serves 
as a carrier for cell delivery, additional considerations for safe application to the clinic include 
adherence to good manufacturing practices (cGMP) for scaffold fabrication and sterilization [172]. 
Additional steps involving scaffold cell-seeding, maintenance, and transfer to the clinic require 
stringent quality control measures and comprehensive protocols to ensure safety and efficacy. To 
minimize the associated treatment costs and improve practicality of cell-based therapy in the clinic 
with or without scaffold carriers, these processes must be streamlined and simplified to avoid 
unnecessary complications and reduce regulatory burdens.  
Clinically-applicable procedures for the regeneration of oral and craniofacial bone using 
gene therapy are highly dependent on the selection of vectors with appropriate safety profiles.  
Primary concerns with viral vectors include their potential to illicit an immune response, exhibit 
insertional mutagenesis, and activate oncogenes, as has been observed with lentiviruses and 
retroviruses. Safer alternatives are adeno-associated vectors (AAVs) and adenoviruses: AAVs are 
non-pathogenic, while adenoviruses do not integrate into the cell genome and thereby are not 
replicated during cell division [173]. While these vectors are currently being tested in FDA-
approved human clinical trials for rare disorders, the development of more efficient non-viral gene 
therapy methods involving DNA, mRNA, or siRNA delivery can be more promising from a 
regulatory approval perspective for regeneration of common tissue defects [174].  
 
2.9  Pre-clinical Studies for Regeneration of Oral Tissues using Gene Therapy   
Adenoviruses have been used experimentally for tissue engineering of tooth-supported 
bony defects. One example is the use of an adenovirus encoding the PDGF-B gene (Ad-PDGF-B) 
on a collagen matrix to treat periodontal lesions in vivo. Clinical, hematological and blood 
chemical tests were done without any significant histopathological changes when Ad-PDGF-B 
was used [175, 176]. Jin et al. demonstrated Ad-BMP7 induced rapid chondrogenesis, osteogenesis 
and cementogenesis in bridging periodontal alveolar bone defects without significant 
inflammatory responses [177]. This is an example of the potential that gene therapy-based vectors 
such as adenoviral BMP have for successfully engineering bone in a preclinical model (see Figure 
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3) when combined with a transduced cell carrier such as gelatin that provides three-dimensional 
support for tissue growth during the regenerative process.  
 
 
Figure 2.3 Regeneration of Periodontal Tissue using Gene Therapy Vectors 
Successful regeneration of alveolar bone and surrounding periodontal tissues using gene therapy 
vectors such as adenoviral BMP-7 (Ad-BMP-7) has been achieved in animal models. Bone 
regeneration and bridging was observed with the use of ex vivo BMP-7 gene transfer using a 
gelatin-based cell carrier in a rat wound model consisting of a large mandibular alveolar bone 
defect. Comparatively, transduction of syngeneic dermal fibroblasts using green fluorescent 
protein (Ad-GFP) or noggin (Ad-noggin) did not result in ectopic bone formation (left panel).  
Mature cartilage and newly-formed bone was observed at Day 21 using Ad-BMP-7 gene transfer 
(right panel). Reproduced with permission from Jin Q-M et al [177]. 
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AAVs have been used to prevent periodontal disease progression in rats. Cirelli et al., 
demonstrated the use of pseudotyped adeno-associated virus vector based on serotype 1 (AAV2/1) 
to deliver TNF receptor-immunoglobulin Fc (TNFR:Fc) to rats subjected to Porphyromonas 
gingivalis (Pg) lipopolysaccharide (LPS)[178]. Animals treated with AAV2/1-TNFR:Fc showed 
sustained levels of serum TNFR protein and sustained levels of Pg-LPS-mediated bone loss. AAVs 
have also been successfully used for the treatment of neurological, cardiovascular and autoimmune 
diseases [179]. 
Lentiviral transfection was used to investigate follicular dendritic cell secreted protein 
(FDC-SP) on the inhibition of osteogenic differentiation of human PDL cells. Xiang et al. used 
FDC-SP transfection on hPDL cell proliferation, osteogenic and fibrogenic phenotypes [180]. Cell 
proliferation and cell cycle tests indicated that transfection with FDC-SP did not affect hPDLC 
proliferation. Moreover, expression levels of type 1 collagen were up-regulated while osteocalcin, 
osteopontin and bone sialoprotein were down-regulated in the transfected cells. Lentiviral vectors 
are considered excellent genetic vector systems by being both efficient and stable in gene delivery 
and therapy [181]. 
With regard to the application of non-viral vectors for growth factor delivery, plasmids 
have been used successfully to enhance cell survival and engraftment with IGF-1 in smooth muscle 
cells. Huang et al. used plasmid DNA encoded BMP-4 in critical-sized cranial defects in rats and 
demonstrated bone regeneration significantly increased both on the edges and center of the defects 
as compared to the control group of the scaffold only [182]. 
 
2.10 Clinical Applications of Cell Delivery  
Cell and gene therapy have the potential to greatly improve current methods of bone 
regeneration through increased bioactivity of scaffolds and localized growth factor delivery. This 
concept is being comprehensively studied to provide a more predictable armamentarium of 
available treatment options for local alveolar bone loss. Reviewed here are documented clinical 
studies using cell-based therapy to the craniofacial complex. Cell-based therapy pre-clinical 
studies are in the process of being transitioned into clinically-applicable approaches that are safe 
and effective in regenerating periodontal tissues.  
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2.10.1 Alveolar bone augmentation/preservation 
Existing studies have investigated the safety of cell-based therapy for alveolar bone 
augmentation: Filho-Cerruti et al. studied the association of platelet-rich plasma (PRP) and 
mononuclear cells from bone marrow aspirate and bone scaffold for bone augmentation in the 
maxillae [183]. An overall graft success rate of 94.7% was reported with enough ridge dimension 
obtained for proper dental implant placement. Documented graft failures were due to infection of 
the maxillary sinus and lack of integration into the host cortical bone. Bone formation with the 
presence of osteoblasts scattered throughout the trabeculae were noted histologically, with 
minimal marginal bone loss noticed during the 4-year study follow-up. Subsequently, Pelegrine et 
al. evaluated in a case series study the clinical and histomorphometric behavior of upper anterior 
extraction sockets treated with an autologous bone marrow graft versus no graft material in the 
control group [184]. Clinical results showed that the use of bone marrow stem cells (BMSCs) 
minimized alveolar bone loss after tooth extraction compared to control. Nevertheless, 6 months 
after grafting, similar outcomes were found by means of mineralized bone. More recently, Kaigler 
et al. conducted a randomized controlled feasibility trial to compare the use of tissue repair cells 
(BMSCs) with conventional GBR (membrane only with gelatin carrier) for alveolar bone 
preservation. At the time of implant placement, a second need of grafting was more frequent (6-
fold greater implant exposure) for sockets treated with GBR. Additionally, it is also important to 
note that the regenerated bone in the test group exhibited greater density and higher vascularization 
with significant acceleration of osteogenesis at 6 weeks.  
 
2.10.2  Sinus augmentation 
Vertical bone augmentation in the sinus antrum is oftentimes an imperative to achieve 
implant stability due to progressive alveolar bone resorption. The use of stem cell therapy as a 
complement to conventional graft and scaffold materials could improve bone formation and 
accelerate regeneration. In a histomorphometric study, Gonshor et al. compared bone formation 
following sinus augmentation procedures using either an allograft cellular bone matrix containing 
native mesenchymal stem cells or a conventional allograft. Results of the test group revealed a 
mean of 32.5% and 4.9% for vital bone and remaining graft material, respectively, over a follow 
up healing period of 3.7 months. Contrastingly, for the control group, only 18.3% of vital bone 
content was found while an increase of up to 25.8% was noticed of remaining graft [185]. These 
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results were consistent with the results obtained by Rickert et al., who aimed to compare bovine-
derived mineral bone seeded with mononuclear stem cells with bovine-derived mineral bone 
mixed with autogenous bone. Significantly greater bone formation was observed in the test 
(17.7%) when compared with the control group (12.0%) at 14 weeks [186].  
Overall, stem cells seeded in allograft or xenograft scaffold particles are capable of 
inducing sufficient new bone volume formation to achieve primary implant stability. Within these 
limitations, the high percentage of vital bone content after a relatively short healing period might 
encourage clinicians to consider implant therapy at an earlier stage post-grafting [187]. However, 
the clinical significance in small defects is very finite and therefore, the use of this approach should 
be further studied in more challenging scenarios with standardized randomized clinical trials. 
 
2.11  Existing Limitations  
Major advances have been made in the reconstruction of intraoral bone defects as a result 
of improvements in scaffolding matrices and application of bioactive factors that enhance the 
regenerative response. However, there are existing limitations in the development of optimized 
scaffolding matrices that meet all the necessary criteria for the regeneration of structurally and 
physiologically functional osseous tissues. As described in this review, current technologies such 
as 3-D printing are being adapted for use in the design and development of natural and synthetic 
matrices that are architecturally similar to bone that allow for controllable features such as 
chemical composition, porosity, and rate of degradation. Likewise, the selection of materials in 
scaffold development for intraoral bone regeneration is limited by the attempt to match the 
properties and rate of regrowth of the developing tissues to the degradation properties of the 
supporting biomaterial. It remains a challenge to balance the preference for FDA-approved 
materials that have been more thoroughly investigated for use in humans with materials that may 
be more mechanically-appropriate for bone regeneration but have been biologically/chemically 
modified or release degradation products which may hinder the regenerative process in situ. This 
further relates to the established regulatory requirements for translating novel treatments to the 
clinic, with more complex strategies involving combinations of materials with cell, growth factor, 
or gene delivery yielding a biologic-device combination product that is more difficult to evaluate 
as opposed to a stand-alone biologic or device product. While current clinical applications of 
growth factors in combination with commercialized material carriers are showing significant 
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improvements in clinical treatment, further optimization of delivery systems in necessary to ensure 
that time-dependent biofactor dose and release kinetics are appropriate for the regenerative repair 
process. Gene therapy is promising in this area of research and is in need of further evaluation to 
determine the most appropriate vectors for growth factor gene delivery that is safe and clinically 
acceptable for further implementation in patient-based studies.  
 
2.12 Future Directions 
There are many exciting opportunities that lie ahead for the reconstruction of craniofacial 
deficiencies including periodontal, alveolar ridge and large mandibular/maxillary discontinuity 
defects.  The innovations that are ongoing in materials science and in biology have offered many 
potential avenues in the laboratory and clinic to extend the field of tissue engineering of oral 
structures such as alveolar bone and soft tissues of the teeth and dental implants.  In particular, 
recent advances in biomaterial design, drug delivery and biologic agents offer less invasive 
technologies to accelerate and more predictably promote tissue repair and regeneration. The ability 
of rapid prototyping, three-dimensional printing, electrospinning, and enhanced drug delivery 
strategies to personalize patient therapies is allowing a more customized approach for oral tissue 
engineering to benefit both clinicians and patients.  Development of scaffolds that act as delivery 
vehicles for drugs that can be controllably released to counter bone degenerative processes is an 
example of a future focus for intraoral tissue engineering strategies, as recently evidenced in a 
study by Ji et al [188] that focused on the incorporation of hydrophilic naringin into elecrospun 
amphiphilic copolymer nanofibers for bone resorption treatment. Further improvements to existing 
materials with a history of use in dental and craniofacial applications, such as calcium phosphate-
based cements, are a promising venue for addressing their existing limitations through the 
improvement of mechanical integrity and incorporation of growth factor delivery vehicles. Lee et 
al [189] present such an approach through the reinforcement of macroporous calcium phosphate 
cement (CPC) with absorbable fibers and simultaneous delivery of rhBMP2 in the CPC matrix 
with VEGF or TGF-β1 in alginate hydrogel microbeads within the matrix. Such combinational 
approaches to address the need for controlled delivery of growth factors at critical stages of the 
regenerative process are important in advancing our ability to predictably regrow lost or damaged 
tissue. Further improvement and streamlining of existing processes and technologies for 
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addressing these tissue engineering strategies will enable their continued entrance into the clinical 
arena to provide more predictable regenerative medicine therapeutics for enhanced patient care.  
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CHAPTER 3 
 
SINGLE PATIENT CASE STUDY USING A 3D-PRINTED BIORESORBABLE 
SCAFFOLD FOR PERIODONTAL REPAIR 
 
Based on a case report published in Journal of Dental Research and sections written as a 
contribution to a book chapter entitled “Bioengineering of the Periodontal Ligament”: 
 
Rasperini G, Pilipchuk SP, Flanagan CL, Park CH, Pagni G, Hollister SJ, Giannobile WV. 
3D-printed bioresorbable scaffold for periodontal repair, J Dent Res. 2015;94(9 
Suppl):153S-7S 
 
Decker AM, Pilipchuk SP, Araujo-Pires AC, Giannobile WV. Bioengineering of the 
periodontal ligament. In: Kapila SD, Goonewardene M, eds. Interdisciplinary Therapy: 
Using Contemporary Approaches for Complex Cases. Monograph 52, Craniofacial Growth 
Series, Center for Human Growth and Development, The University of Michigan, Ann 
Arbor, 2016:195-242. 
 
3.1 Introduction 
Tissue engineered constructs have potential to induce bone-ligament complex regeneration 
to treat disease- or trauma-induced damage to periodontia [1]. Multiphasic designs incorporating 
several biomaterial layers that serve as regenerating platforms for each region of the periodontum 
(i.e., PDL, alveolar bone) are increasingly being investigated in combination with the delivery of 
cells and other biologic factors. These include the layer by layer deposition of a polymer that 
allows for controlled pore size formation depending on printer resolution, or the printing of a mold 
that can be cast to produce the final scaffold shape. Lee et al demonstrated the use of PCL-HA 
layer deposition with microchannels ranging from 100um-600um for the PDL, bone, and 
cementum/dentin regions of a hierarchical scaffold which incorporated the spatiotemporal delivery 
of amelogenin, connective tissue growth factor, and BMP-2 within each of the phases, 
respectively. Seeding of the constructs with dental pulp stem/progenitor cells and subcutaneous 
implantation in immunodeficient mice resulted in aligned PDL-like collagen fiber formation 
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connected to bone tissue that was sialoprotein-positive [2]. Biphasic scaffold designs have also 
been explored combining fabrication technologies such as 3-D printing and electrospinning with 
cell sheet engineering. Vaquette et al developed a construct of PCL with β-TCP for the bone region, 
and an electrospun PCL membrane for the PDL region with placement of several PDL cell 
sheets which improved attachment to the dentin surface relative to constructs that did not 
incorporate the sheets [3]. Hybrid PCL/PLGA and fiber-guiding PCL scaffolds with 
perpendicularly-oriented microchannels were developed by Park et al utilizing computational 
design and solid-free form fabrication for the direct guidance of PDL fibers in vivo, resulting in 
more predictable formation of organized periostin-positive ligamentous structures [4, 5]. Findings 
from these studies indicate that bone-ligament complex regeneration in the clinic has the potential 
to be guided via 3-D printed, hybrid scaffolds with a multi-compartmental architecture designed 
based on patient defect CT scans [6]. The anatomical complexity of PDL tissue makes 
combinatorial approaches and advanced multiphasic scaffold designs appealing for improving its 
structural and functional regeneration.  
Herein we provide the first reported human case of treatment of a large periodontal osseous 
defect with a 3D printed bioresorbable patient-specific polymer scaffold and signaling growth 
factor.  Specifically, 3-D printing technology was used to generate a scaffold which conformed to 
defect site parameters obtained via cone beam computed tomography (CBCT) scans. The treated 
site remained intact for 12 months following therapy.  This report suggests that 3D printed, image-
based scaffolds offer potential for periodontal reconstruction. Limitations gleaned from this case 
and opportunities for treatment of other bony defects are discussed. 
 
3.2 Methods and Materials 
3.2.1 Case Presentation 
A healthy, 53-year old Caucasian male, diagnosed with generalized aggressive 
periodontitis presented for treatment to preserve his dentition.  The patient received full-mouth 
scaling/root planing and 2 years later still showed signs of periodontal stability, but with a resulting 
large labial soft and osseous defect associated with the mandibular cuspid, tooth #22 (Figure 3.1, 
top panels). The patient consented to treatment of the deficiency by a bioengineering approach 
described below.  The study protocol was approved by the University of Milan Institutional 
Review Board, Milan Italy.  
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3.2.2 3D Printed scaffold fabrication 
An .STL format was used as an input data file for the manufacturing process and to 
determine a best fit based on a CT scan of the patient’s defect (400um slice thickness, 400x400um 
voxel size). Magics 15 (Materialise Inc, Leuven, Belgium) was used to subtract STL-generated 
defect from designed scaffold to generate a 3-D design, then further modified using NX 7.5 
(Siemens PLM software, Plano, TX) and Mimics (Materialise Inc; Figure 3.1, middle panels). The 
design consisted of perforations for fixation, an internal port for delivery of recombinant human 
platelet-derived growth factor (rhPDGF-BB), and pegs oriented perpendicularly to the root for 
periodontal ligament formation (PDL) guidance as previously described using PCL scaffolds in a 
rat periodontal fenestration defect model (Figure 3.1, bottom). Selective laser sintering (SLS) 
allows for fabrication of precise scaffold features that can be designed to support structural and 
functional tissue regeneration in vivo. SLS (Formiga P100 system; EOS e-Manufacturing 
Solutions) was used to 3-D print the scaffold with polycaprolactone (PCL) powder (Polysciences 
Inc, Warrington, PA; milled at Jet Pulverizer, Moorestown, NJ) containing 4% hydroxyapatite. 
PCL is a Food and Drug Administration (FDA)-approved, hydrolytically-degradable polymer. 
Geometric interface adaption of the scaffold to the defect was assessed using a patient-specific 3D 
printed prototype model (University of Michigan Medical Innovation Center). Micro-computed 
tomography (eXplore Locus SP, GE Healthcare, London, ON, Canada) scans of prototyped 
mandible with scaffold were used to determine the adaptation ratio based on the methodology for 
periodontal fiber guidance. Measurements of gap distance between scaffold PDL region and 
modeled tooth root were repeated (n=3) to determine mean adaptation for eventual in vivo 
placement (Figure 3.1 lower middle panels; Figure 3.3).  The scaffold was sterilized using 
ethylene oxide (Nelson Laboratories, Salt Lake City, UT). University of Michigan Institutional 
Review Board granted exemption status for evaluation of the scaffold material. 
 
3.2.3 Surgical Procedure and Scaffold Delivery 
The patient was prepared with local infiltration anesthesia (Figure 3.2). A trapezoidal full-
thickness labial flap was elevated encompassing the adjacent teeth. Vertical incisions were 
extended beyond the mucogingival junction to allow relaxation of the flap and ease scaffold 
placement. The tooth root surface was mechanically instrumented and EDTA (Straumann® 
PrefGel®, Institut Straumann AG, Basel, Switzerland) was used as a root modification agent. The 
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scaffold was immersed in 0.5mL rhPDGF-BB (0.3mg/mL) (Gem 21S, Osteohealth, Shirley, NY, 
USA) for 15 min, filled with autologous blood from the defect site, and stabilized over the defect 
with ultrasound-activated resorbable poly-D and L-lactic acid (PDLLA) pins (SonicWeld, KLS 
Martin Group, Tuttlingen Germany). Remaining PDGF-BB solution was applied at the defect site 
prior to scaffold stabilization. The flap was released to allow tension-free primary closure with 
non-resorbable sutures. The patient refrained from mechanical oral hygiene procedures using 
0.12% chlorhexidine rinses for 3 weeks. The patient was prescribed Amoxicillin 875mg + 
clavulanic acid 125mg BID for 6d and Ibuprofen 600 mg as needed for pain post-operatively. 
Sutures were removed 7d following surgery. 
 
3.3 Results 
The scaffold design incorporated pegs 160–380um in length consistent with human PDL, 
the superior PDL region being shorter to accommodate to root proximity. Mean strut length was 
600um for support of extensions in the PDL region, while channel width for growth factor delivery 
was ~500um (Figure 3.1). The interface was determined to have an adaptation ratio of 0.82±0.07, 
which characterizes gap width distribution between scaffold and tissue (Figure 3.3).  In vitro 
release kinetics demonstrated an overall burst release of rhPDGF-BB from the scaffold matrix over 
a 3h period (Figure 3.4).  
The scaffold remained covered for 12m, demonstrating 3mm gain of clinical attachment 
and partial root coverage (Table 3.1). The implanted 3-D scaffold served to fill the human 
periodontal osseous defect without signs of chronic inflammation or dehiscence (Figure 3.5). 
However, at 13m, the scaffold became exposed requiring removal. The biopsy specimen was fixed 
in formalin, evaluated histologically and for scaffold molecular weight.  Based on gel permeation 
chromatography, 75.9% of the scaffold molecular weight remained after 13m (Table 3.2) with 
minimal evidence of bone repair as evidenced by histological analysis (Figure 3.5). 
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Figure 3.1 Customized Scaffold for Peri-osseous Defect  
A customized scaffold was 3-D printed using medical grade polycaprolactone (PCL) to fit the 
periosseous defect using a prototyped model of the defect from the patient’s CBCT scan.  The 
scaffold’s internal region consisted of extended pegs for the support and guidance of periodontal 
ligament formation, perforations for fixation, and an internal compartment for rhPDGF-BB 
delivery, as shown in the cross-sectional view. Micro-computed tomography scans of the PCL 
scaffold fitted into the prototyped defect model (see coronal, middle, apical views) were used to 
determine the topographical adaptation of the scaffold to the root surface. 
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Figure 3.2 Clinical Outcome of Scaffold Implantation  
Clinical attachment loss and alveolar ridge resorption characterized the patient periosseous defect 
involving tooth #22. A trapezoidal full thickness flap was elevated to expose the defect, the root 
surface mechanically instrumented, and EDTA solution applied during root preparation. Prior to 
implantation, the scaffold matrix was immersed in 0.3mg/mL rhPDGF-BB solution for 15 min at 
RT. During placement, the scaffold was filled with autologous blood, positioned over the exposed 
tooth root, and stabilized using PDLLA pins. Tension-free primary intention method was 
employed during wound closure. The implanted 3-D scaffold filled the periodontal osseous defect 
without clinical signs of chronic inflammation or rejection of the PCL-based material during the 
first year.  
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Figure 3.3 Adaptation of 3D-Printed Scaffold 
Adaptation ratio of polycaprolactone scaffold fitted into a prototyped model of the periosseous 
defect was determined as an assessment of the topographic adaptation of the scaffold to the root 
surface. A 100% (ratio of 0.1) adaptable scaffold would indicate a perfect fit. The final design of 
the polycaprolactone scaffold was adaptable to the periosseous defect by 82% ± 7% (mean ± SD). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4  Release Kinetics of rhPDGF-BB from PCL Scaffold 
In vitro release kinetics of recombinant human platelet-derived growth factor BB (rhPDGF-BB) 
from polycaprolactone scaffolds (155.6 ± 0.9 mg) into phosphate-buffered saline from a rhPDGF-
BB loading of 48.2 μg per scaffold for 20 min at room temperature. Each data point represents 
mean ± SD (n= 3). 
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Figure 3.5 Post-operative Exposure and Retrieved Scaffold Matrix  
Postoperative exposure and retrieved scaffold matrix. The top panel shows the initial soft tissue 
dehiscence over the scaffold at 13 mo. The middle panel shows the more extensive exposure and 
wound failure of the scaffold matrix, necessitating removal at 14 mo (middle panels). The bottom 
panel shows histologic analysis of the retrieved scaffold matrix, which was performed with 
hematoxylin and eosin (H&E) and Masson’s trichrome staining. Frozen sectioning of the 
decalcified tissue stained with H&E shows tissue attachment to scaffold remnants (red 
arrowheads). Masson’s trichrome paraffin-embedded sections indicate small islands of new bone 
formation within a milieu of primarily granulomatous tissue (yellow arrowheads). Scale bar = 50 
μm.  
 
 
 
70 
 
 
Table 3.1 Clinical Parameters  
 
 
Table 3.2 Gel Permeation Chromatography: Analysis of Changes in Mean Molecular Mass 
of Polycaprolactone Scaffold Matrix 
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3.4 Discussion  
When applying tissue engineering approaches to the reconstruction of complex tissue 
structures such as the periodontium, biomaterials serve as 3-D templates and synthetic 
extracellular-matrix (ECM) environments for the regenerative process [7]. Printed biomaterials 
represent promising tools, allowing customization to the desired size, configuration and 
architecture of a given defect. Their efficacy in the regeneration of complex structures such as new 
PDL has been shown pre-clinically [5]. Successful use of a 3-D printed PCL splint for the treatment 
of tracheobronchomalacia has been recently reported using a similar approach [8].  We believe a 
limitation of this study was use of the PCL biomaterial that may not be ideal for periodontal 
applications.  It appears that a more rapidly resorbing matrix with a healing window of <1 year 
combined with a less bulky design would be better suited to avoid wound dehiscence, exposure 
and subsequent microbial contamination in a peri-mucosal environment around teeth. Histological 
analysis indicating minimal collagenous tissue ingrowth into the scaffold (Figure 3.5) supports 
the need for a more interconnected internal structure with greater surface area. Selection of a 
biomaterial with a faster rate of resorption (i.e., polylactic-co-glycolic acid (PLGA)) combined 
with a highly porous structure would contribute to greater tissue ingrowth and vascularization. As 
evidenced by gel permeation chromatography results (Table 3.2) which indicate a PCL degradation 
of only 24.1%, improvements in the resorptive properties of the scaffold are intrinsic to improved 
bony infill, which is difficult to achieve with a slowly-degrading polymer. Compartmentalized 
delivery of PDGF-BB to the PDL-forming region of the scaffold and BMP-2 to the bone region 
may further facilitate tissue growth and remodeling. Although PDGF-BB has previously been 
shown to bind and release from a PCL-based scaffold in a biological manner [9], optimization of 
the growth factor release kinetics may further increase PDGF bioactivity in situ. A hybrid PLGA-
PCL scaffold design may also provide optimal mechanical and resorptive properties for 
engineering a PDL-bone interphase. Further studies would focus on the analysis of scaffold 
stiffness to reduce risk of tissue dehiscence.  
 
3.5 Conclusions  
This case represents the first application of a personalized, 3-D bioprinted scaffold to treat 
a periodontal defect. Although this case was not successful long term, we believe the approach 
warrants further study for more personalized oral regenerative medicine clinical applications.  
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CHAPTER 4 
 
INTEGRATION OF 3D PRINTED AND MICROPATTERNED 
POLYCAPROLACTONE SCAFFOLDS FOR GUIDANCE OF ORIENTED 
COLLAGENOUS TISSUE FORMATION IN VIVO 
 
Originally published in Advanced Healthcare Materials:  
Pilipchuk SP, Monje A, Jiao Y, Hao J, Kruger L, Flanagan CL, Hollister SJ, Giannobile WV. 
Integration of 3D Printed and Micropatterned Polycaprolactone Scaffolds for Guidance of 
Oriented Collagenous Tissue Formation In Vivo. Adv Healthc Mater. 2016;5(6):676-87.   
 
 
4.1 Abstract  
Scaffold design incorporating multi-scale cues for clinically-relevant, aligned tissue 
regeneration has potential to improve structural and functional integrity of multi-tissue interfaces. 
The objective of this pre-clinical study was to develop poly(ɛ-caprolactone) (PCL) scaffolds with 
mesoscale and microscale architectural cues specific to human ligament progenitor cells and assess 
their ability to form aligned bone-ligament-cementum complexes in vivo. PCL scaffolds were 
designed to integrate a 3D printed bone region with a micropatterned PCL thin film consisting of 
grooved pillars. The patterned film region was seeded with human ligament cells, fibroblasts 
transduced with BMP-7 genes seeded within the bone region, and a tooth dentin segment 
positioned on the ligament region prior to subcutaneous implantation into a murine model. Results 
indicated increased tissue alignment in vivo using micropatterned PCL films, compared to random-
porous PCL. At 6 weeks, 30um groove depth significantly enhanced oriented collagen fiber 
thickness, overall cell alignment, and nuclear elongation relative to 10um groove depth. This study 
demonstrates for the first time that scaffolds with combined hierarchical mesoscale and microscale 
features can align cells in vivo for oral tissue repair with potential for improving the regenerative 
response of other bone-ligament complexes.  
 
74 
 
 
4.2 Introduction  
Formation of tissues with structural and functional integrity is reliant upon cellular 
alignment and organization that in turn is influenced by nano- and micro-scale environmental cues 
[1-3]. Soft collagenous tissues such as tendon and ligament require aligned collagen fiber 
formation to maintain resistance to mechanical loading. Similarly, the periodontal ligament (PDL) 
is a structure in the oral cavity composed primarily of collagen type III which anchors alveolar 
bone to the tooth root and resists compressive loading--allowing for tooth movement. Periodontitis 
is a chronic oral inflammatory disease associated with damage to the tooth-supporting apparatus 
and subsequent osseous tissue resorption. It is the primary cause of permanent tooth loss estimated 
to affect 47.2% of adults in the United States, with a prevalence of 70% for adults aged 65 years 
and older [4]. Tissue engineering strategies have shown potential to address existing deficiencies 
in clinically-induced periodontal regeneration through combinational approaches using 
biomaterials, growth factors, and cell-based therapy [5, 6]. Existing studies have focused on 
whether precise topographical mesoscale features can influence structural and functional 
properties of PDL-like tissue through contact guidance in vitro [7, 8]. However, their further 
translation and performance in vivo has not yet been described, yet is needed to optimize scaffold 
constructs for oriented, multi-tissue interface regeneration.  
The complex hierarchical organization of periodontal tissues requires multi-phasic 
biomaterial constructs that can recapitulate the structural integrity of the bone-ligament interface 
[9]. Microscale technologies have been used in fabricating scaffolds that facilitate control of 
multiple tissue organization and positioning, as required for the regeneration of a bone-ligament 
interface [10, 11]. Surface topography on the micro- and nano-scale profoundly affects cell 
behavior, including adhesion, migration, alignment, intracellular signaling pathways, and 
ultimately tissue formation in combination with biochemical cues. As such, there is a growing 
emphasis being placed on a multiscale approach to scaffold development that should incorporate 
strategically-positioned, biologically-relevant design features ranging from the nano- to the macro-
scale [12].   Fabricating scaffolds sufficient for clinical application remains a challenge for tissue 
engineering of multi-phase, oriented tissue interfaces.  
Polycaprolactone (PCL)—a hydrolytically-biodegradable polyester approved by the FDA 
for some clinical indications—is easily manufactured into a variety of shapes and porosities with 
variable mechanical properties and has been the material of choice in multi-phasic scaffolds for 
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regeneration of periodontia. Park et al. used 3-D printed wax-based molds to cast PCL for a “bone 
compartment” of an image-based, bi-phasic scaffold “periodontal complex” [13, 14]. Costa et al. 
and Vaquette et al. employed PCL for the bone compartment and electrospun PCL for the PDL 
region, [15, 16] while Lee et al. used a layered 3-D printed scaffold with three PCL interphases for 
the cementum, PDL, and alveolar bone [17]. However, the precise effect of topography on the 
guidance of PDL-like tissue formation in vivo has not been thoroughly explored to understand how 
micro-scale patterning affects the regenerative outcome.  
The objective of this study was to develop a scaffold with micro- and macro-scale cues for 
guided formation of aligned tissue that would meet design criteria for periodontal ligament-like 
architecture. Given PCL's malleability and ability to be formed into polymeric matrices of various 
physical and mechanical properties, 2D PCL films were micropatterned and assessed in vitro to 
determine optimal parameters for PDL cell alignment. This informed the design of a 3D PCL film 
having 250um high pillars to replicate the average thickness of PDL tissue, with grooves embedded 
into the pillars at widths of 15-60um and depths of 10-30um. Films were incorporated into a 3D 
printed PCL region to create a macro-scale bone-ligament interphase reminiscent of the alveolar 
bone-PDL complex in the oral cavity. We integrated 3D printed and micropatterned regions to 
develop a multi-tissue interphase with macro- and micro-specific features of the scaffold. We then 
examined the potential of the designed scaffold construct for guidance of mineralized (bone, 
cementum) and collagenous (PDL-like) tissue formation using subcutaneous implantation in an ex 
vivo model.  Our findings identify the importance of grooved features and the influence of their 
depths on cellular alignment, elongation, and oriented collagenous tissue formation in vivo.   
 
4.3 Methods and Materials  
4.3.1 Preparation and imaging of patterned 2D and 3D films  
 Polycaprolactone films (2D) were prepared by dissolving PCL (MW: 43-50 kDA) in 
chloroform (Sigma) (10% w/v) and spin coating the solution (1st coat at 100 rpm for 8 sec, 2nd coat 
at 800 rpm for 20 sec) onto polydimethylsiloxane (PDMS) (Sylgard 184; Dow Corning) designed 
via established soft lithography techniques with grooves ranging from 10-50um in width, 10 um 
in depth [32]. Briefly, a CAD-based program (LEdit) was used to design micropatterns and define 
the silicon and SU-8 master molds with standard photolithography. All steps for mold fabrication 
were performed at Lurie Nanofabrication Facility (University of Michigan, Ann Arbor, MI). To 
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transfer the pattern of SU-8 molds onto a flexible polymer, PDMS was mixed in a ratio of 10:1 v/v 
of base to curing agent, degassed under vacuum, poured onto molds, and cured (65˚C). PDMS was 
then peeled from SU-8 mold and used as a mold to pattern PCL. Control films were made by spin 
coating PCL onto non-patterned PDMS stamps. Similarly, 3D micropatterned PCL films were 
prepared by casting PCL solution onto PDMS molds with grouped arrays of five different designs: 
(1) 400x400m non-grooved square pillars 250um in height spaced 400um apart, (2) same pillars 
with 10um deep, 60um wide grooves on the perimeter, (3) pillars with 10um deep, 15um wide 
grooves, (4) pillars with 30um deep, 60um wide grooves, and (5) pillars with 30um deep, 15um 
wide grooves. SEM was performed at the Microscopy and Image Analysis Laboratory (University 
of Michigan) using an Amray FE 1900 SEM to image patterned 3D films which were gold sputter 
coated and observed at an acceleration voltage of 5kV.  
 
4.3.2 Surface treatment and MTS assay  
 Amination of films was performed using 10% (w/v) 1,6-hexanediamine for 1hr at 37°C. 
Hydrolysis was achieved using 1M sodium hydroxide solution (4 hours at room temperature). 
Fibronectin treatment consisted of incubating films overnight in phosphate buffered saline (1X 
PBS), exposed to bovine-derived fibronectin solution (10ug/mL, Sigma) for 30min at 37°C, with 
washes in PBS. All non-patterned films were sterilized in 70% ethanol for 30 min and washed in 
sterile dH20 prior to treatment, and again washed in sterile dH2O post-treatment with amination or 
hydrolysis.  Prior to cell seeding, all films were incubated for 30 min in cell culture media 
consisting of Dulbecco’s Modified Eagle Medium with glutamine (DMEM), 10% fetal bovine 
serum (FBS), and antibiotics (100 units/ml penicillin and 100 mg/ml streptomycin). Human PDL 
cells (passages 4-6) were seeded at a density of 1.5x104 cells/film on non-treated and surface-
treated PCL films (n=3). Cell adhesion and proliferation was assessed at days 1 and 5 post-seeding 
by adding MTS solution (CellTiter 96® Aqueous One Solution, Promega Corp, Madison, WI) to 
films washed three times in PBS, and reading triplicates at 490 nm after 2 hr incubation (37°C). 
 
4.3.3 In vitro cell culture and alignment analysis on 2D patterned films  
 To assess PDL cell alignment on patterned 2D substrates, films were seeded with hPDL 
cells (passages 4-6, 1.2x104 cells/film) stained with DilC(12)3 (10ug/mL, BD Biosciences, 
Bedford, MA, USA). Prior to cell seeding, films were surface treated with hydrolysis and 
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fibronectin as described previously. At 24hrs post-seeding, films were washed three times in PBS 
and imaged using fluorescence microscopy (Nikon Eclipse 50i, Nikon Instruments Inc). ImageJ 
(NIH) was used to evaluate cell orientation angle (OA) between 0° and 90° via a virtual axis placed 
in each cell, with the angle between the axis of the cell and direction of the pattern (corresponding 
to 0°) measured for all films (n=4). Results from OA analysis were used to inform the design of 
3D pillared PCL films.  
 
4.3.4 Preparation of biphasic integrated scaffold with 3D-printed and 3D patterned PCL regions 
 To model the interphase between alveolar bone and periodontal ligament, a biphasic 
scaffold based on a previous design was fabricated with individual compartments for bone and 
PDL growth using 3-D printed PCL structures for a bone compartment combined the 
aforementioned 3D micropatterned films for a PDL interface, respectively [13]. PCL scaffold 
geometry for 3-D printing was designed using CAD-based software (NX 7.5, Siemens PLM 
Software), with base dimensions of 5.1 x 4.1 x 2.1 mm, a 1.1 mm high enclosure to contain the 
PCL film, and pore openings of 0.7 x 0.7mm. Selective laser sintering (SLS) was used to fabricate 
the bone compartment using PCL powder (43-50kDa; Polysciences, Warrington, PA) and 4 wt% 
hydroxyapatite (Plasma Biotal Limited) [34, 45, 46]. To assemble the biphasic scaffold, a 
micropatterned 3D PCL film (3.6 x 2.8 mm) containing an array of 20 square pillars and 400um 
circular pores was directly fitted onto the 3D printed PCL bone region. The four corners of the 
upper bone scaffold region (Figure 3B) anchor, stabilize, and integrate the PCL film in place.  
 
4.3.5 In vivo implantation and specimens harvest  
 One day prior to implantation, PCL films was treated with fibronectin and seeded with 
hPDL cells as previously described using in vitro cell culture to allow for cell attachment and 
alignment. The day of surgery, two surgical pockets were made on the dorsa of immunodeficient 
6 week-old NIH III nude mice (20-25g; Charles River Laboratories, Wilmington MA) for 
subcutaneous scaffold implantation (n=6 per time point) under isofluorane anesthesia. The bone 
region was seeded with Ad-BMP7 (MOI=500) expressing hGFs (2.5x105 cells in 8uL fibrinogen 
mixed with 2ul thrombin) and the PDL region seeded with hPDLs (1.5 x105 cells in 15mL 
fibrinogen mixed with 3uL thrombin). A human-derived dentin segment surface-treated with 37% 
orthophosphoric acid and trimmed to scaffold size was press-fit onto 3D patterned PCL film to 
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ensure contact between pillars and dentin surface. Dentin segments derived from healthy human 
teeth were obtained in accordance with a University of Michigan-Institutional Review Board (IRB) 
approved protocol, and animal studies were performed with approval from University of 
Michigan-University Committee on Use and Care of Animals (UM-UCUCA) according to 
ARRIVE guidelines for preclinical studies. Samples were harvested at 3 and 6 weeks and fixed in 
10% buffered formalin phosphate solution for 2 days before being transferred into 70% ethanol.  
 
4.3.6 Micro-computed tomography (Micro-CT), histomorphometry, immunofluorescence, and 
immunohistochemistry  
 Tissue-fixed specimens were embedded in alginate, scanned using micro-CT (Scanco 
Medical) at a resolution of 12um, at 70kV energy and 114uA intensity, and calibrated to 
Hounsfield units (HU). Bone volume (BV) and tissue mineral density (TMD) were determined for 
internal and external regions of the bone compartment using Microview software (Parallax 
Innovations) with a threshold of HU=1050 for bone. After scanning, samples were decalcified in 
10% EDTA, embedded in paraffin, and cut into 5um sections for histological analysis using 
hematoxylin and eosin (H&E) and Masson's trichrome staining to evaluate fibrous tissue 
orientation and collagen formation, respectively. Immunofluorescence staining was performed 
using 4',6-diamidino-2-phenylindole (Prolong Gold Antifade Reagent with DAPI; Life 
Technologies) to label cell nuclei and anti-tubulin antibody with AlexaFluor488 (1:100 dilution, 
Abcam Inc, Cambridge MA) to label microtubules. Stained slides were imaged using fluorescence 
microscopy (Nikon Eclipse 50i) to capture cell nuclear alignment for all groups using a specified 
ROI (150um x 250um). ImageJ was used to quantify percentage of cells aligned perpendicular to 
the dentin segment, with cells considered aligned at an angle of ±20° from the perpendicular at 
90° (i.e., 70° ≤ x ≤ 110°, where x is the alignment angle). Nuclear shape index was used to assess 
cell nuclear elongation. ImageJ was used to threshold the images and run an analysis of elongation 
based on a measure of circularity (C=4*π*area/perimeter2, where C=1 indicates a circle) [19]. 
Masson's trichrome images were further used to assess thickness of collagen bundles oriented 
perpendicular to dentin segment at sites bordering the grooved and non-grooved pillars for samples 
obtained at 6 weeks.   
 Formation of cementum-like tissue was quantified using H&E sections and further assessed 
via immunohistochemical analysis of bone sialoprotein (BSP) positive staining using 
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deparaffinized sections. Before immunostaining, rehydrated sections were treated with 3% 
hydrogen peroxide and blocked in bovine serum albumin to reduce non-specific binding. Sections 
were exposed to primary antibody (1:200, Anti-bone sialoprotein antibody, Abcam, Cambridge, 
MA) for 24 hours at 4°C, washed in PBS with 0.2% Triton-X, and exposed to secondary antibody 
for 1hr (Goat Anti-rabbit IgG H&L (HRP), Abcam). After washes in PBS with Triton-X, sections 
were briefly exposed to a chromogen/substrate solution (DAB substrate kit, Abcam) and counter-
stained (Hematoxylin, Sigma-Aldrich). 
 
4.3.7 Statistical analysis  
 Data were expressed as mean ± standard deviation of the mean. One-way analysis of 
variance (ANOVA) with post hoc Tukey's multiple comparison method was used to perform 
comparative analysis, with a p-value <0.05 (α<0.05) considered significant.  
 
4.4 Results 
4.4.1  PCL surface treatment and ligament cell alignment on 2D grooved PCL films   
Four different surface treatments of non-patterned PCL films were performed prior to cell 
seeding to assess periodontal ligament (PDL) cell adhesion and proliferation relative to non-treated 
films: (1) amination to generate a PCL-NH2 surface chemistry, (2) hydrolysis to reduce surface 
hydrophobicity, (3) fibronectin, and (4) hydrolysis pre-treatment prior to fibronectin coating. 
Significantly higher mean hPDL cell adhesion percentage of the initial cell seeding density was 
shown using treatment of PCL with fibronectin alone and a combined treatment of hydrolysis and 
fibronectin at day 1 post-seeding, relative to a non-treated PCL film. At day 5, the total percentage 
of adhered cells was significantly higher on hydrolysis, fibronectin, and combined hydrolysis and 
fibronectin treatment of PCL surfaces relative to amination and no treatment (Figure 4.1). Based 
on these results, all PCL patterned and control films were hydrolyzed the day before and 
fibronectin-coated the day of hPDL cell seeding to increase cell attachment to the inert PCL 
surface.  
 To create a 3D micropattern design for the PDL region of the scaffold, a 2D pattern was 
first generated to study the parameters that assisted in periodontal progenitor cell alignment. Three 
different molds were fabricated using three groove widths ranging from 10-50um, with a depth of 
10um (Figure 4.2A). PCL was readily patterned, replicating mold features and creating a film that 
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can be easily handled without distorting the features (Figure 2B). Human PDL cells seeded onto 
the surface treated, patterned films showed elongation of filopodia within the grooves, whereas 
cells on a non-patterned PCL surface were randomly oriented (Figure 2C). Quantitative analysis 
of average orientation angle (OA) demonstrated significant differences between the non-patterned 
and patterned groups and significantly higher OA on 50um grooved PCL relative to 25um and 
10um grooved films. No significant differences in OA were observed between the 25 and 10um 
patterned films (Figure 2D). An analysis of the distribution of aligned cells in specific ranges (5° 
to 15° degree ranges) indicated a higher percentage of cells with the lowest OA (0-5°) on the 10um 
(86.9%) grooved surface, followed by 25um (79.8%), 50um (32.3%), and control (6.1%) films 
(Figure 2E). Our results show that cell alignment was highly associated with groove width on 2D 
PCL films.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 PCL Scaffold Surface Modification 
Surface treatment of PCL films using aminolysis, hydrolysis, fibronectin coating, and combined 
treatment of hydrolysis and fibronectin assessed to determine conditions for increased hPDL cell 
attachment. Data shows mean percentage of ligament progenitor cells adhered to non-treated PCL 
films in vitro versus surface-treated PCL at 1 and 5 days post-seeding. (Error bars: ± SD; ** 
p<0.01; *** p<0.001, **** p<0.0001; # indicates p<0.05 relative to non-treated PCL film at each 
timepoint; n=3).  
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Figure 4.2 2D-Micropatterned Film Design and Cell Seeding Assessment  
Micropatterned 2D PCL film design was used to determine effects of groove width on hPDL cell 
alignment in vitro. Films were patterned using three different molds (a) to embed grooved features 
onto the polymer surface (b, surface with 50um wide grooves, Nikon SMZ18 stereo microscope). 
DilC(12)-3 stained hPDL cells seeded on hydrolyzed and fibronectin treated PCL films with non-
grooved (control) and grooved surfaces (c). White arrows indicate direction of grooves (scale 
bar=50um). Average orientation of hPDL cells on control (non-patterned), 50 um, 25 um, and 10 
um grooved PCL films, where 0°  indicates complete alignment with pattern and 90° indicates a 
cell that is perpendicular to a groove (d). Proportion of hPDL cells within a specific orientation 
angle for all PCL film groups, with 0-5° groups indicating highest alignment of cells within 
grooved microfeatures (e). (Error bars: ± SD; * p<0.05; ** p<0.01; **** p<0.0001). 
 
4.4.2 Design of PCL scaffolds with 3D patterned film and 3D printed base  
The tooth root is covered with a layer of calcified tissue known as cementum, into which 
PDL collagen fiber bundles are inserted and further anchored into the alveolar bone. To mimic the 
known anatomical features of the bone-PDL interphase bordering a tooth root, a scaffold 
containing compartments for bone and periodontal ligament tissue formation was designed 
(Figure 4.3A). In detail, the bone region of the scaffold was adapted for selective laser sintering 
based on previous parameters established in our laboratory by Park et al [13]. This region was 
designed to be 5.1x4.1mm with a height of 3.2mm, where the first 2.1mm are part of the base and 
the remaining 1.1mm on the four corners form an enclosure to contain the film and dentin segment 
(Figure 3B). Pore sizes were restricted to a minimum of 700um x 700um given the 3D-printer 
resolution, with composition of the scaffold consisting of PCL mixed with 5% hydroxyapatite 
(HA) to mimic the mineral-based content of natural bone. The PDL region of the scaffold was 
designed to provide architectural guidance for cell alignment and subsequent collagen fiber 
formation using pillars that would act as supportive structures for PDL-like tissue formation 
between calcified tissues (i.e., bone and dentin). Pillar height was 250um to mimic the average 
thickness of human PDL tissue. Based on results of cell alignment on 2D-grooved PCL films, 
pillars were formed with grooves of 60um or 15um and depth of 10 or 30um to investigate effects 
of groove width and depth on PDL-like tissue formation. A porous salt-leached PCL sponge was 
included as a negative control, in addition to non-grooved pillars to assess effect of pillars alone 
on cell and tissue alignment. SEM images indicate the random nature of the porous PCL sponge 
relative to grooved pillars that present clear boundaries for groove width and depth corresponding 
to mold design and overall stability of the 250um high features (Figure 3C).  
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Figure 4.3 3D-Micropatterned Film Design and Ectopic Murine Model 
 Schematic design of the scaffold intergrating 3D printed and micropatterned regions for the bone-
ligament oral complex. Anatomical features of the alveolar bone-periodontal ligament interphase 
present innately at the tooth root surface (a) were used to design a scaffold combining a 3D printed 
PCL region and a 3D patterned PCL film for the bone and PDL regions, respectively (b). A total 
of six groups (c) were tested in vivo by varying the geometry (width, W and depth, D of the 
grooves) of the PCL in the PDL region of the scaffold: (1) random-porous, salt-leached PCL 
sponge, (2) 400x400 um square pillars 250um in height, (3) square pillars with 60um wide and 
30um deep grooves, (4) pillars with 60um wide and10um deep grooves, (5) pillars with 15um 
wide, 30um deep and 15um wide, 10um deep (6) grooves. (d) An ex vivo murine model was used 
to subcutaneously implant the combined scaffold to promote  bone (B) and periodontal ligament 
formation, with a dentin segment (D) press-fit on top of the combined scaffold after cell-seeding 
the PDL region prior to implantation.  
 
 
Cementum covers the dentin surface of the tooth root, but this layer was removed from 
human-derived roots to obtain dentin segments that were cut down to dimensions of the scaffold 
and positioned over 3D micropatterned film regions (Figure 3D). In vivo assessment of tissue 
alignment within the PDL region was performed using a previously established murine model 
utilizing human gingival fibroblast (hGF) cells transduced with adenoviral (Ad) bone 
morphogenetic protein (BMP)-7 to generate bone formation [13, 18]. 
 
4.4.3 Mineralized tissue formation in 3-D printed scaffold region in vivo  
Analysis of bone volume (BV) in samples at 3 and 6 weeks shows a significant difference 
(p<0.0001) in the volume measured encompassing the 3-D printed region of the scaffold versus 
the volume identified within the entire scaffold region. As evidenced by uCT scans of a scaffold 
at 6 weeks (Figure 4.4A) the majority of bone was formed encompassing the scaffold along the 
3D-printed PCL walls. However, no significant differences in BV were observed between weeks 
3 and 6 for both regions. Tissue mineral density (TMD) indicating maturity of bone showed no 
differences between regions when comparing both time points, but TMD increased significantly 
for both the bone region (p<0.0001) and entire scaffold (p<0.001) from week 3 to week 6 (Figure 
4B).  
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Figure 4.4   Bone Volume and Tissue Mineral Density  
Formation of bone in the 3D printed scaffold region seeded with adenoviral BMP7 transduced 
gingival fibroblasts. Micro-computed tomography (uCT) of implanted scaffolds was used for 
bone volume (BV) and tissue mineral density (TMD) analysis of osseous tissue growth in vivo in 
the bone region of the scaffold (a) compared to the formation of tissue in the entire scaffold 
external to bone region at 3 and 6 weeks post-harvesting (b). (Error bars: ± SD; *** p<0.001, 
**** p<0.0001; n=5-6). 
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4.4.4 Histomorphology of soft, mineralized, and cementum-like tissue formation in vivo  
To delineate the histomorphology of soft and mineralized tissue formation in vivo, we 
performed studies using several staining methods. Hematoxylin and Eosin stains at 3 weeks (data 
not shown) and 6 weeks indicated soft tissue formation in the region of 3D patterned film, as well 
as in most of the 3D printed scaffold where bone had not invaded further into the scaffold interior. 
Trichrome staining of PDL regions revealed randomly-oriented collagenous tissue formation in 
groups with porous PCL, while pillared PCL films showed fibrous collagen formation with 
increased directionality towards the dentin segment at 6 weeks (Figure 4.5A). Staining using 
DAPI and tubulin-based markers showed high cell density and extracellular matrix formation in 
the PDL region of the scaffold confined to areas within the inter-pillar distance. Indication of early-
stage formation of an immature cementum-like tissue at 6 weeks on the dentin below the PDL 
region was identified descriptively and also using bone sialoprotein (BSP)-positive staining. The 
amount of new tissue formation that had cementogenesis-like indicators was minimal overall, with 
an average length of 337±66um when averaged for all patterned groups, compared to the 2.7mm 
approximate length of dentin segments.  
 
4.4.5 Effect of 3D patterned design on cell alignment in vivo   
Cell alignment in vivo was evaluated using nuclear alignment and shape index following 
immunofluorescence staining of tissue sections. Our data revealed an increasing tendency of cells 
along the pillar edge to align perpendicular to the dentin surface with increasing groove depth 
(Figure 4.6A), particularly with more cells shown to be aligning further away from the pillar wall. 
At 3 weeks, all groups had a significantly higher percentage of aligned cells compared to porous 
PCL, with the same observation present at 6 weeks, except for non-grooved pillars which were not 
significantly different from the porous sponge. Relative to non-grooved pillars, both of the deeper-
grooved groups (60W, 30D and15W, 30D) exhibited significantly higher alignment at 3 weeks 
(p<0.001 and p<0.01, respectively). At 6 weeks, the differences in alignment were more apparent, 
with all grooved pillars irrespective of groove depth (60W, 10D; 15W, 10D; 60W, 30D; and 15W, 
30D) showing significantly higher cellular alignment (p<0.001 and p<0.0001) relative to non-
grooved pillars. Likewise, grooved pillars with a depth of 30um also had significantly higher 
alignment (p<0.001) relative to pillars with shallower grooves (Figure 6B).  
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Figure 4.5  Histomorphological Assessment of Soft and Mineralized Tissue Formation 
Histomorphological assessment of soft and mineralized tissue formation in the micropatterned 
PDL and 3D printed bone scaffold compartments, respectively. (a) H&E, Masson's trichrome, and 
DAPI (blue)/tubulin(green) staining was performed to assess bone (B) and tissue formation, 
collagen alignment, and cellular alignment in the region of the PCL film or sponge at 3 and 6 
weeks (images shown are at 6 week timepoint only).  Note the formation of fibers approaching the 
dentin surface and bone more distant in the bone region of the scaffold (near bottom of the H&E 
sections). (b) Formation of cementum-like tissue newly-deposited at the dentin (D) surface was 
observed on week 6 samples using H&E staining and immunohistochemical analysis for bone 
sialoprotein (BSP) positive expression. Scale bar = 100um.  
 
 
Nuclear shape index was used to assess nuclear elongation as a complement to the cellular 
alignment data, with values closer to 1 indicating increased nuclear circularity (Figure 6C) [19]. 
At 3 weeks, only deeper grooved pillars had significantly higher elongation values compared to 
both PCL sponge and non-grooved pillars, with the 60W, 30D pillars having more elongated cells 
relative to non-grooved (p<0.0001) and 15W, 30D pillars (p<0.05). Only 60W, 30D pillars had 
significantly higher elongation relative to both of the shallow-grooved pillars at 3 weeks (p<0.01). 
At 6 weeks, all groups had significantly higher elongation relative to cells on the PCL sponge, 
while all grooved pillars (p<0.01-0.0001) also had a significantly lower shape index relative to 
non-grooved designs. However, no significant differences were noted among the grooved pillar 
groups, irrespective of groove depth.  
Overall, these results demonstrate increased cell alignment further from the pillar boundary 
in films with grooves compared to non-grooved pillars, with increased alignment in deeper-
grooved (30um) pillars compared to shallow-grooved (15um) pillars. This can be attributed to soft 
tissue maturation and alignment which correspond to a significant increase in overall cell 
elongation from week 3 to 6, albeit not necessarily perpendicular to the dentin since this 
quantification considers only cell morphology independent of orientation. 
 
4.4.6 Effect of 3D patterned design on oriented collagen thickness in vivo  
The extracellular component of PDL consists of collagen fiber bundles which assist with 
allowing the tooth to withstand substantial compressive forces. We therefore analyzed collagen 
thickness oriented along the pillar wall creating a bundle-like structure perpendicular to the dentin 
segment. Our data showed that collagen thickness at 6 weeks is significantly greater in both deeper-
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grooved pillar groups with grooves of 60um and 15um compared to non-grooved pillars 
(p<0.0001) (Figure 4.7). Only one shallow-grooved group (60W, 10D) showed greater thickness 
relative to 0W, 0D (p<0.001). The 60W, 30W group had a total collagen thickness that was 
significantly higher than other groups, except for its deep-grooved counterpart with narrower 
grooves of 15um (15W, 30D). These results further reinforce the findings shown with cell 
alignment at 6 weeks, indicating that groove depth is a more critical parameter than width for 
encouraging formation of cell alignment and subsequent increase in oriented collagen fiber density  
at sites of increased cellular orientation.  
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Figure 4.6 Immunofluorescence: Cell Alignment and Nuclear Shape Index 
Cell alignment and nuclear shape index assessed using immnufluorescence staining at 6 weeks. 
(a) DAPI (blue) and tubulin (green) shows increased cell alignment further from the pillar 
boundary in films with grooves compared to non-grooved pillars, and in films with deep grooves 
(30um) compared to more shallow grooves (10um). Scale bar = 50um. (b) Mean percentage of 
aligned cell nuclei (within 20° of preferred perpendicular orientation: 70°≤x≤110°) in vivo on PCL 
sponge, non-grooved pillars (0W, 0D), and grooved pillars (60 um and 15um wide (W) grooves) 
with varying groove depths (D) (10 um—red outline, and 30um—blue outline). (c) Mean nuclear 
shape index analysis indicating cellular elongation in vivo on all groups based on measure of 
nuclear circularity (C=4*π*area/perimeter²). (Error bars: ± SD; ** p<0.01; *** p<0.001, **** 
p<0.0001; # indicates p<0.05 relative to PCL sponge at each timepoint; n=5 in each group).  
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Figure 4.7 Collagenous Tissue Alignment using Micropatterned Films 
Collagen thickness at inter-pillar distances bordering grooved or non-grooved features used to 
determine oriented tissue formation at 6 weeks in vivo. (a) Masson's Trichrome stining of samples 
indicates increased collagen orientation perpendicular to dentin (D) segment at the pillar boundary 
in the presence of grooves (scale bar = 100um). (b) Mean thickness (um) of oriented collagen 
bundles in vivo at non-grooved (0W, 0D) and grooved (15-60um wide, 10-30um deep) pillar 
borders at 6 weeks based on Masson's Trichrome staining.  (Error bars: ± SD; ** p<0.01; *** 
p<0.001, **** p<0.0001; n=5).  
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4.5 Discussion 
Promoting orientation of cells in a specific and structurally-relevant direction via substrate 
guidance has been shown to stimulate cell behavior and create organized tissues in vitro that mimic 
their native form and function, including cardiac and nerve tissues [20]. Overall, micro- and meso-
scale cues have been strongly implicated in aligned cellular and fibrillary collagen formation in 
vitro. Gilchrist et al found that a width of 500um was the maximum in vitro meso-scale boundary 
for guidance of neo-tissue alignment using mesenchymal stem cells [21]. Likewise, highly aligned 
tissue formation consisting of fibrillary collagen was observed when cells were arranged 
longitudinally end-to-end. This in vitro finding is consistent with our observations in vivo of highly 
aligned cell formation on pillar walls which appears to correspond to increased collagen fiber 
formation seen with Trichrome staining at sites of increased cell alignment.  In fact, our study 
identified a strong positive correlation (r=0.863, data not shown) between cell alignment and 
collagen thickness based on values obtained from these measurements (Figure 6-7).  
Cellular morphology assessed using both cellular alignment angle and nuclear elongation 
suggests significant (p<0.0001) and overriding effects of groove depth over width. Our results 
indicate increased preferential alignment of cells in vivo on grooved substrates over a non-grooved 
surface. Nano- and micro-structured groove widths and depths have been extensively investigated 
using a variety of cells to determine optimum parameters for cell alignment using in vitro models 
[22]. While results can be cell-specific, fibroblasts in particular have been shown to have a nano- 
and micro-limit of alignment ranging from 50-100nm to 500um [23-25]. Likewise, several studies 
have reported increased cell alignment with increasing groove depth, both on nano- and micro-
levels [26-28]. There are strong indications that in particular cases the depth can reinforce, if not 
override, cellular guidance via groove width.  Increase in cell alignment and collagen fiber 
alignment may also be a factor of the cell’s innate ability to align in vitro and in vivo. Aubin et al 
showed cells with intrinsic ability to form aligned tissue in vivo are more likely to organize into 
oriented tissue in vitro in presence of guidance-based microarchitecture [29]. 
 Previous studies successful in achieving aligned collagenous tissue formation using 
substrates with cell-guiding cues have utilized electrospun fibers composed of naturally- and 
synthetically-derived polymers. Jiang et al reported increased PDL-like tissue formation with 
mature collagen fibers using aligned PCL-polyethylene glycol (PEG) nanofibers embedded into 
porous chitosan scaffolds and seeded with bone marrow mesenchymal stem cells [30]. Similar 
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findings have been observed in applications for neural and cardiac tissue regeneration: Koepsell 
et al noted increased cellular orientation of intervertebral disc-derived cells on increasingly aligned 
electrospun PCL fibers resulted in higher ECM production, including collagen and 
glycosaminoglycans, while Ifkovits et al found enhanced collagen alignment on oriented 
poly(glycerol sebacate) fibers when seeded with cardiocytes and implanted subcutaneously [31, 
32]. However, it remains difficult to create three-dimensional scaffolds using these techniques 
without the presence of a more complex and customizable system such as a 3-D printer that could 
position fibers in directions relevant to the anatomical structure of tissue we attempt to model, 
thereby recapitulating its unique geometric complexity. Additive manufacturing has been used 
extensively for guided tissue regeneration of PDL-like structures, but micro-level control over 
scaffold structure is constrained by limited resolution and material selection [14, 17].  To address 
these limitations, our approach focuses on using a combination of 3-D printing and 
micropatterning to create a scaffold with the dual function of presenting features on the macro and 
micro-level for guidance of bulk and oriented tissue formation (i.e., mineralized and soft tissue). 
To our knowledge, this is the first reported attempt to quantify cell alignment on a micropatterned 
polymeric construct implanted in vivo. While numerous aforementioned publications have 
signaled the importance and potential of guiding aligned tissue formation using this approach, 
existing studies have focused on in vitro assessment of cellular alignment, without further 
translation into in vivo models.   
 The development of a 3-D pattern consistent with known geometric parameters of the 
human periodontal ligament (i.e., 250um average thickness), including presence of collagen I and 
III fiber bundles that orient perpendicular to the alveolar bone and tooth root (Figure 3), was 
executed to assess the role of groove width and depth using an in vivo model. The 3-D printed 
bone region and PDL film consisted of defined openings to create porosity within the bulk 
structure, promoting nutrient exchange and cellular migration between the regions. Seeding of 
AdBMP-7 expressing hPDL cells in the bone region resulted in bone formation that was mostly 
external to the interior region of the 3-D printed scaffold as shown using histology and micro-CT 
analysis (Figures 4 and 5A, respectively), a limitation of the model inherent in the non-localized 
expression of the growth factor that likely resulted in its diffusion to the exterior regions of the 
scaffold, as has been observed in other studies [33, 34].  The use of a non-loading model may have 
contributed to lack of significant increase in bone volume between weeks 3 and 6, although 
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existing bone was found to mature over time, as evidenced by increase in tissue mineral density. 
Likewise, due to limited bone growth below the PDL region of the scaffold, no integration between 
the bone and PDL regions was observed. This is an important indicator of bone-ligament complex 
regeneration and requires future improvements in the design of the bone compartment and 
localization of bone-stimulating growth factor delivery. Specifically, native bone-PDL integration 
consists of Sharpey’s fiber insertions into osseous tissue that stabilize and connect the soft tissue. 
A bone region which promotes formation of such attachments below the PDL compartment 
through incorporation of increased and possibly directional porosity would improve regeneration 
of this multiphasic tissue complex. To fully and successfully realize periodontal tissue regeneration 
using a multiphasic scaffold, cementum must be formed along the dentin surface. While our data 
does not show definitive mature cementum, BSP-positive staining (Figure 5B) does suggest early-
stage mineralized, cementum-like tissue formation localized at the boundary between the dentin 
segment and inter-pillar areas filled with collagenous soft-tissue.  
 Our results detailing cellular alignment and collagen formation are indicative of the need 
for guidance of cellular alignment to promote oriented collagen formation in vivo. In fact, Wang 
et al had previously shown that grooved substrates resulted in alignment of synthetized collagen 
matrix in vitro parallel to the grooves, preceded by the alignment of cells [35]. In this study, we 
show that this holds true using a micropatterned substrate under in vivo conditions, albeit with the 
added factor of groove depth as an important precursor to the percentage of aligned cells (Figure 
6) and resultant thickness of oriented collagenous tissue (Figure 7). It is important to note that 
while cellular alignment and increased collagen thickness is seen at pillar boundaries, the existing 
space of 400um between the pillars does not currently allow for aligned tissue formation in that 
area within a period of 6 weeks. There is likewise the potential of tissue formed between pillars to 
lose orientation given large inter-pillar distances. Therefore, an improvement to the current 
patterned film design to better replicate periodontal ligament fiber architecture and increase fiber 
density would consist of reducing this distance to 100-150um, given that the average thickest 
formation of oriented collagenous tissue at 6 weeks was ~35um for one side of the 30um-deep 
grooved pillars.  Another area of further study may include an analysis of whether there is a limit 
to the aligned tissue formation boundary layer away from the pillar surface, since the given results 
are an indication of the capacity for aligned tissue formation at only 6 weeks in vivo.  
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Future improvements in addition to scaffold morphology would involve introduction of 
other factors that play a crucial role in formation of functional periodontal ligament, including 
growth factors such as platelet derived growth factor (PDGF) and mechanical stimulation at 
physiological levels, which has been show to modulate PDL cell gene activity [8, 36]. Increased 
control and localization of bone-stimulatory growth factor protein release such as BMP would 
further benefit osseous tissue formation within the bone compartment. While the use of gene 
therapy significantly increases sustained growth factor release and stability in vivo, further 
improvements in minimizing growth factor diffusion from the target site would greatly improve 
its application in scaffold-based therapies [37]. Such strategies could include the direct adsorption 
or chemical conjugation of BMPs onto the scaffold surface, or tethering of viral vectors expressing 
BMP genes to PCL surfaces using chemical vapor deposition [38-41].  
  In attempting to transition scaffold-based designs from the bench-top to clinical 
applications that can benefit patients, use of 3D printing has become a promising strategy for 
creating customized implants with potential to mimic patient-based bulk defects, even for cases of 
periodontal therapy [42, 43]. In guided regeneration of ligamentous structures, the combination of 
3D printed and micropatterned regions into one construct is an innovative approach that can 
provide a means of re-establishing the interfacial integrity of aligned tissue formation in bone-
ligament complexes. Although the scaffold design used in this study was simplistic relative to a 
true periodontal defect involving bone resorption, it can be easily adapted to more complex defects 
using patient-based computed tomography scans to design the 3D printed region, and create an 
overlay of a micropatterned film in the region of missing PDL. The results of our study indicating 
the importance of groove depth over width for aligned tissue formation in vivo can play a vital role 
in the establishment of a design that can incorporate this cell-guiding parameter into future grafts 
meant for the purpose of inducing structurally-relevant alignment of PDL tissue. Future translation 
of micropatterned constructs into the clinic may provide greater opportunities for more controlled 
tissue regeneration using not only ridge-groove structures, but also other relevant designs that can 
help orient tissue based on incorporated material boundaries. The combination of a custom-
designed 3-D printed scaffold and a micropatterned region fit to control the structural integrity of 
new tissue growth is a clinically-relevant approach that holds significant potential for regeneration 
of collagenous tissue not only in periodontal and orthopaedic applications, but other areas of tissue 
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engineering with a strong focus on improving collagen fiber orientation as it relates to tissue 
structure and function.  
 
4.6 Conclusion 
In summary, the findings from this preclinical study indicate that groove micro-depth has 
a significant effect on guiding cellular alignment and collagenous tissue orientation in vivo, 
overriding the effects of groove micro-width. The 3-D patterned scaffold conceived and designed 
in this study further presents a novel and unique combination of 3-D printing and micropatterning 
to enhance the micro- and macro-level design of scaffolds with the aim of regenerating multiple 
tissues and their interfaces. Using a combination of gene therapy and topographical guidance cues 
to achieve osseous tissue formation and oriented collagen fibers has potential for bone-ligament 
regeneration for treatment of periodontal osseous defects. Overall, these findings are supportive of 
the advantageous effects of using 3-D printed, micropatterned substrates as architectural templates 
for guided regeneration of oriented collagenous tissues.  This approach may have significant 
potential for clinical applications in the development of bone-ligament constructs for dental and 
orthopaedic clinical scenarios. 
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CHAPTER 5 
 
IN VIVO ASSESSMENT OF PERIODONTAL REGENERATION VIA 
IMMOBILIZATION OF GENE THERAPY VECTORS ON 3D-PRINTED, 
MICROPATTERED SCAFFOLDS – A PILOT STUDY 
 
Contributions to the data collection/analysis that are part of this chapter were made by:  
Drs. Jie Hao and Ning Yu (Periodontics and Oral Medicine, University of Michigan).  
 
 
 
5.1 Introduction   
Current clinical therapies cannot predictably regenerate bone-ligament interfaces in tooth-
supporting tissues damaged by trauma or disease.  We previously developed a scaffold with 3D-
printed, micropatterned features for guidance of osseous and soft tissue formation in vivo [1]. 
However, bone formation within the scaffold resulted from in vitro transduction of cells with 
adenoviral (Ad) vectors expressing bone morphogenetic protein (BMP-7) prior to implantation. 
This study investigates a more clinically-relevant gene delivery approach by localized 
immobilization of AdBMP7 and platelet-derived growth factor (AdPDGF) onto scaffold ‘bone’ 
and ‘PDL’ regions, respectively, for evaluation in a subcutaneous murine extra-orthotopic model.  
While growth factors have been delivered via physical absorption onto scaffolds, this method lacks 
the ability to control the spatiotemporal release of the GF and specifically target the GF for 
immobilization.  
Chemical vapor deposition (CVD) is a technique that allows for the functionalization of 
complex 3D scaffold architectures: the surface is made to present a variety of functional groups 
(i.e., amine, carboxylic acid, ketones, aldehyde) depending on the chemical composition of the 
binding biomolecules. CVD-based polymer coatings have been shown to be biocompatible and 
approved by the FDA for use in certain applications. Improved growth factor binding to material 
surfaces treated with CVD-based polymer coatings have been shown, as in the formation of 
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oxygen-terminal groups on nano-crystalline diamond surfaces to allow for interaction with 
recombinant human (rh) bone morphogenetic protein-2 (rhBMP-2) through an affinity that 
resembles that of specific receptor-ligand interactions. Several studies have explored the idea of 
using such polymer coating for localized gene delivery through the use of gene vectors that can be 
immobilized to the material surface so as to enable the infection of implanted or endogenous cells, 
with the added benefit of reducing the risk of virus dispersion while also reducing the necessary 
administration dose and increasing transduction efficiency. Zhang et al showed that adenovirus 
expressing runt-related transcription factor 2 (AdRunx2) can be immobilized onto 
polycaprolactone (PCL) through the deposition of amine-reactive active ester groups, such that an 
anti-adenovirus antibody could be conjugated to the material surface via an amide chemical bond, 
followed by AdRunx2 attachment to the PCL surface via antibody-antigen interaction. The treated 
PCL surface with AdRunx2 was incubated in the presence of bone marrow stromal cells (BMSCs), 
resulting in high alkaline phosphate (ALP) activity and subsequent matrix mineralization [3-5].  
Most recently, Hao et al adopted this technique to investigate adenoviral vector conjugation 
to a variety of materials, including polylactic-co-glycolic acid (PLGA) and titanium, as well as 
PCL [1] (Figure 5.1). Immobilization of AdPDGF-BB and AdBMP7 resulted in transduction of 
seeded human periodontal ligament (hPDL) cells, resulting in the production of both PDGF-BB 
and BMP7. Enzyme-linked immunosorbent assay (ELISA) was used to determine the production 
of Collagen types I, III, and V as well as osteopontin, ALP, and osteocalcin, all of which allowed 
for an examination of whether hPDL cells were differentiating. Additionally, a scaffold with 3D 
geometry was used for combinational gene delivery, such that one compartment of the scaffold 
was immobilized with AdBMP7, and the other with AdPDGF-BB. Interestingly, while PDGF 
expression was not significantly reduced by the presence of BMP7 expression in the nearby 
compartment of the scaffold when compared to its expression in a control experiment which used 
Ad-empty vector in place of AdBMP7, the expression of BMP7 was significant reduced in the 
presence of concurrent PDGF-BB expression.  A previous study investigating the repair of 
periodontal defects in beagle dogs using BioGlass/silk scaffolds with AdPDGF-B and AdBMP7 
showed that AdPDGF recruited PDL cells more effectively (by 6-fold) compared to AdBMP7, 
while AdBMP7 itself promoted PDL cell differentiation to osteoblasts. The combined use of both 
adenoviral growth factors resulted in increased PDL, alveolar bone, and cementum regeneration 
compared to groups that delivered each adenovirus separately without combining with the other, 
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thereby having a synergistic effect on wound healing [6].  
 The primary goal of this study is to expand upon the Hao et al work showing the potential 
of gene therapy vector delivery and apply it to a second-generation, improved 3D-printed, 
micropatterned scaffold (described in Chapter 4), in order to investigate the best methodology of 
obtaining periodontal regeneration using an ectopic model initially, then progressing to the rat 
fenestration defect. This is the first known investigation of CVD-coated materials for the purpose 
of delivering gene therapy vectors to stimulate regeneration in vivo. In addition, this study also 
focuses on determining the optimal scaffold design for use in a rat fenestration defect model based 
on previously observed limitations of the existing scaffold design described in Chapter 4. 
 
Figure 5.1 Immobilization of Gene Therapy Vectors on Biomaterial Surfaces 
The immobilization of biomolecules (i.e., adenoviral vectors) on a polymer surface (i.e., PCL, 
PLGA) can be achieved using chemical vapor deposition (CVD) polymerization of substituted 
paracyclophanes. This consists of (1) coating the material with a layer of pentafluorophenol (PFP)-
ester groups using CVD polymerization, (2) immobilizing an anti-adenovirus antibody onto the 
surface, and (3) further immobilization of the adenovirus (i.e., AdBMP, AdPDGF) through 
antigen-antibody interaction. This surface modification technique can be used on 2D and 3D 
surfaces without compromising biocompatibility (i.e., introducing components which would be 
cytotoxic). This method is versatile, such that a surface can be made to present a variety of 
functional groups (i.e., amine, carboxylic acid, ketones, aldehyde) depending on the chemical 
composition of the binding biomolecules. Figure used with permission from [2].  
 
5.2  Materials and Methods 
5.2.1 Preparation of scaffolds for ectopic murine model  
The 3D-printed region of the scaffold was designed and fabricated as previously described 
[1]. Briefly, the design was performed using CAD-based software (NX 7.5, Siemens PLM 
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Software) such that the base had dimensions of 5.1 x 4.1 x 2.1 mm, a 1.1 mm high enclosure to 
contain the PCL film, and 0.7 mm wide pores. The scaffold was 3D printed using PCL powder 
(43-50kDa; Polysciences, Warrington, PA) and 4 wt% hydroxyapatite (Plasma Biotal Limited) via 
selective laser sintering (Formiga P100 system; EOS e-Manufacturing Solutions). The 
micropatterned region of the scaffold was altered from the previous design such as to: (1) decrease 
the inter-pillar distance from 400um to 150um, while retaining the same height (250um), (2) 
reduce the pillar length x width measurement from 400um x 400um to 300um x 300um, (3) 
increase the base porosity using water-based leaching of sugar particles (diameter = 125um), and 
(4) increase biomaterial degradation rate by forming the patterned film using PLGA. The pillar 
groove design consisting of 15um wide, 30um deep grooves was selected among the previous 
designs described [1] due to the previous results showing that groove depth (i.e., 10um vs. 30um) 
was a determining factor in the amount (i.e., width at pillar boundary) of aligned tissue formation.  
As previously reported, a CAD-based program (LEdit) was used to design the new 
micropatterns and define the silicon and SU-8 master molds with standard photolithography, with 
mold fabrication performed at Lurie Nanofabrication Facility (University of Michigan, Ann Arbor, 
MI). Polydimethylsiloxane (PDMS, Sylgard 184; Dow Corning) was mixed in a ratio of 10:1 v/v 
of base to curing agent, degassed under vacuum, poured onto SU-8 master molds, cured (65˚C), 
and peeled to reveal the pattern. The pillars were formed via casting of 2.5% PLGA (75:25, 
137kDa, Evonik Industries) onto the PDMS mold until they were filled. A solution of 10% PCL 
containing sieved sugar particles (125um diameter) was then cast onto the pillars in order to form 
a layer approximately 250um thick. The films were dried under vacuum for a period of 24 hours 
before placement in deionized water to dissolve away the sugar particles.  
 
5.2.2 Preparation of scaffolds for rat fenestration defect  
Preparation of the micropatterned film was undertaken as described in Section 5.2.1, except 
that a solution of PLGA-PCL (50/50) was used instead of PLGA alone, based on results from the 
pilot study using this formulation in the ectopic murine model. Additionally, instead of the 3D-
printed scaffold region created using SLS, the “bone” region of the scaffold was formed by mixing 
sugar particles (ranging from 100-400um in diameter) with 10% PCL solution and casting into a 
glass dish to produce a 250um thick base that was dried overnight under vacuum before being 
placed in deionized water to allow for sugar particle leaching out of the film.  
106 
 
 
 
5.2.3 Chemical vapor deposition (CVD) and gene therapy vector immobilization 
Scaffolds (i.e., 3D-printed region and micropatterned film, or amorphous region and 
micropatterned film) were coated with a layer of amine-reactive polymer using a custom-built 
CVD system, as previously reported (Hao et al). Briefly, the coating process consisted of fixing 
the scaffolds inside the deposition chamber at 15°C, with the starting material sublimated at 120°C, 
followed by pyrolyzation at 540°C to form into a stream of reactive di-radical vapor which 
deposited and polymerized on the scaffold surface (pressure of 0.1 mbar, argon as carrier gas). The 
scaffolds were turned to the other side and the process repeated to ensure that the coating deposited 
on all sides. After this process, scaffolds either stored under vacuum until further use of sterilized 
in 70% ethanol (1hr) to prepare for virus immobilization and subsequent cell seeding, as needed.  
 The experimental groups consisted of immobilizing adenovirus encoding BMP7 for the 
“bone” region of the scaffold (i.e., 3D printed scaffold or amorphous PCL film) and adenovirus 
encoding PDGF-BB on the “PDL” region of the scaffold (i.e., porous micropatterned film). 
Control groups consisted of immobilization with adenovirus without any growth factor gene (i.e., 
empty adenovirus, or Ad-empty). After sterilization, scaffolds were treated with 10 μg/mL solution 
of goat anti-adenovirus (AbD Serotec; 0151- 9004) polyclonal antibody in phosphate-buffered 
saline (PBS), determined based on a previously established saturation point.  The scaffolds were 
incubated in solution overnight (4°C), rinsed 5 times (5 minutes each) with PBS, followed by 
incubation in 12 mL cold adenovirus solution (4 hrs at 4°C), then rinsed in PBS (5 times, 5 minutes 
each). The adenovirus solution (1012 particle number) contained either vectors not expressing any 
gene (Ad-empty), or vectors expressing PDGF-BB or BMP7 genes (prepared by University of 
Michigan Vector Core), depending on which scaffold region was being treated. After the final PBS 
wash, the scaffolds were ready for cell seeding (i.e., human periodontal ligament (hPDL) cells in 
the “PDL” region of the scaffold or human gingival fibroblasts (hGFs) in the “bone” region of the 
scaffold).  
 
5.2.4 Scanning electron microscopy (SEM), immunofluorescence, and enzyme-linked 
immunosorbent assay (ELISA) 
Scanning electron microscopy (SEM) was performed at Microscopy and Image Analysis 
Laboratory (University of Michigan) using an Amray FE 1900 SEM to image patterned 3D films 
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with Ad-empty, or patterned 3D films after hPDL cell seeding (passages 4-6, 1.2x104 cells/film) 
to observe cell behavior on the re-designed films, as well as to confirm micropattern parameters 
(i.e., height, inter-pillar distance, porosity). Prior to imaging, the films were gold sputter-coated 
and observed at an acceleration voltage of 5kV. To further examine cell behavior on the re-
designed micropatterned films, immunofluorescence staining was performed using 4',6-
diamidino-2-phenylindole (Prolong Gold Antifade Reagent with DAPI; Life Technologies) to 
label cell nuclei and anti-tubulin antibody with AlexaFluor488 (1:100 dilution, Abcam Inc, 
Cambridge MA) to label microtubules. Stained scaffolds were imaged using fluorescence 
microscopy (Nikon Eclipse 50i) to examine cell orientation within grooves and on pillar sides.  
Additionally, to confirm the transduction of seeded hPDL and hGF cells and verify bioactivity of 
the growth factors (BMP7, PDGF-BB), an ELISA assay (R&D Systems, Minneapolis, MN, USA) 
was performed to quantify the release of each growth factor at 1 and 3 days post-seeding in the 
respective scaffold region (n=3).  
 
5.2.5 In vivo implantation: Ectopic murine model and rat fenestration defect  
 The first pilot study (n=12, detailed in Figure 5.6) consisted of repeating the same 
implantation of the 3D-printed, micropatterned scaffold using an ectopic murine model, as 
described in Chapter 4. However, as described in the above methodology, the scaffolds were 
immobilized with AdBMP7 in the 3D-printed base region or with AdPDGF-BB in the 
micropatterned film region prior to cell seeding with hGF cells (2.5x105 cells in 8uL fibrinogen 
mixed with 2ul thrombin) or hPDL cells (1.5 x105 cells in 15mL fibrinogen mixed with 3uL 
thrombin), respectively, one day prior to implantation. The control group (n=6) consisted of all 
scaffold regions being immobilized with Ad-PDGF or AdBMP7 but with no prior to cell seeding. 
The day of surgery, a human-derived dentin segment (surface-treated with 37% orthophosphoric 
acid and trimmed to scaffold size) was press-fit onto the patterned film. Two surgical pockets were 
made on the dorsa of immunodeficient 6 week-old NIH III nude mice (20-25g; Charles River 
Laboratories, Wilmington MA) for subcutaneous scaffold implantation under isofluorane 
anesthesia. Unlike in the previous study reported in Chapter 4, there was no additional cell seeding 
the day of the surgery. Samples were harvested at 6 weeks and fixed in 10% buffered formalin 
phosphate solution for 2 days before being transferred into 70% ethanol for micro-CT scanning, 
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followed by decalcification. Dentin segments derived from healthy human teeth were obtained in 
accordance with a University of Michigan-Institutional Review Board (IRB) exempt protocol.  
 The second pilot study (detailed in Figure 5.10) consisted of implanting the scaffold 
described in Section 5.2.2 in a rat fenestration defect, using the following groups: Experimental 
group (n=5) consisting of AdBMP7 and AdPDGF-BB immobilization with hGF and hPDL cell 
seeding, and control group (n=5) without any cell seeding to examine if tissue regeneration would 
occur without pre-seeding the scaffold. Athymic rats (250g, Charles River Laboratories Inc., 
Wilmington) were ordered, general anesthesia performed under isofluorane during periodontal 
defect creation, with a single fenestration defect (3 x 2mm2) created for each animal on the buccal 
side of the right mandible such that the distal root of the first molar tooth was exposed. The 
cementum layer was also carefully removed to expose the dentin surface, after which the patterned 
film (with AdDGF-hPDL) was positioned with the pillars against the dentin, followed by the 
amorphous PCL film (with AdBMP7-hGF) directly above. The site was sutured and closed with 
surgical staples, with administration of analgesic subcutaneously at 24 hrs post-surgery. After 3 
weeks, specimen were harvested and fixed in 10% buffered formalin phosphate solution for 2 days 
before being transferred into 70% ethanol for micro-CT scanning, followed by decalcification. All 
animal studies were performed with approval from University of Michigan-University Committee 
on Use and Care of Animals (UM-UCUCA) according to ARRIVE guidelines for preclinical 
studies.  
 
5.2.6 Micro-computed tomography (micro-CT) and histomorphometry 
Micro-CT was used to determine the adaptation ratio of 20% barium-sulfate coated 
patterned films to the rat fenestration defect site. The ratio was calculated by determining how 
closely the pillars were to the tooth root, with measurements taken at each column and row of the 
patterned film (1.3mm x 1.65mm), calculating the distance from the two edges and the center of 
each pillar to the tooth root. Micro-CT was also used for purposes of evaluating bone regeneration 
post-implantation: Tissue-fixed specimens were embedded in alginate, scanned using micro-CT 
(Scanco Medical) at a resolution of 12um, at 70kV energy and 114uA intensity, and calibrated to 
Hounsfield units (HU). Bone volume (BV) and tissue mineral density (TMD) were determined for 
internal and external regions of the bone compartment using Microview software (Parallax 
Innovations) with a threshold of HU=1050 for bone. After scanning, samples were decalcified in 
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10% EDTA, embedded in paraffin, and cut into 5um sections for histological analysis using 
hematoxylin and eosin (H&E).  
 
5.2.7 Statistical analysis  
Data were expressed as mean ± standard deviation of the mean. One-way analysis of 
variance (ANOVA) with post hoc Tukey's multiple comparison method was used to perform 
comparative analysis, with a p-value <0.05 (α<0.05) considered significant.  
 
5.3 Results 
Design changes to the original micropatterned film were implemented in order to address 
limitations previously encountered, including inter-pillar spacing being too wide, slow degradation 
rate of polycaprolactone (PCL) used to form the film, and need for increased porosity of the film. 
The interpillar distance was reduced to 150um, with pillar dimensions decreased to 300um, and a 
base porosity of approximately 60% achieved using sugar-leaching. SEM images of the new 
pattern design that was covered with CVD-based polymer coating and subsequently had Ad-empty 
immobilized via antibody-antigen interaction confirms the presence of adenovirus particles at a 
magnification of 10,000X (Figure 5.2A). In fact, the virus was observed not only on top of the 
pillars, but also on pillar sides (image not shown), indicating that the polymer coating extends well 
into 3D patterned (i.e., grooves).  
Additionally, given that both sides of the film were coated with polymer during treatment, 
presence of virus particles was also confirmed at the base of the patterned film (Figure 5.2B). To 
further investigate cell behavior (i.e., induced alignment) on the new patterned films, hPDL cells 
seeded on the films were fixed and imaged using SEM, revealing induced cell alignment at the 
inter-pillar spaces as well as along the pillar grooves (Figure 5.3). Single cells were observed 
aligning along grooves, with an entire sheet of cells covering the tops of the pillars such that they 
were undistinguishable from a top-down view. Additional assessment to examine the orientation 
of cell nuclei along the patterned films was made by labeling the cells with DAPI and tubulin, with 
the result showing the congregation of cells within pillar grooves (Figure 5.4A). There is overall 
a tendency of the cells to align parallel to the pillar grooves, both within the film region and on the 
edges (Figure 5.4B).  
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Figure 5.2 Scanning Electron Microscopy of Micropatterned Films with Adenovirus 
Scanning electron microscopy (SEM) images of micropatterned film consisting of 250um high 
pillars (A), confirming the presence of attached adenovirus (Ad-empty) (at 10,000X). The base of 
the micropatterned film (B), formed with polycaprolactone (PCL) using salt-leaching, is also 
confirmed to have immobilized adenovirus, even within the pores of the film.  
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Figure 5.3 Alignment of Periodontal Ligament Cells on Micropatterned Films  
Alignment of seeded human periodontal ligament cells (hPDLs) 3 days post-seeding on 
micropatterned films was confirmed using SEM: (A) denotes the region of interest—two areas 
where cell alignment in observed, at the pillar grooves (red square, magnified in C and D) and the 
inter-pillar region (blue square, magnified in B). White dotted lines denote the pillars of the film. 
Arrows indicate direction of cellular alignment between pillars (blue) and along grooves (red).  
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Figure 5.4  Immunofluorescence Staining of Aligned Cells on Micropatterned Films 
Immunofluorescence staining of hPDL cells on micropatterned film to observe cell behavior 
(i.e., alignment, denoted by arrows). (A)  DAPI (blue) and tubulin (green) shows increased 
density of cells within pillar grooves (15um wide, 30um deep), with aligned cell nuclei (DAPI) 
along the micropillar grooves as seen on the side of the patterned film (B). White dashed lines 
designate pillar regions.  
 
Once virus immobilization to the scaffold was confirmed using Ad-empty, an ELISA assay 
was performed to ensure growth factor bioactivity following transduction of hGF and hPDL cells 
with AdBMP7 and AdPDGF at the 3D printed and micropatterned regions of the scaffold, 
respectively. The two regions of the scaffold were treated and analyzed separately rather than as 
an assembled unit. Results (Figure 5.5) showed significant (p<0.05) increase in both the BMP and 
PDGF growth factor production when comparing Day 1 and Day 3 growth factor levels. At Day 
1, PDGF production was 58.1±13.9 ng/mL compared to 220±78.7 ng/mL at Day 3. BMP7 
production was only 3.8±2.4 ng/mL at Day 1 compared to 132.9±43.8 ng/mL at Day 3. These data 
confirmed that cells were transduced post-seeding onto scaffold regions immobilized with each 
respective adenovirus encoding BMP7 or PDGF-BB. Compared to values reported for 2D PCL by 
Hao et al, both PDGF and BMP7 production, particularly by day 3, was higher using the same 1012 
particle number.   
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Figure 5.5   PDGF-BB and BMP7 Production by Transduced hPDL Cells In Vitro 
Production of BMP7 and PDGF-BB proteins was confirmed using an ELISA assay to verify that 
human periodontal ligament (hPDL) and human gingival fibroblast (hGF) cells were transduced 
with AdPDGF-BB (immobilized on patterned film) and AdBMP7 (immobilized on 3D printed 
base), respectively, after 1 and 3 days post-cell seeding.  
 
  
In order to investigate whether localized transduction of cells (i.e., only cells that come in 
contact with specific scaffold region) in turn improves the spatiotemporal availability of growth 
factors, particularly resulting in bone formation localized to the 3D-printed region, the scaffold 
complex was tested in a pilot study using the same ectopic murine model from which results of 
cell alignment and bone formation were assessed in Chapter 4. Here, the focus was to examine 
how cells transduced with AdBMP7 and AdPDGF-BB regenerated tissue compared to cells that 
were exposed to Ad-empty (Figure 5.6). After implantation, tissue samples were harvested at 6 
weeks. Figure 5.7 shows the resulting micro-CT images of all samples from the experimental 
(n=6) group that included dual growth factor delivery—no bone was formed in the control groups 
(Ad-empty), as indicated by bone volume measurements in (A). There is noticeable variation in 
bone formation within the 3D-printed region, with some bone tissue invasion seen occurring into 
the micropatterned film region (directly below the dentin segment). However, there are no 
significant differences between total bone volume and the volume of osseous tissue found to be 
localized to the 3D printed region. Overall, bone volume and tissue mineral density measurements 
show significant (p<0.05) increases in bone formed in the experimental group compared to control 
group. These results were further confirmed using hematoxylin and eosin staining (Figure 5.8) 
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which shows bone formation within the 3D printed region, but also its invasion into the 
micropatterned film region, such that the inter-pillar space shows immature bone formation in 
place of PDL-like (soft) tissue. There appears to be an improved integration of tissue between the 
3D printed and patterned regions of the scaffold as a result of improved patterned film base 
porosity, as opposed to the distinct separation of tissue between the “bone” and “PDL” regions of 
the scaffold that was observed in results reported in Chapter 4. One additional observation is that 
the presence of bone tissue in the patterned film region stabilized the film such that the pillars did 
not change in size (i.e., expanded) as much as in the absence of bone formation (see Figure 5.9). 
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Figure 5.6  Ectopic Murine Model using CVD-Coated Scaffolds 
The ectopic murine model shown here was used to implant scaffolds for a period of 6 weeks. The 
scaffolds were designed to have the following regions: (1) A 3D-printed polycaprolactone (PCL) 
base for the regeneration of alveolar bone that serves as a region for the covalent attachment of 
adenoviral BMP7 (AdBMP7) via chemical vapor deposition (CVD)-based polymerization, with 
further transduction of the human gingival fibroblast (hGF) cells that are seeded on its surface 
prior to implantation; (2) A micropatterned film consisting of 250um high, 300um wide pillars 
with 15um wide, 30um deep grooves. The pillars (formed via casting of 2.5% PLGA (75:25, 
137kDa) onto a silicone mold) are spaced 150um apart and attached to a base with 60% porosity 
formed via casting of a 10% PCL solution containing sugar particles (125um diameter) that are 
dissolved in water after the films are dried. The films allow for immobilization of AdPDGF-BB 
via CVD-based coating, followed by seeding with human-derived periodontal ligament (PDL) 
cells. The control group (n=6) differed from experimental group (n=6) in that the CVD-coated 
regions of the scaffold were incubated with empty adenovirus vector (Ad-empty). Schematic of 
functional groups shown on sample CVD-coated polymer surface modified from [5]. 
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Figure 5.7  Bone Volume and Tissue Mineral Density using Ectopic Murine Model 
Micro-CT images (I-VI, top panel) at 6 weeks post-implantation of 3D-printed, micropatterned 
scaffolds (n=6) using an ectopic murine model, showing formation of bone in the 3D-printed 
scaffold region immobilized with AdBMP7 and seeded with human gingival fibroblasts prior to 
implantation. There is a variation in bone formation through the 6 experimental samples (I-VI), 
with noticeable infiltration into the patterned film “PDL region” of the scaffold in some of the 
samples (III, VI). Samples in control group (with Ad-empty vector) not shown given lack of any 
bone formation.  The bone volume (BV) (shown in A.) and tissue mineral density (TMD) (shown 
in B.) analysis of osseous tissue growth in vivo in the bone region of the scaffold compares the 
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total volume of bone formed to the volume specifically localized to the 3D-printed region of the 
scaffold (*p<0.05). 
 
Additionally, as noted in the Methods section, this study differed from the previous ectopic murine 
model study (Chapter 4) in that there was no additional cell pre-seeding on the day of implantation; 
instead, all cells were encapsulated in the fibrin/thrombin gel prior to seeding onto the patterned 
film and bone region in order to reduce the step of additional cell seeding the day of surgery. 
However, in the pilot study, it was noticed that this use of a gel in place of direct cell-seeding 
seemed to inhibit cellular alignment at the pillar sites. As a result, a single animal was used (n=1) 
as a means of testing whether direct cell seeding on the PLGA pillars day prior to surgery (without 
growth factor delivery), allowed for cellular orientation (Figure 5.9). The results confirmed that 
direct cell seeding was essential in order to ensure cell alignment within the grooves, which might 
otherwise be blocked by the use of a hydrogel as a cell delivery vehicle. This is significant given 
that oriented tissue formation (at a scale that would allow for generation of quantifiable data) was 
not observed in most of the experimental and control groups.  
 
 
Figure 5.8  Hematoxylin and Eosin (H&E) Staining of Scaffolds after 6 Weeks In Vivo 
Hematoxylin and eosin (H&E) images of scaffolds harvested at 6 weeks post-implantation. Bone 
formation with varying volume is seen in the 3D printed region of the scaffolds with AdBMP7-
hGF (A and B, at 2X). Likewise, infiltration of the bone into the patterned film (with AdPDGF-
hPDL) region is noticeable in the magnified images (10X) in the lower panel. The control group 
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(C) shows no bone formation, as expected given the use of Ad-empty. Scale bar corresponds to 
150um (top panel) and 500um (bottom panel). B = bone, P = pillar.  
 
Figure 5.9  Tissue Alignment in Scaffolds Seeded with hPDL Cells  
Hematoxylin and eosin (H&E) images of scaffold with patterned film that show guidance of tissue 
alignment at inter-pillar regions. Noticeable reduction in inter-pillar space is observed due to 
hydrolysis of PLGA over 6 week period in vivo. Arrows correspond to cell nuclei shown to be 
perpendicular to the dentin segment.  
 
 Based on the results reported from the ectopic murine model pilot study, an additional pilot 
study was performed, this time with the implantation of CVD-treated scaffolds with AdBMP7 and 
AdPDGF in a rat fenestration defect (Figure 5.10). Here, as described in the Methods section, the 
3D printed “bone” region was substituted with an amorphous film with porosity achieved using 
sugar-leaching. As with the patterned films, the amorphous film was verified to have immobilized 
gene therapy vectors on the surface using SEM imaging, in addition to observing hGF cell 
attachment and response (Figure 5.11). Additionally, based on previously-noted limitations, the 
following improvements were made: (1) micropatterned film was formed using PCL-PLGA 
(50/50) to decrease the observed “swelling” of the pillars as a result of increased rate of hydrolysis 
seen with PLGA in vivo, (2) direct, one-time delivery of cells onto the patterned film and 
amorphous bone regions the day prior to surgery. The groups tested in the study consisted of (1) 
AdBMP7-hGF and AdPDGF-hPDL on the amorphous PCL “bone” region and patterned PCL-
PLGA “PDL” region, respectively and (2) AdBMP7 and AdPDGF immobilization on the 
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respective regions of the scaffold, without cell seeding (i.e., no hPDL or hGF pre-seeding the day 
before surgery). The aim was to determine whether bone regeneration in particular could be 
induced without the need to cell seed prior to implantation, which would enable the elimination of 
an additional step in the scaffold preparation process prior to surgical use.  
 
 
 
 
 
Figure 5.10  Rat Fenestration Defect Model using CVD-Coated, Micropatterned Films 
Rat fenestration defect created in athymic rats exposing the distal root of the first molar to allow 
for implantation of a scaffold consisting of (1) patterned PLGA/PCL region for delivery of 
AdPDGF-hPDL and (2) amorphous PCL region for delivery of AdBMP7-hGF. Scaffolds (n=5) 
were implanted and remained at the site for 3 weeks prior to harvesting. Control group (n=5) 
consisted of the same scaffold regions, with Ad-PDGF-no cells in the patterned film and Ad-
BMP7-no cells in the amorphous film regions. Schematic of functional groups shown on sample 
CVD-coated polymer surface modified from [5]. 
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Prior to implantation, in order to verify the scaffold fit within the fenestration defect, 
micropatterned films and the amorphous “bone” region were coated with 20% barium sulfate and 
micro-CT scanned at the defect site (Figure 5.12). The calculated adaptation ratio revealed that 
the pillars were fit well against the tooth root, with minimal spacing in between (adaptation ratio 
= 90%±1%). After 3 weeks in the rat fenestration defect, rat mandibles were harvested, fixed, 
and imaged using micro-CT. The results reveal lack of noticeable bone formation within the defect 
site (confirmed using bone volume fraction (BVF) calculations) in the control group (without cell 
seeding), compared to robust bone formation in the experimental group (Figure 5.13). However, 
while there is significant presence of bone in this group, it is mostly confined to spaces outside of 
the defect. Measurements of the bone fill within the defect site only for the exprimental group 
reveals an average BVF of 14.2%, with the highest fill at 36.2% and the lowest at 6.2%. Further 
assessment using histology (H&E) showed increased PDL-like tissue formation in the 
experimental group, with limited orientation in the control group (Figure 5.14). Likewise, there 
were clear differences in the tissue morphology at the amorphous PCL film site in vivo when 
comparing the experimental and control groups, with bone islands only visible in sections derived 
from groups that included hGF cell transduction with AdBMP7 prior to implantation.  
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Figure 5.11 AdBMP7-Immobilized Amorphous PCL Films with and without Cell Seeding  
Amorphous PCL film for the “bone” region of the scaffold complex used in the rat fenestration 
defect with immobilization of AdBMP7 and with/without cell seeding. The porous, amorphous 
surface without cells is seen is (A) at 206X, with (B) showing a region at 10,000X in order to 
identify presence of adenovirus vector. Image (C) shows the film seeded with hGF cells at the 
same magnification as (A), and (D) showing more precise features of the cell spreading and 
adhesion on the film surface with a magnified view (1000X). * denotes areas of cell presence on 
the amorphous film.  
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Figure 5.12  Adaptation of Micropatterned Films at Rat Fenestration Defect Site 
Positioning of scaffolds along tooth root surface in vivo. The adaptation ratio of the patterned film 
to the rat fenestration defect site was calculated based on micro-CT images of 20% barium-sulfate 
coated scaffolds. The ratio was calculated by determining how closely the pillars (indicated by 
yellow arrows) were to the tooth root, with measurements taken at each column (A) and row (B) 
of the patterned film, calculating the distance from the two edges and the center of each pillar to 
the tooth root.  
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Figure 5.13    Bone Regeneration: CVD-Coated Scaffolds with and without Cell Seeding 
Micro-CT images of control (A) and experimental (B) groups showing lack of bone formation at 
the rat fenestration defect site 3 week post implantation or significant bone formation, respectively. 
Panel B indicates robust bone formation located mostly outside of the defect site (shown by arrows 
and outlined using dashed orange line). Measurements showed an average defect fill (bone volume 
fraction) of 14.2% , with the highest fill at 36.2% and the lowest at 6.2%. 
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Figure 5.14 Hematoxylin and Eosin (H&E) Staining of Scaffolds after 3 Weeks in Vivo  
Hematoxylin and eosin (H&E) images of defect site at 3 weeks post-implantation of a 
micropatterned film and amorphous film to promote PDL and bone regeneration, respectively. 
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Images in (A) and (B) correspond to experimental groups with AdPDGF-hPDL cells and 
AdBMP7-hGF cells, and images in (C) show tissue regeneration in control group (Ad-empty-
hPDL and Ad-empty-hGF, in the patterned film and amorphous film regions, respectively). PDL-
like tissue formed in region with micropatterned pillars is seen at 20X and 40X, with distinct 
perpendicularity to the tooth root, which is lacking in the control group. Images (D., experimental) 
and (E., control) compare the regions where the amorphous film was positioned, showing distinct 
bone islands in the experimental group (with AdBMP7-hGF cells).  
 
5.4 Discussion 
The results of this study indicate the potential to use CVD-based polymer coating for 
immobilization of AdBMP7 and AdPDGF for the purposes of transducing cells locally in specific 
scaffold regions prior to implantation. Immobilization of the vectors allows for reduced risk of 
virus dispersion (i.e., systemic effects) and transduction of surrounding tissue compared to ex vivo 
transduction of cells that are not necessarily contained to the defect site post-implantation. 
Specifically, this surface modification technique immobilizes the virus onto the material surface 
via antigen-antibody interaction, such that the virus is released from the PCL/PLGA surface only 
when it comes in contact with and binds to protein receptors on the target cell’s membrane, 
followed by its entry into the cell thorough the cell’s phospholipid bilayer. The virus particle 
number (PN) selected for immobilization onto the scaffold surface was based on previous 
verification of total virus attachment on the surface, which indicates that use of a PN of 1012 
resulted in higher virus attachment density on PLGA (~90 PN/ROI using PN=1012 compared to 
~20 PN/ROI using PN=1011) with no significant differences observed on PCL PLGA (~250 
PN/ROI using PN=1012 compared to ~190 PN/ROI using PN=1011) with an ROI of 101.4 μm2. 
Multiplicity of infection (MOI), which corresponds to the number of virus particles used to target 
a cell (i.e., MOI=300 where the ratio is 300:1) was also determined based on the results from the 
study by Hao et al, where a range of 50-400 MOI was tested, with MOI=300 being optimal. Given 
that the total amount of virus attached to the scaffold surface increased using a higher PN, SEM 
images as well as the total number of cell transduced was shown to increase correspondingly, 
thereby confirming that the virus stays on the polymer surface [2]. The primary use of SEM 
imaging of the virus particles on the surface in this study was not only to confirm its presence, but 
also ascertain that the complex 3D morphology of the scaffold allowed for equal distribution of 
viral particle attachment throughout the scaffold.  
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  Likewise, the use of cell transduction in order to stimulate growth factor expression in place 
of direct growth factor delivery has advantages such as extending the otherwise transient GF 
bioactivity, as well as avoiding short half lives and dissolution rates that are too fast. Gene therapy 
has been investigated widely as an alternative to direct growth factor delivery, specifically with 
the use of adenoviruses, which show high transduction efficiency in vivo [7]. The selection of 
PDGF-BB and BMP7 for this study stems from the fact that recombinant PDGF and BMPs (i.e., 
rhBMP2) are already FDA-approved for clinical use in periodontal and oral surgery (i.e., alveolar 
ridge augmentation, sinus elevation). Both growth factors are known as stimulators of 
mesenchymal progenitor cell recruitment, with BMP having osteo-inductive properties [8]. In this 
study, we show that CVD-based immobilization of growth factors (BMP7 specifically) yields bone 
in vivo while allowing for the local transduction of cells only at designated regions of the scaffold, 
as opposed to ex vivo transduction of cells prior to cell seeding onto a scaffold. In support of other 
groups who have previously used CVD for the purposes of gene therapy vector delivery [2, 4, 6] 
this study also confirmed that virus immobilization and subsequent growth factor expression is 
successful on geometrically complex (i.e., 3D-printed, micropatterned) scaffolds (Figures 5.2, 
5.5).  
Various improvements from the previous study reported in Chapter 4 were made prior to 
implementing the immobilization of growth factors, including the use of polymer (PCL-PLGA) 
for the micropatterned film with a faster rate of degradation compared to PCL alone. The use of 
PLGA alone resulted in deformation to the pillars on the patterned film (as observed in the ectopic 
murine model pilot study, Figures 5.8 and 5.9), despite 75:25 PLGA, which has a slower 
degradation rate given the higher ratio of lactic acid to glycolic acid. However, due to the faster 
rate of hydrolysis than PCL, the result is increased deformation that is more prevalent and 
noticeable with time, especially in the absence of bone tissue which may limit the hydrolysis rate 
and also stabilize the polymer in place which reduces any noticeable deformation during 
histological analysis. Overall, the re-designed patterned film was shown to support cellular 
alignment (Figures 5.3, 5.4), given that despite the difference in the polymer, the topographical 
cues incorporated into the material remained the most important factor in determining cellular 
behavior. This was not transferred over to in vivo cell alignment in the first pilot study (Figure 
5.8) given that the cells were encapsulated in a thrombin/fibrinogen hydrogel during seeding, 
which is likely to have prevented cellular contact with grooves in order to allow for contact 
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guidance in the first 24 hours prior to implantation. This was improved upon in the rat fenestration 
defect study (as well as a single mouse assessment), resulting in improved tissue alignment 
observed in sections stained with H&E (Figures 5.9, 5.14).  
The variation in bone volume among scaffold groups in the experimental group (ectopic 
murine model) was greater than expected, with approximately half of samples in the experimental 
group showing osseous tissue infiltration into the patterned “PDL” region. A potential explanation 
of this is because the 3D printed scaffold region is immobilized with gene therapy vectors on all 
sides of the scaffold, such that the top region onto which the patterned film is press-fit is also in 
contact with the transduced hGF cells which can migrate along the porous “PDL” film base into 
the pillar regions (Figure 5.7). When comparing this result to the bone regeneration observed in 
the rat fenestration defect pilot study, there is a noticeable decrease in the osseous tissue presence 
in the defect site relative to the areas adjacent to it (Figure 5.13). However, due to the thickness 
of the patterned film (~500um), the amorphous PCL film designated to serve as a vehicle for 
transduced hGF cells ended up being positioned mostly outside of the defect. In order to better  
customize the scaffold for use in a rat fenestration defect, the next generation of scaffolds 
(discussed in Chapter 6) had the following improvements: (1) Decreased pillar height from 250um 
down to 100um (average thickness of native rat PDL), (2) reduced base thickness of patterned film 
to 100um, and base thickness of amorphous film to 150um for a total combined scaffold width of 
250um, given that the rat fenestration defect depth is on average 500um (250um [amorphous film] 
+ 100um [pillar height] + 150um [patterned film porous base] = 500um total).  
Additionally, in the rat fenestration defect pilot study, we failed to observe bone formation in 
the control groups (i.e., no cell pre-seeding prior to implantation). The option of implanting the 
prepared scaffold without cell seeding (i.e., allowing for transduction of the endogenous cell 
population) would be a more clinically-relevant approach that would eliminate an additional step 
in the preparation process. A potential explanation for why no bone formation was observed is that 
once the material is implanted (i.e., biomaterial, medical device, prosthesis), there is a foreign body 
reaction—the material comes in contact with inflammatory cells (i.e., macrophages, foreign body 
cells) [9-12]. The use of nude mice/athymic rats (i.e., lack of a thymus gland resulting in the 
absence of T cells) allows for implantation and engraftment of human-derived cells. However, 
other immune-derived cells are present which interact with the implanted material at the 
tissue/biomaterial interface: the presence of viral vectors can activate macrophages. Likewise, 
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when the scaffold is exposed to host proteins (i.e., albumin, fibrinogen, fibronectin, and others) 
that may form a layer on the surface prior to it coming in contact with host cells. As such, this may 
prevent host cells from being exposed to the immobilized gene therapy vectors (i.e., AdBMP7), 
thereby resulting in the lack of bone formation observed [10]. Overall, it is possible that the 
adenovirus may infect macrophages or other inflammatory cells that come in contact with the gene 
therapy vectors in place of the host cells: a number of studies have verified that macrophages can 
be infected with adenovirus, in response to which they undergo pro-inflammatory nectoric death 
in vivo, with a recent study further confirming this through the identification of an adenovirus 
receptor in mice macrophages [21, 22]. Given this likelihood of infection, the immobilized 
adenovirus is not able to access the host cell population, thereby requiring a different scaffold 
design in order to mask it from host proteins and inflammatory cells until later in the wound healing 
stage when the gene therapy vectors can be made available to transduce the host cell population 
instead. For example, the scaffold may be designed in layers such that the outer regions are not 
immobilized with the adenovirus while the inner regions are, allowing the presentation of the gene 
therapy vectors to the host cell population over a prolonged period of time corresponding to the 
rate of scaffold degradation. Likewise, it may be possible to mask certain layers of the scaffold 
during CVD coating using low-melting polyester wax so as to allow spatial control of virus 
immobilization on dedicated regions of the scaffold [23]. An additional strategy to attract host 
cells to the scaffold may be to incorporate the initial delivery of BMP7 and PDGF without the use 
of adenovirus into the scaffold in order to allow these growth factors to recruit cells through their 
mitogenic/morphogenic and chemotactic properties in the first stages of the wound healing 
process, followed the exposure of scaffold sites with immobilized adenovirus during scaffold 
degradation, allowing for the transduction of the host cells and pro-longing growth factor 
expression.  
Other ideas for scaffold design can be based on previous studies that have successfully 
transduced host cells in vivo as opposed to ex vivo: A previous study by Liao IC et al addressed 
this limitation through the fabrication of adenovirus-encapsulated fibrous scaffolds via 
electrospinning (i.e., polyethylene glycol (PEG)-based porogen was incorporated into the fiber 
shells during the fabrication  process, leaving a space inside the fibers on the order of nanometers 
for the transport of viral particles), showing that viral vector-based macrophage cell activation was 
reduced due to the encapsulation of the adenovirus within core-shell polycaprolactone (PCL) 
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fibers. Specifically, when macrophages were cultured in vitro on virus-encapsulated scaffold, they 
were shown to produce anti-viral cytokines that are pro-inflammatory at much lower levels than 
macrophages with direct exposure to adenoviruses. At the same time, virus-encapsulated scaffolds 
cell seeded with human embryonic kidney (HEK 293) cells showed prolonged transgene 
expression for a period of more than 1 month [13]. This suggests a potential future direction of 
investigation, focusing on immobilizing the adenovirus in such a way that it can be encapsulated 
within the scaffold and transduce the host cells over time as the biomaterial degrades in vivo.   
 
5.5 Conclusion  
This study supports the potential of polymer-immobilized delivery of gene therapy vectors 
for in vivo tissue regeneration, with ongoing studies investigating use of CVD-coated scaffolds in 
a cell-free approach. There is clear indication that immobilization of gene therapy vectors onto the 
scaffold surface has potential to be used clinically where both the periodontal ligament and bone 
are damaged. In this study, noticeable tissue alignment (guided by scaffold morphology) and 
significant bone formation (possibly due to transduced hGF cell expression of BMP7 via 
immobilized gene therapy vector) was observed in a pilot study using a rat fenestration defect. In 
a potential clinically-relevant scenario, this reduces the additional step of having to transduce 
patient cells ex vivo prior to cell seeding—instead, once the scaffold is fully prepared (including 
steps involved in surface modification), all that remains is to seed patient-derived cells prior to 
implantation. Future research will focus on optimizing both the scaffold geometry and gene 
therapy vector localization in order to make the final regenerative outcome more predictable.  
Additionally, this chapter introduces the use of an amorphous PCL film for the “bone” 
region of the scaffold, eliminating the use of the 3D-printed region for the rat fenestration defect, 
primarily due to the size constrains of the 3mm x 2mm defect with a depth of approximately 
0.5mm. This highlights some of the limitations of using current 3D printing technology, not limited 
to selective laser sintering, for periodontal tissue engineering given that many printers still have 
relatively low resolution that does not enable the formation of scaffolds with adequate porosity for 
smaller defects [14]. Typically, when designing a scaffold for a patient or animal defect, CT 
imaging data is needed to approximate the defect, as was done here using the rat fenestration defect 
model. However, technical limitations exist and need to be addressed in the future to better assist 
the translation of this approach to clinical defects, given the following: (1) potential for errors 
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associated with the import of CT scan data during image acquisition (i.e., pixel sizes, thickness of 
slices) that can produce errors during virtual reconstruction, (2) difficulty obtaining high-quality 
scans that allow for accurate scaffold design approximations especially in the potential presence 
of human/animal movement, and (3) scaffold manufacturing that can produce so-called “stair-
step” artifacts as well as irregular surface features that are not originally present in the design, and 
may not seem relevant on the macro-scale, but can have significant effects on the micro-scale 
levels at which cells sense the surface, especially in bone-ligament interfaces that exist in the 
periodontium where the PDL region may be only 100um (rat) or 250um (human) in width [15-20].  
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CHAPTER 6 
 
EFFECT OF IMMOBILIZED ADENOVIRAL PLATELET-DERIVED GROWTH 
FACTOR (PDGF) AND BONE MORPHOGENETIC PROTEIN (BMP-7) DELIVERY 
ON PERIODONTAL TISSUE REGENERATION IN VIVO USING 
MICROPATTERNED SCAFFOLDS 
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Italy), Tobias Fretwurst (Department of Oral- and Craniomaxillofacial Surgery, Center for Dental 
Medicine, University Medical Center Freiburg, Germany), Lena Larsson (Department of 
Periodontology, Institute of Odontology, University of Gothenburg, Sweden), Ning Yu 
(Periodontics and Oral Medicine, University of Michigan).  
 
6.1 Introduction   
The development of biomaterial systems intended for the regeneration of specific tissue 
typically includes the consideration of multiple design criteria, including scaffold material 
selection, topography, as well as intended inclusion of growth factors and/or cells natively 
expressed in the tissue. Design for the regeneration of periodontal tissue specifically requires the 
consideration of its anatomical complexity: the alveolar bone-periodontal ligament (PDL)-
cementum complex consists of alveolar bone transitioning into bundle bone that houses Sharpey’s 
fibers which are extending from the PDL, a collagen III-rich collagenous soft tissue that further 
anchors into the cementum, a mineralized layer that covers the tooth root’s dentin surface (Figure 
A1.1 in Appendix). Many studies have examined the scaffold design that would allow for multi-
tissue regeneration relevant to periodontal tissue engineering [1-5]. Most recently, 3D-printed, 
micropatterned scaffolds detailed in Chapters 4-5 were developed with emphasis on the use of 
grooves in the PDL scaffold compartment for promoting cellular alignment and subsequently 
aligned collagenous tissue formation [6]. Previous studies have established that topography allows 
for the functional regulation of cells derived from various types of tissues, including myocardium 
134 
 
 
and nerve [7-10]. To build upon previous findings, this study focused on improving the existing 
scaffold design for better adaptation to a fenestration defect of a rat model, while also introducing 
growth factors through adenoviral BMP-7 and PDGF-BB immobilized onto the scaffold surface 
through chemical vapor deposition (CVD)-based polymer surface modification to improve both 
the localization and spatio-temporal distribution of gene therapy vectors.  
Bone morphogenetic protein (BMP) is a widely known growth and differentiation factor, 
as well as a chemotactic agent, stimulating cell migration, angiogenesis, and differentiation of 
MSCs into bone forming cells and cartilage.  Platelet derived growth factor (PDGF) has been 
shown to promote the regeneration of alveolar bone, PDL, and cementum, with PDL and alveolar 
bone cells showing the presence of PDGF cell surface receptors, thereby effecting their chemotaxis 
and proliferation. PDGF-BB specifically has been shown as a safe and effective treatment of 
periodontal osseous defects, with clinical data confirming that it can be used to achieve significant 
improvements in clinical and radiographic parameters in moderate-to-severe cases of 2 and 3-wall 
periodontal infrabony defects [11-12].  The selection of PDGF-BB and BMP-7 for this study stems 
from previous work establishing the optimal methods for transduction of human gingival fibroblast 
(hGF) cells with Ad-BMP7 and PDL cells with AdPDGF-BB. For example, Jin QM et al 
previously used Ad-BMP7 ex vivo gene transfer to transduce syngeneic dermal fibroblasts, 
showing osteogenesis, cementogenesis, and bridging of periodontal bone defects in a rat wound 
repair model. Likewise, Chang PC et al confirmed that AdPDGF-B delivery via a collagen matrix 
to rat alveolar bone defects could have clinical applications for treatment of bone in the oral and 
craniofacial regions [13-15].  
Other groups have also pursued this method in combination with biomaterials to serve as 
scaffolds for tissue regeneration, including the following: Zhang et al recently showed that use of 
a mesoporous bioglass (MBG)/silk fibrin scaffold in combination with AdBMP7 and AdPDGF in 
beagle dog periodontal defects promoted periodontal regeneration when both gene therapy vectors 
were used in unison as opposed to individually [16]; previous to that, Zhang et al had also shown 
that chitosan/collagen scaffolds combined with AdBMP7 or AdPDGF-B and seeded with hPDL 
cells did not show cytotoxicity, with AdPDGF-hPDL resulting in higher proliferation rate while 
scaffolds with AdBMP7-hPDL resulted in  hPDL cells having a stronger tendency to differentiate 
towards a osteoblast phenotype in vitro. This study also showed in vivo implantation of the 
scaffolds in beagle dog periodontal defects resulted in significant increases in bone formation using 
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AdBMP, but the combination of both growth factors produced the highest increase through 
synergistic effects [17]. However, the main limitation of using adenoviral-based gene therapy 
vectors has been the potential for virus dispersion and lack of spatio-temporal control of gene 
expression.   
Most recently, Hao J et al used chemical vapor deposition (CVD)-based polymer coatings 
as surface treatment for 2D and 3D-shaped biomaterials to examine the transduction of hPDL and 
hGF cells with AdPDGF-BB and AdBMP7, respectively, to examine the production of these 
growth factors in vitro [18]. Based on their findings and methodology, it is possible to have more 
defined control over cell transduction such that only those cells that are in contact with certain 
regions of the scaffold can be transduced. Chapter 6 confirmed that this strategy can be applied for 
the transduction of hPDL cells on patterned regions of the scaffold developed specifically for a rat 
fenestration defect, with immobilization of either AdBMP7 or AdPDGF-BB. This study further 
investigates the effects of combined and single growth factor delivery (BMP7, PDGF-BB) on 
periodontal regeneration in combination with changes in the topography of the PDL region of the 
scaffold (i.e., patterned versus amorphous), presenting the first known in-depth assessment of 
scaffolds with immobilized gene therapy vectors applied as an implant in vivo, for periodontal 
tissue engineering or otherwise.  
 
6.2 Materials and Methods 
6.2.1 Preparation and surface modification of scaffolds for rat fenestration defect  
Preparation of the micropatterned films (for the “PDL” region of the scaffold) and 
amorphous films (for the “bone” region of the scaffold) was undertaken as described in Chapter 5 
(Sections 5.2.1 and 5.2.2), with some modification described here. Briefly, a solution of 5% 
PLGA-PCL (50/50) ((75:25, 137kDa, Evonik Industries) was used to cast the pillar spaces within 
a PDMS mold with a design to accommodate the parameters necessary for a rat fenestration defect 
(Design specifications: 100 um (pillar height), 150 um (inter-pillar distance), 150 um x 150um 
(pillar length x width), with 15um wide/30um deep grooves). A solution of 10% PCL was cast 
onto the filled pillars while adding sugar particles (≤75um), in order to create a base of 150um in 
thickness. After drying overnight under vacuum, the sugar was leached out in deionized water. An 
amorphous PCL film based was formed in a similar manner, with a final base thickness of 250um, 
such that the combined scaffold construct could fit within a 0.5mm deep fenestration defect. 
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Similarly, in order to test the effect of topography on PDL regeneration, an amorphous and porous 
PCL-PLGA (50/50) film was also formed (total thickness of 250um) using the same technique. 
Following scaffold fabrication, each of the films was surface treated on each side using chemical 
vapor deposition (CVD), as previously described. Briefly, the coating process consisted of fixing 
the scaffolds inside the deposition chamber, the starting material sublimated at 120°C and 
pyrolyzed 540 °C to allow for deposition and polymerization on scaffold surface. Afterwards, all 
films were sterilized in 70% ethanol (1hr) to prepare for virus immobilization and subsequent cell 
seeding.   
For gene therapy vector immobilization, scaffolds were treated with 10 μg/mL solution of 
goat anti-adenovirus (AbD Serotec; 0151- 9004) polyclonal antibody in phosphate-buffered saline 
(PBS), incubated in solution overnight (4°C), rinsed in PBS (5 times by 5 min), incubated in 12 
mL cold adenovirus solution (4 hrs at 4°C), and again rinsed in PBS (5 times by 5 min). The 
adenovirus solution (1012 particle number) either had empty vectors without a transgene (Ad-
empty), or vectors expressing PDGF-BB or BMP7 genes (prepared by University of Michigan 
Vector Core). Human periodontal ligament (hPDL) or human gingival fibroblast (hGF) cells were 
seeded onto the “PDL” (patterned or amorphous) region and “Bone” (amorphous) region of the 
scaffold, respectively, with 5.0*105 cells per film (both sides), allowing for the cells to attach 
before transferring them to a well with fresh medium. Afterwards, all scaffolds with seeded cells 
were incubated overnight prior to analysis/surgical implantation.  
 
6.2.2 Scanning electron microscopy (SEM), barium sulfate treatment 
Scanning electron microscopy (SEM) was performed at Microscopy and Image Analysis 
Laboratory (University of Michigan) using an Amray FE 1900 SEM to image patterned 3D films. 
Prior to imaging, the films were gold sputter-coated and observed at an acceleration voltage of 
5kV. Each scaffold region (i.e., patterned film and amorphous film) was exposed to 20% barium 
sulfate for 30 minutes prior to being placed into a sample pre-made rat fenestration defect (~3mm 
x 2mm) on a dried, sterilized mandible for micro-CT scanning to check on the scaffold adaptation.  
 
6.2.3 In vivo implantation: Rat fenestration defect  
 The in vivo study design consisted of the following 5 groups (Figure 6.1): (1) a negative 
control with CVD-treated, amorphous (“PDL” region) and amorphous (“bone” region) films with 
Ad-empty in all regions, (2) a positive control with CVD-treated, patterned film with amorphous 
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film and AdPDGF-hPDL and AdBMP7-hGF, respectively, (3) a CVD-treated, patterned film and 
amorphous film with AdBMP7-hGF in both regions, (4) a CVD-treated amorphous films, one with 
AdPDGF-hPDL and the other with AdBMP7-hGF delivery, and (5) a CVD-treated, patterned film 
and amorphous film with Ad-empty in all regions. The time points tested specific to tissue 
regeneration were at 3 and 6 weeks. Two groups (positive and negative controls) were also 
extended to a 9 week time point (n=6), with the intention of looking at retention of human-based 
cells at early and late time points, as well as the mechanical properties of regenerated bone and 
PDL-like tissue both at weeks 3 and 9. As such, groups (1-2) for the 3 week time point had a total 
number of n=10 for the positive/negative control groups and n = 6 for the remaining groups (3-5), 
groups (1-5) for the 6 week time point has an n=6, and groups (1-2) for the 9 week time point had 
a total of n=5.  
 Athymic rats (250g, Charles River Laboratories Inc., Wilmington) were ordered, general 
anesthesia performed under isofluorane during periodontal defect creation, with a single 
fenestration defect (3 x 2mm2) created for each animal on the buccal side of the right mandible 
such that the distal root of the first molar tooth was exposed. The cementum layer was also 
carefully removed to expose the dentin surface, after which the “PDL” region film (i.e., patterned 
or amorphous) was positioned with the pillars against the dentin, followed by the amorphous PCL 
film directly above. The site was sutured and closed with surgical staples, with administration of 
analgesic subcutaneously at 24 hrs post-surgery. After 3, 6 and 9 weeks, specimen were harvested 
and fixed in 10% buffered formalin phosphate solution for 2 days before being transferred into 
70% ethanol for micro-CT scanning, followed by decalcification. All animal studies were 
performed with approval from University of Michigan-University Committee on Use and Care of 
Animals (UM-UCUCA) according to ARRIVE guidelines for preclinical studies.  
 
6.2.4 Micro-computed tomography (micro-CT) and histomorphometry 
Micro-CT was also used for purposes of evaluating bone regeneration post-implantation: Tissue-
fixed specimens were embedded in alginate, scanned using micro-CT (Scanco Medical) at a 
resolution of 12um, at 70kV energy and 114uA intensity, and calibrated to Hounsfield units (HU). 
Bone volume (BV) and tissue mineral density (TMD) were determined for internal and external 
regions of the bone compartment using Microview software (Parallax Innovations) with a 
threshold of HU=1050 for bone. After scanning, samples were decalcified in 10% EDTA, 
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embedded in paraffin, and cut into 5um sections for histological analysis using hematoxylin and 
eosin (H&E).  
 
6.2.5 Immunohistochemistry for anti-human nuclear staining 
Sections, about 5 μm thick, were de-waxed and incubated in DIVA antigen retrieval solution 
(Biocare medical, Concord, CA) at 60°C over night. The sections were incubated with 3% bovine 
serum albumin (BSA) for blocking of unspecific binding followed by incubation overnight at 4°C 
with primary antibody mouse anti-human nuclei diluted 1:100 (MAB 1281, EMD Millipore Corp, 
Temecula, CA) over night at 4°C. The sections were then incubated with MACH4 polymer 
(Biocare medical) for 30 min. Positive cells were detected using DAB substrate (Biocare medical). 
The sections were counterstained using haematoxylin. 
 
6.2.6 Immunofluorescence, periostin fluorescence intensity profiles 
Sections, about 5 μm thick, were de-waxed and incubated in DIVA antigen retrieval solution 
(Biocare medical, Concord, CA) at 60°C over night. The sections were incubated with 3% bovine 
serum albumin (BSA) for blocking of unspecific binding followed by incubation overnight at 4°C 
with the following primary antibodies (Dilution 1:500): anti-periostin (rabbit polyclonal, ab14041, 
Abcam, USA) and anti-collagen III (mAB ab6310, Abcam, USA), The sections were then 
incubated with Alexa-conjugated secondary antibodies: Alexa-488 anti-mouse (dilution 1:200) 
and Alexa-555 anti-rabbit (dilution 1:200) for 2 hours at room temperature. The sections were 
treated with 4',6-diamidino-2-phenylindole (Prolong Gold Antifade Reagent with DAPI; Life 
Technologies) to visualize the cell nuclei. Additionally, a separate analysis of periostin-stained 
slides only were performed for each group. Specifically, in order to compare the mean fluorescence 
intensity of periostin at sites of regenerated PDL-like tissue to sites directly opposite on the same 
sample where there is native PDL, a total width of 100um (approximate rat PDL width) was 
selected in the regenerated and native PDL regions in order to calculate the ratio of periostin 
intensity for each group (n=6) (i.e., mean periostin intensity at regenerated tissue site/mean 
expression at native site). In addition to this quantification, an expression profile was generated 
for samples from each group. Finally, in order to quantify scaffold displacement and total PDL-
like tissue width in all groups, toluidine blue staining was performed (n=6) to allow better 
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distinction between the bone and soft tissue areas. Slides were de-waxed and stained with toluidine 
blue for approximately 1hr prior to washing in deionized water.  
 
6.2.7 Nanoindentation  
Mandibles reserved for nanoindentation were frozen after harvesting at 3 and 9 weeks post-
implantation. Sample preparation for mechanical testing consisted of the following: thawing the 
frozen sample, trimming the mandible to only retain the molars by cutting off the incisors and 
ramus using a low-speed diamond wheel saw (South Bay Technology Inc, San Clemente, CA), 
embedding the trimmed sample in epoxy resin (EMBED 812 Embedding Kit, Electron Microscopy 
Sciences, Hatfield, PA), sectioning using a microtome (Leica Biosystems Inc, Germany), and 
polishing using silicon carbide abrasive paper (2400 grit) under water irrigation for two minutes 
followed by cleansing to remove particles using ultrasonication in water for 15 minutes. Prior to 
nanoindentation using the 950 TI TriboIndenter (Hysitron Incorporated, Minneapolis, MN), the 
sample was glued to a steel stub (Ted Pella, Inc., CA).  Indentation was performed using a standard 
Berkovich diamond probe with a penetration depth of 500 nm, and 3 seconds for each load, hold, 
and unload [19, 20-22]. Fused silica was used as the calibration standard. The reduced modulus 
(Er) and hardness (H) were calculated using the load-displacement curve based on five indents 
(each 10um apart, in accordance with ASTM standards) at the following four regions for each 
sample (i.e., distal root of first molar): (1) regenerated PDL-like tissue at original defect site, (2) 
regenerated alveolar bone at the original defect site, (3) native alveolar bone, and (4) native PDL 
at the region directly opposite of the defect site. Specifically, the Er (GPa) is calculated based on 
Oliver-Pharr analysis using Equation (1), where S (µN/nm) is the contact stiffness (obtained from 
the unload curve slope, where P is the indentation force and h is displacement), and A is the 
projected area (nm2) of elastic contact:  
      𝐸𝑟 =
√𝜋
2
𝑆
√𝐴
 , where  𝑆 =
ⅆ𝑃
ⅆℎ
|
𝑃𝑚𝑎𝑥
                                          (1) 
The hardness, H (MPa), is calculated using Equation (2), where Pmax is the maximum indentation 
force (µN), AC is the projected area (nm
2) of contact:  
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𝑃max
𝐴𝑐
                             (2) 
All testing was performed at the Michigan Center for Materials Characterization (MC2, University 
of Michigan).  
 
6.2.8 Statistical analysis  
Data were expressed as mean ± standard deviation of the mean. One-way analysis of variance 
(ANOVA) with post hoc Tukey's multiple comparison method was used to perform comparative 
analysis, with a p-value <0.05 (α<0.05) considered significant.  
 
6.3 Results 
 The in vivo study that is the main focus of this chapter was based on the examination of 
how scaffold topography (primarily in PDL region of the scaffold) and selection of growth factor 
delivery (i.e., PDGF-BB vs BMP7) influenced periodontal regeneration. As seen in Figure 6.1, 
the groups were divided primarily based on whether PDL scaffold region was patterned or 
amorphous, and the type of immobilization (i.e., AdBMP7, Ad PDGF, or Ad-empty). Given that 
the previous pilot study showed that cells should be included (i.e., seeded prior to implantation) in 
order to allow time for transduction, all groups included cell seeding. This in vivo experiment was 
used to test growth factor delivery on a scaffold consisting of two layers: an amorphous PCL region 
for the delivery of AdBMP-7 to promote bone regeneration, and a patterned PLGA/PCL region 
for the delivery of AdPDGF-BB to promote PDL tissue regeneration. The groups tested included 
single growth factor delivery (i.e., AdBMP-7 only) to both regions of the scaffold. The negative 
control consisted of an amorphous film in both regions of the scaffold, with an adenovirus 
encoding an empty vector (Ad-empty vector). Prior to implantation, the scaffolds fabricated to fit 
the defect (3mm x 2mm x ~0.5mm) were barium sulfate coated to allow for contrast during micro-
CT scanning. Figure 6.2 shows the scaffold assembly: First, the micropatterned (or amorphous) 
“PDL” region film (PCL-PLGA) is placed such that the pillars are oriented towards the tooth root. 
The amorphous film (PCL) designed for the “bone” region of the scaffold is then positioned 
directly on top such that the entire two films are able to fit within the defect. This adjustment to 
the scaffold thickness (250um total for each film) was made following the results of the pilot rat 
fenestration defect study described in Chapter 5.  
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Figure 6.1 Scaffold Groups with/without Growth Factor Delivery in Fenestration Defect  
The scaffold design consisted of either a patterned or amorphous PLGA/PCL film for the ‘PDL’ 
region, and an amorphous PCL film for the ‘bone’ region. Adenovirus encoding growth factors 
were immobilized onto the surface of each scaffold region for dual (i.e., PDGF-BB in the patterned 
or amorphous ‘PDL’ region, and BMP7 in the amorphous ‘bone’ region) or single (BMP7 in the 
PDL and bone regions) growth factor (GF) delivery. As a control, both regions were also used for 
delivery of an empty adenoviral vector (Ad), with the scaffolds consisting of an amorphous film 
for the ‘PDL’ region serving as the negative (-) control group. All films were seeded with hPDL 
cells or hGF cells, in the PDL and bone regions of the scaffold, respectively. Schematic of 
functional groups shown on sample CVD-coated polymer surface modified from [30]. 
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Figure 6.2 Micropatterned Scaffold Design and Adaptation at Rat Fenestration Defect 
Barium sulfate-coated regions of the scaffold (micropatterned film in a, amorphous film in b) are 
shown on a micro-CT scan of a rat fenestration defect to confirm that the scaffold total thickness 
(500um) conforms to the defect area without over-filling it. SEM images of the PLGA-PCL 
patterned films (100X) are shown with corresponding measurements of pillar height (100um), 
inter-pillar distance (150um), and thickness of the porous film base (150um).  
 
After the mandibulae were harvested at weeks 3-9 post-implantation, micro-CT scans were 
performed for groups at 3 and 6 weeks, revealing that at 3 weeks, limited bone formation was 
visible in the groups with Ad-empty, compared to groups involving any form of growth factor 
delivery. By week 6, all groups had almost completely covered tooth roots (including patterned + 
Ad-empty), except for the negative control (Figure 6.3). Analysis of total bone volume at the 
defect site only (Figure 6.4) confirmed significant (p<0.05) increases in bone formation in all 
groups that had growth factor delivery compared to groups with Ad-empty, with lesser differences 
noted at 6 weeks; tissue mineral density did not show a very noticeable variation among groups at 
3 or 6 weeks, except for higher values for TMD for groups with dual GF delivery compared to 
BMP7 delivery only (Figure 6.5). This was further confirmed using an examination of the 
percentage of bone fill within the original defect site, showing significantly higher (p<0.05) bone 
fill in all groups with growth factor expression compared to the negative control at both 3 and 6 
weeks. At 3 weeks, the positive control group bone fill was not significantly different from the 
empty vector group with a patterned film, and by 6 weeks, all of the groups with growth factor 
expression did not different in the % of bone fill compared to the empty vector group with 
patterned film. When comparing changes in bone volume between the 3 and 6 week time points, 
significant increases were observed in the negative control (p<0.05, from 38.2% to 48.1%), empty 
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vector with patterned film (p<0.05, from 45.6% to 62.7%), and the positive control (p<0.01, from 
49.9% to 68.6%). Bone fill in the Ad-BMP7 only group (mean change from 59.3% to 60.3%) and 
dual growth factor expression using amorphous films group (mean change from 65.8% to 68.0%) 
did not show any significant changes (Figure 6.5).   
 
Figure 6.3 Bone Regeneration at 3 and 6 Weeks Post-Implantation 
Micro-CT images showing regeneration of bone at 3 and 6 weeks post-implantation of the 
scaffolds with delivery of adenovirus with empty vector, single growth factor (AdBMP7), or dual 
growth factor (AdBMP7 and AdPDGF-BB). As indicated by arrows, there is increased coverage 
of the distal root of the first molar in groups with delivery of AdBMP7 at 3 weeks. By 6 weeks, 
significant increases in bone regeneration are noted across all groups.  
 
 
Figure 6.4 Transverse Section View of Bone Regeneration at Defect Site 
Micro-CT images showing transverse section of defect site with minimal (A) and maximal (B) 
bone fill, which is used to determine the total bone volume within the defect at 3 and 6 weeks post-
implantation.  
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Figure 6.5    Bone Volume, Tissue Mineral Density, and Bone Fill (%) at 3 and 6 Weeks In 
Vivo 
Bone volume and tissue mineral density values were obtained based on uCT scans at weeks 3 and 
6 post-implantation. The 3 weeks, significant difference (p<0.05) were observed between the 
patterned ‘PDL’ film group with single (BMP7) GF expression, and the patterned (P) and 
amorphous (A) films with dual GF expression for TMD, with differences also observed at 6 weeks 
between the patterned group with single GF expression and amorphous group with dual GF 
expression. No significant differences in bone volume were observed among the groups with any 
form of GF delivery (outlined in blue) at weeks 3 and 6. However, at week 3, all of these groups 
had significantly higher BV compared to the amorphous group with empty vector (***p<0.001, 
****p<0.0001), or patterned group with empty vector (#p<0.05). By week 6, both the patterned 
group with empty vector and all other groups with any form of GF delivery had significant higher 
(*p<0.05, **p<0.01) volume of bone formation compared to the negative control (-). Bone fill 
within the defect site (%) was compared among all groups at weeks 3 and 6, with similar pattern 
of increased bone formation at defect site observed for groups with growth factor expression and 
patterned film with empty vector.  
 
 Hematoxylin and eosin (H&E) stains at 3 weeks show increased PDL-like tissue present 
especially in groups with patterned film + AdBMP7-hGF, as well as groups with a patterned film 
and dual growth factor delivery (Figure 6.6). Bone formation is seen at sites close to the PDL-like 
tissue in all groups, but, interestingly, there is a very clear tendency of the bone to concentrate with 
the inter-pillar regions, which is observed at all groups with a patterned film. While this may 
indicate that the patterning may attract osteoblasts due to the difference in material topography, it 
also explains why there may be bone formation observed quantitatively (as shown in Figure 6.5) 
in the patterned film + AD-empty vector group that is significantly higher compared to the negative 
control at week 6. However, this also appears to impede the intended orientation of tissue at the 
pillar grooves so as to form PDL tissue. At the same time, PDL-like tissue does form between the 
tooth root and regenerated bone, although the patterned film is located behind this initial layer of 
new bone as opposed to being in front of it, as intended by the design and incorporation of the 
amorphous region for BMP7-hGF delivery. At week 6, H&E images reveal that more of the tissue 
bordering the tooth root is becoming increasingly aligned perpendicular to the dentin, as indicated 
by arrows in Figure 6.7, except for the negative control group (amorphous “PDL” film + Ad-
empty). Likewise, immunofluorescence images reveal how closely the soft tissue formation is 
consistent with PDL-like tissue, which also expresses periostin and collagen type III. Figure 6.8 
shows increased collagen III expression specifically in the patterned film + AdBMP7-hGF group 
as well as the positive control (patterned film + AdPDGF-hPDL). Periostin is more consistently 
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expressed through the PDL-like tissue in groups with dual growth factor delivery only (i.e., with 
AdPDGF-hPDL in the “PDL” region of the scaffold). By week 6 (Figure 6.9), collagen III 
expression remains consistent with what is observed at week 3, except for an increase in this 
protein expression in the patterned group with Ad-empty. Overall, groups with patterned films and 
either single (BMP7) or dual (BMP7 and PDGF) growth factor expression appear to have more 
PDL-like tissue by week 6, compared to the negative control and amorphous + dual growth factor 
delivery groups.  
 
Figure 6.6   Hematoxylin and Eosin (H&E) Staining at 3 Weeks In Vivo 
Hematoxylin and eosin (H&E) staining to evaluate tissue formation at rat fenestration defect site 
along patterned films or amorphous films (with dual growth factor delivery (AdPDGF and 
AdBMP7), single growth factor delivery (AdBMP7), or empty vector) at 3 weeks post 
implantation in rat fenestration defect. Blue arrows indicate general orientation of cell nuclei 
relative to the tooth root (TR). Scale bar is 100um for all images. TR = tooth root, AF = amorphous 
film, PF = patterned film, B = bone.  
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Figure 6.7  Hematoxylin and Eosin (H&E) Staining at 6 Weeks In Vivo 
Hematoxylin and eosin (H&E) staining to evaluate tissue formation at rat fenestration defect site 
along patterned films or amorphous films (with dual growth factor delivery (AdPDGF and 
AdBMP7), single growth factor delivery (AdBMP7), or empty vector) at 6 weeks post 
implantation in rat fenestration defect. Blue arrows indicate general orientation of cell nuclei 
relative to the tooth root (TR). Scale bar is 100um for all images. TR = tooth root, AF = amorphous 
film, PF = patterned film, B = bone.  
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Figure 6.8   Immunofluorescence: PDL-Like Tissue at 3 Weeks In Vivo 
Immunofluorescence analysis of fibrous connective tissue formation along patterned films or 
amorphous films (with dual growth factor delivery (AdPDGF and AdBMP7), single growth factor 
delivery (AdBMP7), or empty vector) at 3 weeks post implantation in rat fenestration defect. Scale 
bar is 100um for all images. TR = tooth root, AF = amorphous film, PF = patterned film, B = bone. 
Dashed white lines represent regions of PDL-like soft tissue formation corresponding to areas 
where periodontal ligament and cementum were removed along the tooth root during formation of 
the rat fenestration defect. 
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Figure 6.9   Immunofluorescence: PDL-Like Tissue at 6 Weeks In Vivo 
Immunofluorescence analysis of fibrous connective tissue formation along patterned films or 
amorphous films (with dual growth factor delivery (AdPDGF and AdBMP7), single growth factor 
delivery (AdBMP7), or empty vector) at 3 weeks post implantation in rat fenestration defect. Scale 
bar is 100um for all images. TR = tooth root, AF = amorphous film, PF = patterned film, B = bone. 
Dashed white lines represent regions of PDL-like soft tissue formation corresponding to areas 
where periodontal ligament and cementum were removed along the tooth root during formation of 
the rat fenestration defect. 
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Further analysis of ratio of mean periostin intensity (PDL-like tissue versus native PDL 
tissue, Figure 6.12), shows significantly higher expression at 3 weeks for the patterned + 
AdBMP7-hGF group compared to the amorphous + Ad-empty group (negative control). Overall, 
at 3 weeks the ratios are lower for the Ad-empty groups compared to all groups with growth factor 
delivery. At 6 weeks, the ratios for the positive control group and single growth factor delivery 
group are significantly higher (p<0.05) compared to the negative control. Individual plots of the 
intensity profiles (shown in Figures 6.10 and 6.11) show that the regenerated tissue areas have 
periostin intensity profiles are either close to the native PDL tissue or much lower (i.e., observed 
at week 3 for groups with Ad-empty, and at week 6 for groups with Ad-empty as well as 
amorphous film with dual growth factor delivery). To complement these findings, additional 
assessment was performed using toluidine blue-stained sections (Figure 6.13A) for all groups 
(n=6) to determine scaffold displacement from the defect site (given significant amounts of bone 
observed to have formed in front of the patterned film), as well as the average width of the PDL-
like tissue. Figure 6.13B shows significantly narrower PDL tissue (i.e., closer to the average rat 
PDL width of 100um) for groups that have the patterned film included, with much higher widths 
(~230um for the amorphous group with dual growth factor delivery, and up to 400um in the 
negative control) for groups with amorphous film for the “PDL” region of the scaffold. This pattern 
is observed at 6 weeks as well, with the positive control group having a mean thickness of ~100um, 
while the remaining groups with patterned film showing PDL-like tissue widths slightly greater 
than 100um. Both of the amorphous film groups have widths that are between 200-400um. Another 
interesting assessment is the scaffold displacement (“PDL” scaffold region in particular) from the 
defect site (Figure 6.13C). At week 3, significant differences in displacement are noted between 
the patterned + single growth factor delivery and pattern +dual growth factor delivery groups (with 
the positive control group showing more displacement relative to the pattern + AdBMP7-HGF 
group). This is in line with the previous observations of increasing bone formation at inter-pillar 
spaces, which appear to stabilize the scaffold at the defect site such that the new formed tissue 
does not push it away as much as seen in other groups. By week 6, significant differences are 
observed between the patterned film + Ad-empty and the negative control only.  
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Figure 6.10  Average Intensity Profile: Periostin Expression at 3 Weeks In Vivo 
Periostin expression average intensity profiles for representative samples from 3 experimental and 
2 control groups harvested at 3 weeks post implantation in a rat fenestration defect. Periostin 
expression is observed at both the original defect site and the native PDL site. The blue line 
indicates average native PDL intensity values as a comparison to the values observed at 
regenerated sites with PDL-like tissue. TR = tooth root, P = pulp. Scale bar = 100um.  
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Figure 6.11    Average Intensity Profile: Periostin Expression at 6 Weeks In Vivo 
Periostin expression average intensity profiles for representative samples from 3 experimental 
and 2 control groups harvested at 6 weeks post implantation in a rat fenestration defect. Periostin 
expression is observed at both the original defect site and the native PDL site. The blue line 
indicates average native PDL intensity values as a comparison to the values observed at 
regenerated sites with PDL-like tissue. TR = tooth root, P = pulp. Scale bar = 100um. 
 
 
 
 
 
 
 
Figure 6.12  Comparison of Periostin Intensity between Native and Regenerated PDL 
To compare periostin expression among groups at 3 and 6 weeks, the mean fluorescence intensity 
was calculated for the PDL-like tissue formation at the defect site (n=6), and compared to the mean 
periostin fluorescence values obtained at the native PDL site (n=6) for the same sample. Significant 
(p<0.05) difference were observed at 3 weeks between the group with a patterned film at the ‘PDL’ 
region of the scaffold with BMP-7 expression, and the group with an amorphous film at the ‘PDL’ 
region with an empty vector. At 6 weeks, the same significant differences were seen between the 
two groups, as well as between the amorphous film with empty vector group and the patterned 
film with dual GF delivery group. 
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Figure 6.13   Scaffold Displacement and Total PDL-like Tissue Width at Defect Site 
Toluidine blue-stained section (A) of a sample group containing a patterned film with dual growth 
factor delivery at 6 weeks post-implantation, with improved visibility of the bone (B) formation 
regions surrounding the patterned (PF) and amorphous (AF) films. Measurements of total PDL-
like soft tissue width (red arrows, graph shown in B) and scaffold displacement (blue arrows, graph 
shown in C) were made to determine variations among groups, focusing on effects of both growth 
factor delivery and “PDL” scaffold region morphology (i.e., amorphous vs. patterned). Data points 
specific to patterned films are outlined using dashed black lines. Statistical significance indicated 
using * (p<0.05).  
 
Finally, another consideration during the analysis of this data was whether the implanted 
human-derived cells would remain at the defect site or be replaced entirely with the host cells by 
the specific harvest time points of 3, 6 and 9 weeks. Results from anti-human nuclear staining 
shown in Figure 6.14 indicate that, in fact, human-derived cells are not entirely replaced by the 
host cells, with cells close to the scaffold surface (which retains the dark brown color of the stain). 
Overall, it appears that there are more human-derived cells in the negative controls (no growth 
facto delivery) compared to the positive controls at both weeks 3 and 6. Likewise, the non-specific 
staining of the scaffold that is specifically striking in the amorphous scaffold groups appears to 
decrease, potentially as a result of scaffold degradation over time.  
As an additional assessment of the tissue regeneration at the interface of the PDL-like tissue 
and new alveolar bone, nanoindentation was performed on the positive and negative control groups 
at weeks 3 and 9 (Table 6.1). The indentation was performed on both the native bone and PDL 
tissue and the regenerated bone and PDL-like tissue for each sample (n=3). Values are reported as 
a range due to heterogenicities in the tissue architecture, as previously done in other studies [20-
22]. As expected, at 3 weeks the reduced elastic modulus (i.e., stiffness) range is higher for both 
the native (1.5-6.9GPa) and regenerated (1.5-4.3 GPa) bone relative to native (0.18-1.7GPa) and 
regenerated PDL (0.2-1.0 GPa). At 9 weeks, this pattern repeats with native (2.4-10.9GPa) and 
regenerated (2.4-6.3GPa) bone having a higher stiffness than ranges recorded for native (0.2-
2.8GPa) and regenerated (0.1-1.9GPa) PDL, given that bone is known to be much stiffer compared 
to non-mineralized tissue (i.e., PDL). Hardness values show the same result: at 3 weeks, native 
(0.03-0.17GPa) and regenerated (0.02-0.15GPa) bone is shown to have higher values than native 
(0.01-0.04GPa) and regenerated (0.008-0.03GPa) PDL. By week 9, native (0.07-0.15GPa) and 
regenerated (0.02-0.12GPa) bone is shown to have hardness values higher than those observed in 
native (0.01-0.07GPa) and regenerated (0.005-0.02GPa) PDL-like tissue. Overall, at week 3 the 
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reduced modulus range for the regenerated PDL measured in positive control samples (0.2-
1.0GPa) versus negative control samples (0.2-0.8GPa) fall within the range of values observed in 
native PDL (0.18-1.7GPa). This is also observed for regenerated bone (1.5-4.3GPa) in the positive 
and negative (1.7-3.8GPa) controls versus native bone (1.5-6.9GPa). Figure 6.15 confirms that 
presence of dual growth factor expression resulted in regenerated bone stiffness matching the 
stiffness of native bone on the uninjured side, with no significant differences between the two 
groups at weeks 3 and 9. This was further confirmed at weeks 3 and 9 for PDL-like tissue stiffness 
in the positive control groups versus native PDL stiffness measured in un-injured regions.  
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Figure 6.14  Anti-human Nucleus Staining at 3, 6, an d 9 Weeks Post-Implantation  
Anti-human nucleus staining was performed on samples harvested at 3, 6 and 9 weeks post-
implantation to determine of human-based cells remained present at the defect site or migrated 
outside of it over the course of the implantation period. A comparison of empty vector and dual 
growth factor delivery groups is presented, with specific regions of human cells indicated (yellow 
arrows). The amorphous scaffold remnants result in unspecific brown-colored staining using 
MACH4, therefore the human nucleus-positive cells are identified using both the background 
brown stain and blue stain which identifies cell nuclei. A = amorphous film, TR = tooth root, B = 
bone. Scale bar = 100um.  
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Table 6.1 Nanoindentation (DRY): Bone-PDL Interface of Regenerated Tissue vs. Native Tissue  
 
 
*corresponds to sig. diff. between negative and positive control groups at same time point, same 
          tissue (i.e., regenerated bone at 3 or 9 weeks, PDL-like tissue at 3 or 9 weeks)  
        *p<0.05, **p<0.01, ***p<0.001 
 
        # corresponds to sig. diff. between negative controls or sig. diff. between positive controls at 3 and 9  
           weeks (for same tissue type)  
        #p<0.05, ##p<0.01, ###p<0.001 
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Figure 6.15   Comparison of Elastic Moduli for Regenerated and Native Tissues at 3 Weeks 
and 9 Weeks Post-Implantation  
Box plots showing the reduced elastic modulus values obtained at 3 and 9 weeks post-implantation 
at sites of the negative control (Ad-empty, amorphous film), positive control (AdBMP7 and 
AdPDGF, patterned film), and native tissue. In (A), the values represent stiffness of bone in both 
controls relative to the native bone stiffness measurements at the non-injured site, while in (B) the 
values represent stiffness of the PDL in both controls relative to the native uninjured PDL. At 3 
weeks and 9 weeks, there are no significant differences between the positive control bone and 
native bone stiffness values. PDL tissue stiffness in negative and positive controls shows no 
difference from native PDL at week 3, but by week 9 stiffness of negative control PDL is 
significantly lower compared to the positive and native PDL stiffness, with no differences 
observed between the positive control and native PDL stiffness values.  
 
6.4  Discussion  
 
This study was designed to examine the effects of scaffold topography (i.e., patterned 
versus amorphous) coupled with delivery of immobilized gene therapy vectors (i.e., BMP7 and 
PDGF-BB) for periodontal tissue regeneration. As shown in Figure 6.1, the design incorporated a 
negative control (Ad-empty) and a group with single growth factor delivery (Ad-BMP7 only in 
both regions of the scaffold). The scaffolds compartments were adjusted to contain films that each 
separately had a thickness of 250um, for a total combined thickness of 500um, allowing for a 
calculated fit within the 500um deep fenestration defect (Figure 6.2). Implantation of the scaffold 
in vivo showed increased root coverage in groups with BMP7 production, as expected. No 
significant differences in BV were observed among the groups with BMP7 production at the defect 
site specifically (Figure 6.4), where all regions contained the same amorphous film with 
AdBMP7-hGF. In accordance with previously reported results using the ectopic murine model 
(Chapter 6), groups with Ad-empty vector did not show noticeable coverage of the root at 3 weeks 
(Figure 6.3), but by 6 weeks the patterned film group with Ad-empty, as is also confirmed using 
BV and bone defect fill measurements (Figure 6.5), had significantly higher defect fill compared 
to the negative control. As later observed histologically, there appears to be a potentially osteo-
conductive effect of the patterning, with new bone consistently seen to be forming in regions 
between the pillars (Figures 6.6-6.7).  
Material surface topography and roughness are important parameters in determining cell 
response: Fibroblasts have a preference for attaching to smooth surfaces, while bone-derived cells 
prefer a surface that is rough. This corresponds to the design of the scaffold compartments for bone 
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and PDL regeneration, where the amorphous PCL region has more surface area with greater cell-
based perception of roughness compared to the somewhat smoother and more structured 
morphology of the patterned films (as seen in SEM images, Figures 5.3 and 5.12). Nevertheless, 
the tendency of bone to form at the inter-pillar regions indicate that other factors, such as the 
presence of patterning on the pillar sides, may override the lack of its porosity relative to the 
amorphous films. Interestingly, grooves measuring 10um in width have previously been shown to 
result in significantly increase both adhesion and viability of osteoblastic cells [23, 24]. Here, 
pillars had grooves with widths of 15um, and depths of 30um, based on previously-established 
parameters that were shown to promote aligned collagenous tissue formation. In future studies, it 
would be worthwhile to examine whether increasing groove width (i.e., 30-60um) would decrease 
the tendency of bone to localize at inter-pillar regions. It is also known that micro-rough surfaces 
with different topographies show enhanced osseointegation (i.e., functional/structural connection 
that forms between load-bearing implant surface and existing bone), as evidenced by the use of 
dental implant design featuring threads that promote implant stability. Depending on the type of 
implant (i.e., V-shaped, square threads), thread pitches (groove + ridge) can range from 0.8-
1.5mm, with thread widths from 0.1-0.6mm. The patterned film pillar pitch (0.3mm) and pillar 
width (0.15mm) is not far from this range, with recent studies indicating that an even smaller dental 
implant pitch may benefit osseointegration [25]. It is therefore reasonable to suggest that the 
patterned film may inadvertently be functioning as a more osteo-conductive surface than the 
amorphous film, both being comprised of PCL, especially given that bone formation between 
pillars is observed even in the groups with Ad-empty delivery (i.e., lacking AdBMP7-hGFs) as 
seen in Figure 6.6.  
When comparing these results to the rat fenestration defect pilot study described in Chapter 
5, there are significant differences histologically (see Figure 5.14), given the lack of bone 
formation between pillar regions. However, the film pattern dimensions are also significantly 
larger, consisting of 300um x 300um pillars with heights of 250um and 150um inter-pillar spacing. 
The formed PDL-like tissue is much wider than what would be observed in native rat 
periodontium, which is addressed in this study by large reductions in pillar height to 100um, 
resulting in PDL-like tissue width (Figure 6.13B) that is within the 100um approximate width in 
native rat PDL, specifically in groups that contain the patterned film. Groups with the patterned 
film that tends to have inter-pillar region bone formation integrating with PDL-like tissue provide 
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better control of tissue spacing that is otherwise lost in the groups with amorphous “PDL” films. 
Another important distinction to note between the earlier pilot study scaffold design and the design 
presented here is the significantly reduced thickness of the amorphous “bone” film. Previously, 
the patterned film would cover the defect such that the amorphous film would be positioned 
directly on top. Here, the film thickness was reduced by ~2X to allow for complete insertion into 
the region where alveolar bone is removed during formation of the defect. It is likely that this 
served as a barrier to the migration of hGFs producing BMP7 towards the patterned film and inter-
pillar regions. The patterned film porous base was also thinned by ~100um, thereby eliminating 
an additional barrier that may have reduced infiltration of BMP7-expressing cells or BMP7 itself 
into the inter-pillar spaces. Additionally, the amorphous film is more porous than the patterned 
film or its base, such that additional bone (i.e., BMP) can infiltrate into that region, but in the 
patterned film region it tends to navigate around the patterned film region as that is the easier route 
with less restriction given the increased polymer density. Anchoring the scaffold in place in order 
to prevent its displacement from the root would likely stabilize it and possibly limit infiltration of 
bone at inter-pillar regions.  
In order to better understand the sequence of events that results in the observed tissue 
regeneration seen in this study, it is worthwhile re-visit the wound healing process that sets into 
action as soon as the fenestration defect is created (Figure A1.2 in Appendix): Removal of the 
bone-PDL-cementum complex results in injury to vascularized tissue, forming a provisional 
matrix that includes fibrin, activated platelets, endothelial cells, and inflammatory cells. Activation 
of platelets causes the release of PDGF (synthesized and stored in platelet alpha granules), 
contributing to angiogenesis, which involves vascular endothelial growth factor (VEGF)—a 
PDGF sub-family of growth factors. Transforming growth factor beta (TGF-β), a platelet-derived 
cytokine, promotes the chemotaxis and proliferation of osteoprogenitor cells which are recruited 
by cell signaling through BMPs, with the interaction of progenitor cells with BMPs further 
resulting in the induction of bone-forming osteoblasts [26]. With regard to PDL regeneration, 
fibroblasts are the dominant cells of the proliferative stage in wound healing, during which they 
synthesize collagen in response to platelet-, macrophage-, and mesenchymal cell-specific growth 
factor release (i.e., PDGF, FGF, IGF, described in more detail in Chapter 2). As a result, even in 
groups that have only Ad-empty immobilized, there is still observed bone and soft tissue 
regeneration. However, based on micro-CT, histomorphometric, and immunofluorescence data, 
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there are visible advantages of incorporating additional (human-derived) cells producing BMP and 
PDGF (BMP7 and PDGF-BB, specifically), delivered via a scaffold with macro- and micro-
topographical cues intended to promote the regeneration of the bone-PDL-cementum complex that 
is structurally- and functionally-consistent with that of native tissue.  
Incubation of hPDL cells on the patterned film with immobilized AdPDGF overnight prior 
to implantation at the distal root of the first molar ensures that transduction is limited to only those 
cells that come in direct contact with the film, while also giving the cells adequate time to begin 
aligning within the pillar grooves such that they will already be positioned perpendicular to the 
root surface when the film is implanted. Likewise, the amorphous film region is also immobilized 
with AdBMP7 and seeded with hGFs in order to ensure the localization of BMP-producing cells 
specifically to the region of the defect where bone is removed. Using adenoviral gene therapy 
vectors ensures that only the transduced cells produce growth factors—future generations of these 
human-derived cells would likely be unaffected. However, it appears that human-derived cells 
continue to remain at the defect site even into week 9 post-implantation, as evidenced using anti-
human nuclear staining (Figure 6.14) of positive and negative control groups. At 3, 6, and 9 weeks, 
the Ad-empty (negative control) group appears to have greater presence of human-derived cells 
compared to the amorphous “PDL” film group with AdBMP7-hGFs and AdPDGF-hPDLs. A 
potential explanation is that the presence of the growth factors promotes the regenerative process 
which increases cell turn-over with time. Likewise, the extended expression pattern of BMP and 
PDGF above what is typically found in the wound environment may cause migration of the 
elevated growth factor concentrations in the wound site (i.e., BMP) towards other areas of the 
scaffold besides the “bone” region. Given that PDGF is also known to induce osteoblast 
chemotaxis, its presence may further favor infiltration of the area with osteoblast progenitor cells. 
Overall, as has previously been reported by Zhang Y et al using scaffold-based, combined and 
separate delivery of AdBMP7 and AdPDGF in dog furcation defects, the presence of both growth 
factors contributed to a more robust regeneration of the periodontium [16]. In this study, bone 
regeneration is observed to be robust in all groups with either single or dual growth factor 
expression, while PDL-like tissue is more evident (based on combined collagen III, periostin 
staining) in groups with a patterned film and single as well as dual growth factor expression at 
weeks 3 and 6 post-implantation (Figures 6.8, 6.9). This is further confirmed when analyzing the 
mean periostin fluorescence intensity at weeks 3 and 9. Periostin is a mesenchymal stem cell 
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marker that is found in collagen-rich connective tissues such as tendons and periosteum. PDL-
specific periostin has been shown to positively regulate PDL cell mineralization and 
cytodifferentiation. Due to its importance as an ECM protein involved in maintaining the 
homeostasis of periodontal tissues, as well as showing strong expression during PDL cell 
differentiation, a more thorough assessment of its expression in all groups tested was performed.   
At 3 weeks, higher mean periostin intensity values were observed for all groups involving growth 
factor expression (highest being in the group with AdBMP7-hGF in both regions). By week 6, the 
highest values were observed in groups with a patterned film and either dual or single growth 
factor expression [28, 29].  
Interestingly, a very recent study by Sowmya et al consisting of a tri-layered 
nanocomposite hydrogel scaffold also utilized film-like layers for the delivery of cells and growth 
factors to rabbit maxillary periodontal defects. The scaffold layers were positioned as follows: 
chitin-PLGA/nanobioactive glass ceramic (nBGC)/cementum protein 1 (cementum layer), chitin-
PLGA/FGF-2 (PDL layer), and chitin/PLGA/nBGC/platelet rich plasma growth factors (alveolar 
bone). Implantation of the scaffold with the growth factors resulted in complete closure of the 
defect and healing, with confirmed regeneration of new cementum, fibrous PDL, and alveolar bone 
compared to a scaffold alone without growth factors, at 1 and 3 months post-implantation [27]. 
Compared to this study, which did not incorporate a specific layer for cementum regeneration. 
These results may indicate that in order to observe cementum regeneration, which is lacking in 
this study, a separate growth factor or scaffold compartment may be needed to ensure the full tri-
layer periodontal complex formation.   
Nanoindentation was used to further elucidate the functional characteristics of the 
regenerated bone-PDL complex. Several studies have used micro- and nano-indentation to 
determine the mechanical properties of the native periodontium in rats. Grandfield et al reported 
12.1 ± 3.4 GPa (8.7 - 15.5 GPa range, under wet conditions) in the rat alveolar bone region at the 
molar PDL-bone interface [19]. It is important to note that in native periodontal tissue, the region 
of alveolar bone where PDL fiber bundles (i.e., Sharpey’s fibers) insert is called the bundle bone, 
whereas the alveolar bone is the region of bone into which bundle bone (i.e., inner wall of alveolar 
socket) transitions. While this is anatomically identifiable in native PDL (see Figure A1.1 in 
Appendix), in the samples tested this transition as not as obvious in the regenerated tissue regions. 
As such, the indentations were performed at the regions of bone closest to the PDL region (the 
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bundle bone region). Ho SP et al previously performed nano-indentation under the same loading 
conditions, albeit using hydrated human tissue, showing a range of Er = 2-8GPa for bundle bone, 
which falls within the range of values reported here (Table 6.1). Another study performed to 
characterize PDL-bone attachment sites in human molars shows an Er range of 0.01-0.05 GPa for 
PDL tissue (0.1-1.0 GPa for PDL-AB region) and 0.2 – 9.6 GPa range for bone tissue. Hardness 
values were reported to range from 0.01-0.15 GPa for bone regions of the periodontium and 0.01-
0.03 GPa for the PDL-AB regions, using nanoindentation [20-22]. Although there are no major 
discrepancies between the presented and reported values, it is important to mention that a variety 
of factors may affect the stiffness and hardness ranges, including the hydration state (i.e., testing 
under wet versus dry conditions), probe geometry, and loading conditions.  
Having established that the stiffness and hardness of native PDL and bone regions reported 
here correlate to previously reported values, the main purpose of the presented results is to compare 
and contrast these same values among the positive (patterned film/amorphous film + AdPDGF-
hPDL/AdBMP7-hGF), negative (amorphous film/amorphous film + Ad-empty/Ad-empty) control 
groups, and determined native PDL and AB stiffness and hardness values. These are load-bearing 
tissues that integrate over time, making these parameters important in determining whether the 
regenerated tissue is mechanically similar to its native counterpart. As previously noted, there is 
heterogeneity in the bone tissue which is specifically identifiable using nanoindentation as opposed 
to microindentation, given that there are regions of lamellar bone integrating with bundle bone, 
thereby giving the observed range of values. Overall, the positive and negative control values for 
bone and PDL fall within the native bone and PDL values, respectively at 3 and 9 weeks. As 
expected, the largest difference the lowest and highest reported stiffness values is seen in the bone 
regions (native: Δ5.4GPa, positive control: Δ2.8 GPa, negative control: Δ2.1 GPa), compared to 
the PDL regions (native: Δ1.5 GPa, positive control: Δ 0.8GPa, negative control: Δ 0.6 GPa). 
Interestingly, the highest values for both the regenerated bone and PDL tissues relative to the native 
bone and PDL tissues are observed in the positive control group (patterned film + dual growth 
factor delivery) (i.e., 1.0 GPa for positive control versus 0.8 GPa for negative control in PDL-like 
tissue, and 4.3 GPa for positive control versus 3.8 GPa for negative control in bundle bone tissue). 
This is an indication that the regenerative process may be more complex in the positive control 
given that involvement of dual growth factor delivery, with increased potential for having more 
mature tissue relative to the negative control tissue sites at the earlier time point of 3 weeks. At 9 
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weeks, the tissue in both group is expected to be more mature. Here, we observe that again the 
stiffness values for both positive and negative control regenerated PDL and bone regions falls 
within the range observed in native bone. Again, the positive controls have a range with highest 
values (i.e., 1.9 GPa for PDL in positive control versus 0.7 GPa for PDL in negative control, and 
2.8 GPa in native PDL; 6.3 GPa for positive control bone versus 4.0GPa for negative control bone, 
with 10.9GPa in native bone). Comparing week 3 and week 9 values clearly shows an increase in 
the lowest values reported within the regenerated bone stiffness range for all groups. All of the 
groups also show an increase in the highest value reported within the stiffness range for bone, 
although this value increases more prominently in the positive control samples (4.3 GPa at 3 weeks 
to 6.3 GPa at 9 weeks) compared to the negative control (3.8GPa at 3 weeks to 4.0 GPa at 9 weeks). 
For the PDL region values, there is also an increase in stiffness range for the positive control (i.e., 
1.9 GPa from 1.0GPa) compared to a slight decrease observed in the negative control (i.e., 0.8GPa 
to 0.7GPa). Statistically, there are significant differences (p<0.05) between the Er (regenerated 
bone) for the negative and positive controls at both 3 and 9 weeks, as well as the Er (PDL-like 
tissue) between the negative and positive controls at 9 weeks (p<0.01), such that the values for the 
patterned film/dual growth factor delivery are higher. Comparing the same groups between 3 and 
9 weeks shows significantly higher Er values for PDL-like tissue (p<0.05, in patterned film/dual 
growth factor delivery group), and higher values for regenerated bone (p<0.01, in amorphous 
film/Ad-empty group), over time.  
Figure 6.15 further illustrates the ranges reported in Table 6.1 with statistical analysis of 
differences in stiffness between the positive or negative control and native tissue (PDL or bone), 
with results confirming that positive control group tissue stiffness matched that of native tissue at 
both time points for PDL and bone., with no significant differences between them. Likewise, 
positive control values were significantly higher for bone and PDL stiffness when comparing to 
negative control values at 3 and 9 weeks, except for PDL-like tissue at the 3 week time point being 
of the same general stiffness for both negative and positive controls. While Table 6.1 presents the 
effects of time and growth factor presence/patterning on tissue regeneration, Figure 6.15 focuses 
on both the effects of growth factor expression (given statistical comparison between the negative 
and positive control groups), as well as provides a comparison to native PDL and/or bone tissue 
values in a box plot that emphasizes the differences in the range of values for all groups evaluated, 
emphasizing the importance of growth factor expression over time on tissue regeneration.   
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When considering the reported hardness values at weeks 3 and 9, the values for the native 
bone region (0.03-0.17 GPa and 0.07-0.15 GPa) are typically higher than the native PDL region 
(0.01-0.04 GPa and 0.01-0.07 GPa), as expected. Once again the negative and positive control 
values fall within the range reported for native bone at weeks 3 and 9, although the week 9 positive 
control lowest value is outside the range (0.02GPa), while it also has the highest value (0.12GPa) 
within the range compared to the negative control group. Interestingly, the PDL-like tissue 
hardness range for both the positive (0.005-0.02 GPa) and negative (0.06-0.02 GPa) controls is 
just slightly inside the range of native PDL hardness (0.01-0.07 GPa) at week 9. Overall, the 
hardness range for PDL is seen to increase for both groups from week 3 to week 9. This may 
indicate that as the tissue matures, there are increasing heterogeneities in the region given increased 
collagenous tissue formation that also has a tendency to vary in stiffness and hardness in varying 
parts of the PDL. Statistically, there are significant differences between both the PDL-like tissue 
(p<0.05) and regenerated bone (p<0.05) for the negative and positive controls at week 3. At week 
9, only the regenerated bone values for both negative and positive controls show significant 
differences (p<0.001), indicating harder tissue in the patterned film/dual growth factor delivery 
group. Comparing weeks 3 and 9, only the amorphous film/Ad-empty groups shows a significantly 
increased (p<0.05) range of values for PDL-like tissue hardness. Based on values extracted from 
nano-indentation, this data permits the conclusion that, at week 9, the positive control group tissue 
overall is more mature and closer to native tissue modulus values compared to the negative control. 
This further supports the previously discussed data that highlights the improved regeneration of 
the periodontal complex in groups with customized biomaterial micro-architecture and dual 
growth factor delivery.  
 
6.5  Conclusion  
 
 This study explores the effects of surface topography combined with growth factor delivery 
on periodontal tissue regeneration.  There are clear indications that dual growth factor delivery 
(i.e., combined delivery of PDGF-BB and BMP-7) leads to improved bone formation and 
regeneration of PDL-like tissue, as evidenced by a thorough assessment of protein expression (i.e., 
collagen III, periostin), and tissue mechanical properties. While the surface topography does not 
serve to provide guidance for oriented PDL tissue orientation (as originally intended) due to the 
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displacement of the scaffold from the defect site and infiltration of the inter-pillar regions with 
osseous tissue, there is nevertheless important indications that the patterning has effects on the 
overall integrity of the final bone-PDL interface. Moreover, this study confirms that gene therapy 
vectors can be immobilized onto the scaffold surface in order to localize the transduction of cells, 
specifically for subsequent implantation in vivo. Future studies can focus on improved scaffold 
stabilization at the defect site,  as well as potential improvement of the scaffold fabrication process 
to allow encapsulation of gene therapy vectors within the scaffold such that transduction can take 
place in vivo instead of in vitro prior to implantation.  
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CHAPTER 7 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The “Future Directions” section of this chapter includes excerpts from sections written as a 
contribution to the following article:  Fretwurst T, Larsson L, Yu SH, Pilipchuk SP, Kaigler D, 
Giannobile WV. “Periodontal Tissue Bioengineering: Is the Future Now?” Compendium of 
Continuing Education in Dentistry (publication pending).  
 
7.1 Conclusions 
 
 Novel tissue engineering strategies are required for the regeneration of lost periodontal 
tissues due to instances where clinically-based periodontal therapy is not predictable or fails to 
promote the regeneration of the alveolar bone-PDL-cementum complex. While many studies have 
examined the interplay among different biomaterial scaffolds, growth factors, and cells necessary 
for predictable tissue regeneration, there is still a lack of specifically-established parameters that 
are required to obtain tissues that are not only structurally, but also functionally similar to native 
periodontium that further matches its hierarchical architecture. As described throughout the 
chapters, this work focuses on the use of specific technologies (3D-printing and micropatterning) 
that allow for the scaffold to be fabricated with macro- and micro-scale cues that can guide the 
formation of aligned tissue. There is clear evidence that patterning does in fact promote aligned 
soft tissue formation, as shown using the ectopic murine model. More specifically, increased 
groove depth is shown to be a more significant parameter in determining the percentage of aligned 
tissue relative to groove width. In combination with gene therapy vectors, the 3D-printed, 
micropatterned scaffold is able to improve the bone-PDL-like regeneration that is needed to 
recapitulate the structural integrity of the periodontal complex, as described in Chapter 4. 
However, improved localization of growth factor expression as well as increased rate of 
degradation to allow more rapid replacement of the biomaterial with native tissue is necessary to 
further improve upon the existing scaffold design.  
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 Chapter 5 explores the application of a re-designed scaffold incorporating PLGA to 
promote increased degradation of the “PDL” scaffold region in ectopic murine model and rat 
fenestration defect model pilot studies. In addition, to allow for more predictable delivery of gene 
therapy vectors while also localizing the transduction of cells to specific regions of the scaffold 
(i.e., AdBMP7 transduced cells to the “bone” region and AdPDGF-BB transduced cells to the 
“PDL” region), a novel surface immobilization technique is explored using chemical vapor 
deposition (CVD). Based on the results of these findings, immobilization of gene therapy vectors 
is a potential solution for increased control over transduced cells and limitation of potential 
adenovirus dispersion that is of greater concern when the virus is not immobilized onto the surface. 
As discovered in Chapter 6, the architecture and overall dimensions of the scaffold at the defect 
site are critical parameters in determining the localization of the growth factors, given that a 
decrease in the amorphous “bone” region film thickness to better fit within the rat fenestration 
defect allowed for more localized expression of the AdBMP7-transduced cells on the scaffold 
surface such that the regenerated bone was within the defect site where alveolar bone was removed, 
as opposed to being mostly ectopic, as originally was found in the fenestration defect pilot study 
in Chapter 5. A more thorough focus on the selection of growth factors for each region of the 
scaffold showed that both single (BMP7) and dual (BMP7 and PDGF-BB) delivery promoted the 
formation of a bone-PDL-like tissue complex most similar to what is natively present in vivo. 
However, this regeneration was observed specifically in regions that included the presence of a 
patterned film, especially when comparing the results for groups with dual growth factor delivery 
combined with an amorphous film versus patterned film for the “PDL” region of the scaffold. The 
primary conclusion from the results observed on Chapter 6 is that the combination of scaffold 
topography (i.e., patterning, albeit more so for bone anchoring than oriented PDL formation) and 
growth factor delivery (i.e., BMP7 alone or in combination with PDGF-BB) resulted in improved 
periodontal tissue regeneration in a mechanically-loaded defect model. 
 
7.2 Future Directions  
 
There are numerous future directions that can be pursued to better understand how the 
existing scaffold design and controlled growth factor delivery can be improved for more 
predictable periodontal tissue regeneration, and further extended into more general cases of bone-
ligament regeneration. The primary techniques used in this work for scaffold design were 3D 
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printing and micropatterning. Three-dimensional (3D) printing—also referred to as additive 
manufacturing—allows for the use of a variety of materials, including metals and polymers, to 
create 3D structures with defined geometries. Formation of 3D constructs is achieved via printing 
with inkjet, laser-assisted, and extrusion-based techniques, with variability in the use of selected 
materials and final resolution capabilities. Designs generated for 3D printing come from computer-
aided design (CAD) software or images from clinical scans obtained using computed tomography 
(CT), magnetic resonance imaging (MRI), or X-rays. Although the most common approach has 
been to use synthetic polymers to generate material “scaffolds”, most recently bioprinting has 
allowed for direct printing of living cells in combination with materials—increasing their 
complexity and improving biological properties [1, 2]. This may serve as a future direction for 
investigating how growth factors and cells could be incorporated into scaffolds so as to allow for 
a more versatile platform of delivery with a focus on achieving proper tissue alignment [3]. More 
importantly, this may present a technique for creating scaffolds with encapsulated gene therapy 
vectors that can transduced cells in vivo over time as the scaffold degrades, without the need for 
pre-seeding with cells, thereby eliminating a potential barrier to clinical translation. Consideration 
of the regulatory requirements that pertain to such novel therapies is critical, thereby prioritizing 
treatments that are safer, more defined, and simpler in terms of the number of components used 
(i.e., limited need for additional steps such as cell seeding prior to implantation, limited use of 
virus-derived materials).  
It is further important to anticipate and more thoroughly address the challenges that are 
likely to be encountered in the translation of this work to clinical applications. These are specific 
to the use of viral vectors, as well as human-derived cells not native to the host. As discussed 
earlier, the immobilization of viral vectors onto the polymer surface reduces the risk of systemic 
effects that would otherwise be more likely given the presence of virus that has potential to 
disperse. However, the presence of adenovirus still has potential to lead to infection of cells that 
were not the intended target, given the lack of cell-specific targeting that is currently only 
controlled for by saturating the virus-immobilized polymers with cells. A potential way of 
addressing this may be to use non-viral vectors for gene therapy, which have the disadvantage of 
having lower cell transduction efficiency, but at the same time avoid the main drawbacks of viral 
vectors (i.e., cytotoxicity, immunogenicity) that render them safer due to reduced pathogenicity 
and overall bio-safety [14]. Another translational barrier is the use of cells not originally derived 
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from the host (i.e., hPDL and hGF cells). Given that these are human-derived and have been shown 
to have high transduction efficiency using adenovirus, these cells were incorporated into the 
scaffold regions and transduced prior to implantation to ensure growth factor expression at the 
defect site, given that lack of cell seeding resulted in a lack of bone and PDL-like tissue formation 
at 3 weeks in the rat fenestration defect. To improve this aspect of scaffold design, it would be best 
to incorporate host-derived cells if cell seeding is required prior to implantation, such that the 
scaffold could be sterilized and ready for implantation into any patient given the availability of 
their native cells. Since it may be difficult to retrieve and expand hPDL and hGF cells from a 
human patient, it would be relevant to further investigate if another, more easily accessible patient-
derived cell population could be obtained that would show high transduction efficiency with 
adenovirus or a non-viral gene therapy vector.  
Potential incorporation of electrospun fibers into scaffold regions specific to areas intended 
for PDL regeneration may further improve the percentage of seeded cells (or native cells in cell-
free scaffolds) that could be controllably aligned at the defect site [4-5]. Other techniques still 
utilizing additive manufacturing for achieving PDL-like tissue alignment may also be considered, 
such as the recently reported use of 3D-printed, angulated grooves reminiscent of PDL-like tissue 
orientation regions (i.e., parallel, oblique, and perpendicular) that were able to predictably promote 
cell alignment in vitro [6]. Given that the periodontium is comprised of multiple tissues, it is 
appropriate to use 3D-printed constructs that have defined areas for bone soft (i.e., periodontal 
ligament) and osseous tissue regeneration. Such materials include both biphasic and triphasic 
scaffold constructs, which have areas for the cementum/dentin interface, as well as the periodontal 
ligament/alveolar bone formation interface [7-10]. Further advantage of these compartments is that 
each can be used to deliver cells (i.e., dental, PDL, and bone stem/progenitor cells), and/or growth 
factors (i.e., bone morphogenetic protein (BMP), platelet-derived growth factor (PDGF)). 
As was earlier described in Chapter 3, a first-in-human case report of a custom-designed, 
3D-printed PCL scaffold for the treatment of a large peri-osseous defect was reported in 
combination with platelet-derived growth factor (PDGF-BB) delivery [11]. The scaffold was 
fabricated using selective laser sintering (SLS), which allows for material powder to be fused 
together to form a structure based on a CAD file of the scaffold that was designed from cone beam 
computed tomography (CBCT) scans of the patient defect. This novel approach provides a 
promising future application of 3D-printing for customized scaffold designs that can be tailored to 
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meet patient-specific needs based on defect site and location, with the added ability to deliver 
growth factors. However, given that the primary limitation of this study was the prolonged 
degradation of PCL, it would be beneficial to reduce the bulk of polymer used in future 
applications, while also incorporating more precise features for guiding PDL tissue alignment in 
addition to osseous tissue regeneration.  
The ongoing evolution of 3D printers that are able to produce materials with higher 
resolution features and with the use of a variety of materials (including more rapidly degradable 
polymers such as PLGA) will enable the fabrication of scaffolds that are more precisely adaptable 
to patient defects, accounting for a variety of factors such as variations in material properties based 
on the expected defect milieu (i.e., transition from bone to ligament tissue) and intended rate of 
tissue regeneration at the site [12]. To date, 3D-printed materials with specific focus on bone 
regeneration have been more prevalent in oral based tissue engineering applications. Scaffold 
porosity is especially relevant in the design and fabrication of these constructs, as it is critical in 
ensuring adequate micro-architecture for tissue ingrowth at the defect site, in addition to proper 
vascularization and a tailored rate of biodegradation. 3D printing technology can further help 
customize pore size, morphology, and interconnectivity. For example, 3D printed glass-ceramic 
scaffolds with hexagonal designs show a high fatigue resistance compared to conventional 
architectures, with obtained strengths that are up to 150 times greater than values reported for 
composite or polymeric scaffolds, making these especially appropriate for use at load-bearing sites 
[13]. Improvement of the scaffold designs reported here based on these future directions has high 
potential for their continued evolvement for use in periodontal tissue engineering, with further 
translation into bone-ligament interface engineering. 
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Figure A1.1 Anatomy of the Periodontium.  
Periodontal ligament (PDL) region shown between the tooth root (TR) and alveolar bone (AB), 
where Sharpey’s fiber (SF) bundles (i.e., bundle bone region) are shown between the PDL and 
AB regions.  
 
Images compiled from: Oral Histology Learning Modules from Syrian Clinic and  School of Dental Sciences, 
Universiti Sains Malaysia. 
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Figure A1.2  Wound Healing Process Involving BMP and PDGF 
Overview of the wound healing process occurring after bone fracture, showing the cell signaling 
pathways and types of cells that proliferate as a result of fracture. Recruitment of osteoprogenitor 
cells occurs in response to bone morphogenetic protein (BMP)-related expression, with other key 
growth factors involved in angiogenesis and tissue repair, including platelet derived growth factor 
(PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor beta (TGF).  
 
Image used from:  Ghodadra N and Singh K. Recombinant human BMP-2 in the treatment of bone fractures. 
Biologics; 2008, 2(3):345-54.  
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Table A1.1  Effects of growth factors on periodontal cells in vitro. 
Growth 
factor 
Cell type Effect Studies 
 
 
 
 
 
 
 
PDGF 
Cementoblasts • Increased DNA synthesis and osteopontin 
mRNA expression 
[51] 
Dental follicle 
cells 
• Stimulated DNA synthesis and expression of 
CSF-1 and MCP-1  
[181] 
Gingival 
fibroblasts 
• Increased mitosis  
• No increase in proliferation or chemotaxis 
[73, 182] 
Osteoblasts • Increased proliferation and interleukin-6 
transcription 
• Inhibited differentiation 
• Blocked osteopontin, osteonectin 
[54-56] 
PDL cells • Stimulated proliferation (with or without 
allograft)  
• Induced matrix synthesis and increased cell 
migration and mitosis 
[52, 53, 
65, 73]  
 
 
 
 
 
 
 
BMP2 
Cementoblasts • Inhibited differentiation and mineralization [183] 
Dental follicle 
cells 
• Stimulated osteoblast/cementoblast 
differentiation 
• Increased mineralization and ALP 
[184, 
185] 
Gingival 
fibroblasts 
• Decreased mitosis  
• At high doses, inhibited mineralization and 
OCN 
[73, 186] 
Osteoblasts • Increased proliferation, mineralization, and 
expression of ALP and OCN  
[187] 
PDL cells • Increased mineralization and expression of 
mineralization markers 
• At doses >10ng/mL, induced 
apoptosis/cytotoxicity  
• Stimulated osteoblast differentiation 
• Decreased mitosis 
[72-74] 
 
 
 
 
BMP-7 
Cementoblasts  • Increased mineralization and mineralized tissue 
markers 
[102] 
Dental follicle 
cells 
• Increased mineralization and ALP expression [184] 
Osteoblasts • Increased proliferation, mineralization, and 
expression of ALP and OCN 
[75, 76, 
187] 
184 
 
 
PDL cells • Reduced proliferation 
• Induced ALP 
[188] 
 
 
 
 
 
 
 
 
 
FGF-2 
Cementoblasts • Stimulated DNA synthesis 
• Decreased mineralization and expression of 
OCN  
• Modulated expression of OPN 
[189] 
Dental follicle 
cells 
• Stimulated DNA synthesis and expression of 
CSF-1 and MCP-1 
[181] 
Gingival 
epithelial cells 
• Increased proliferation [107] 
Gingival 
fibroblasts 
• Increased proliferation [190] 
Osteoblasts 
  
• Promoted differentiation  
• Induced proliferation 
• Decreased mineralization gene expression 
[105, 
191] 
PDL cells • Increased proliferation (alone and combined 
with DFDBA or FDBA), migration, and 
extracellular matrix production 
• Maintained differentiation potential 
• Stimulated OPN 
• Inhibited ALP expression, mineralization, and 
OCN 
[103, 
104] 
 
 
 
GDF-5 
CT fibroblasts • Increased proliferation [192] 
Dental follicle 
cells 
• Reduced ALP activity [193] 
Osteoblasts • Increased early differentiation and matrix 
production  
• Modulated proliferation 
[114, 
192] 
PDL cells • Increased proliferation and matrix synthesis 
• Decreased ALP activity 
[113] 
Teripara
tide  
PDL cells  • Modified proliferation & survival and 
expression of mineralized markers (dependent 
on maturation state) 
[123, 
124] 
ALP: alkaline phosphatase, BMP: bone morphogenetic protein, CSF-1: colony 
stimulating factor-1, FGF-2: fibroblast growth factor-2, GDF-5: growth/differentiation 
factor-5, MCP-1: macrophage chemotactic protein-1, OCN: osteocalcin, OPN: 
osteopontin, PDGF: platelet-derived growth factor, PDL: periodontal ligament 
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Table A1.2 Preclinical animal models of growth factor delivery for periodontal and implant 
applications 
 
Growth 
factor 
Model Animal Results Studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
PDGF-
BB 
 
 
 
 
 
 
 
 
 
 
 
Furcation 
defect 
Canine • Stimulated PDL formation (early stage) 
• Promoted periodontal regeneration (late 
stage)  
[64] 
GBR at 
implants 
Canine • With IGF-1, significantly increased 
histologic bone-implant  
contact and peri-implant bone fill  
• With IGF-1, increased early (3 week) 
bone formation at immediate implants 
• With ePTFE membrane and IGF-1, 
increased bone gain and histologic  
parameters versus membrane alone or 
membrane + DFDBA 
[57, 65, 
66] 
Periodontal 
defect 
Canine • After flap surgery, increased new bone, 
cementum and PDL 
• With IGF-1, promotes periodontal 
regeneration  
[58-60, 
63] 
Non-
human 
primate 
• Significantly increased new attachment [61-63, 
77] 
Ridge 
augmentation 
Canine • With block graft, increased histologic 
bone formation 
• With bone mineral and collagen 
membrane, supports lateral bone 
formation 
• With biphasic calcium phosphate and 
collagen membrane, supports GBR 
• With xenograft scaffold, promoted 
bone regeneration similar in quality  
to native bone 
• With xenograft, improved radiographic 
results when used  
without collagen membrane 
[68, 69] 
[67] 
 
 
 
 
rhBMP-2 
 
Extraction 
socket 
Rat • Increased speed and quantity of bone 
formation 
• Induced proliferation and 
differentiation of mesenchymal cells 
[84] 
Furcation 
defect 
Feline • Early ankylosis may resolve with 
polymer carrier 
[194] 
186 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rhBMP-2 
GBR at 
implants 
Canine • Resorbable and ePTFE membranes 
delay early (1 month) bone formation  
but may result in increased or similar 3-
month bone formation vs. no 
membrane  
• Increased bone augmentation for 
implants placed in extraction sockets 
and  
for implant-site circumferential and 
fenestration defects 
• BMP2-coated implants provide 
increased bone formation, histologic  
bone apposition, and osseointegration 
• Improved late (3-month) bone 
formation for ACS versus PLGA 
carrier  
[83, 96, 
133, 
148, 
195] 
Periodontal 
defect 
Non-
human 
primate 
• Increased bone and cementum 
regeneration 
[77] 
Canine • Increased quantity and speed of bone 
formation  
• Bone quantity formed correlated with 
residual bone height 
• Limited cementum regeneration 
• Induced ankylosis and root resorption 
• No benefit for calcium phosphate 
cement carrier 
[78-80, 
82, 83] 
Ridge 
augmentation 
Rat • Significant horizontal and vertical bone 
augmentation  
• ePTFE membranes improve bone 
contour 
• Increased bone formation with ACS+ 
bone graft material 
• Potential carriers: absorbable collagen 
sponge, hyaluronic acid polymer,  
• collagen-calcium hydroxyapatite-TCP 
complex, PLGA/gelatin sponge 
[90, 92-
94] 
Canine • Increased histologic and radiographic 
bone formation, +/- bone graft 
• Increased incidence of seromas and 
wound failure  
• Possible decreased bone quality when 
combined with bone graft  
• With xenograft block, supported bone 
formation 
[81, 91, 
92, 
122] 
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• Late-stage implant stability comparable 
to native bone  
Non-
human 
primate 
• Increased ridge width and bone quality 
in TCP/HA/ACS and  
CaP cement carriers 
[196] 
Sinus 
augmentation 
Canine • Enhanced histologic bone formation [85] 
Rabbit • Increased bone volume for 
collagenated BCP/BCP carriers 
[86] 
Goat • Increased radiographic bone formation [89] 
Non-
human 
primate 
• Increased vertical bone gain [87] 
Mini-pig • BMP-2 coatings did not improve peri-
implant bone gain 
[88] 
BMP-4 Ridge 
augmentation 
Rat • Improved bone quality and comparable 
quantity versus BMP-2 
[90] 
 
 
 
 
 
 
 
 
 
BMP-7 
 
Furcation 
defect 
Canine • Significantly increased histologic bone, 
cementum, and new  
attachment in class III furcations 
[95] 
GBR at 
implants 
Canine • Implant-coating applications [96] 
Non-
human 
primate 
• Stimulated cementum formation [99] 
Ridge 
augmentation 
Rat • Increased bone formation in xenograft 
block versus control 
[197] 
Sinus 
augmentation 
Non-
human 
primate 
• Comparable radiographic and 
histologic bone formation and  
residual lateral wall defect reduction 
versus bone graft 
[98, 
198] 
Mini-pig • With xenograft, increases speed and 
quality of osseointegration at  
simultaneous implants 
[100, 
101] 
Socket 
augmentation 
Rabbit • Histologic increased speed of healing 
by 4-6 weeks 
• Significantly increased ALP activity 
and calcium 
[97] 
FGF-2 Furcation 
defect 
Canine • Significantly increased regeneration of 
cementum, PDL,  
and bone vs. controls 
[110, 
111] 
 
 
 
 
 
GBR at 
implants 
Canine • Improves peri-implant GBR (β-TCP) 
• GDF-5 coating may increase bone 
formation (dose-dependent) 
[199, 
200] 
Implant 
coating 
Rabbit • Improved implant stability as 
determined by pull-out test 
[119] 
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GDF-5 
Periodontal 
defect 
Canine • Significantly increased perio. 
regeneration in PLGA (dose-
dependent),  
β-TCP, ACS carriers, with bone 
formation for β-TCP stable up to 24 
wks 
• Beta-TCP/PLGA carrier may cause 
ankylosis 
[116-
118, 
201] 
Non-
human 
primate 
• Supported periodontal regeneration 
with β-TCP carrier 
[115] 
Ridge 
augmentation 
Canine • With xenograft block, supported bone 
regeneration 
[122] 
Sinus 
augmentation 
Mini-pigs • Enhanced bone formation with β-TCP [120, 
121] 
Teriparat
ide 
Extraction 
socket 
Osteopen
ic rats 
• Increased bone mineral density and 
anabolic effects  
[125] 
GBR at 
implants 
Canine • Significantly improved bone formation 
•  
[127, 
128] 
Periodontal 
defect  
Ovarecti
mized 
rats 
• Preventative effects on periodontal 
bone loss 
[126] 
ACS: absorbable collagen sponge, ALP: alkaline phosphatase, BCP: biphasic calcium 
phosphate, BMP: bone morphogenetic protein, bTCP: beta tricalcium phosphate, 
ePTFE: expanded polytetrafluoroethylene, FGF: fibroblast growth factor, GBR: guided 
bone regeneration, GDF: growth/differentiation factor, HA: hydroxyapatite, IGF: 
insulin-like growth factor, PDGF: platelet-derived growth factor, PDL: periodontal 
ligament, PLA: polylactic acid, PGA: polyglycolic acid 
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Table A1.3 Clinical application of growth factor and protein delivery in periodontics, 
osseointegration, and pre-prosthetic surgical procedures 
 
Growth 
factor/ 
protein 
Indication Evid
ence 
level 
Efficacy and safety Refere
nces 
 
 
PDGF-BB  
Periodontal defects ★★
★ 
• Gain in PD, CAL and BOP 
• Increasing of radiographic bone level 
 
 
[50, 
135-
138] 
Furcation 
involvements 
★ • Gain in PD, CAL and BOP 
• Increasing of radiographic bone level 
Alveolar bone 
augmentation/prese
rvation 
★ • Accelerate the healing process 
 
BMP-2 
 
 
 
BMP-7 
Alveolar bone 
augmentation/prese
rvation 
 
★★ • Accelerate the healing process 
• Histological findings high proportion 
of newly formed bone 
 
 
 
[141-
144, 
146-
149] 
 
 
Sinus augmentation 
★★ • In combination with 
allogeneic/autologous bone graft: 
histologic findings similar to 
autologous bone and adequate 
vertical bone gain (BMP-2) 
• In combination with bovine-derived 
xenogeneic graft: histologic findings 
show less new bone compared to 
xenograft alone but adequate vertical 
bone gain (BMP-2, BMP-7) 
 
GDF-5 
Periodontal defect ★ • Gain in CAL  
[150, 
151] 
Sinus augmentation ★ • Histologic results similar to 
autologous bone 
• Adequate vertical bone gain 
FGF-2 Periodontal defects ★ • Early radiographic bone fill [152] 
 
 
Teriparati
de 
 
 
Peri-implant bone 
★ • Gain in PD and CAL 
• Increasing radiographic bone level 
 
 
[154, 
155] 
• Greater bone-to-implant contact in 
the periosteal and medullary 
compartment 
• Minimal effect on cortical 
compartment 
• Slight higher bone-volume-per-
tissue-volume 
Evidence level= (★) Slight clinical evidence; (★★) Moderate clinical evidence; (★★★)  
Robust clinical evidence; Clinical parameters= (PD) pocket depth; (CAL) clinical attachment level; (BOP) 
bleeding on probing 
